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 Meiner Familie 
 
 
 
Das Lied von der Wirklichkeit 
 
In der Wirklichkeit gibt es Träume. 
In der Wirklichkeit sind sie echt. 
Wenn ich Träume hie und da versäume,  
ist es nur, weil ich auch schlafen möcht. 
 
Doch die Wirklichkeit ist ein Märchen,  
das die Wissenschaft nicht kapiert. 
Denn der Wissenschaftler spaltet Härchen,  
und der Träumer ist bereits frisiert. 
 
Phantasie ist nichts für die Experten,  
die das Leben fürchten und den Tod.  
Psychopathen kann man nicht verwerten. 
In der Schule gibt´s ein Lexikon: 
Was geschrieben ist, gilt als bewiesen. 
Wenn´s im Lauf der Zeit, sich als falsch erweist,  
schreibt der Professor halt ein neues Buch. 
Denn der Mensch will immer was beweisen,  
im Gegensatz zur Gans. 
Doch er kann´s nicht, und er wird entgleisen,  
Solang er glaubt, er kann´s. 
 
In der Wirklichkeit gibt´s nie Beweise, 
denn die Wirklichkeit, die ist wahr. 
Komm mit mir auf eine wahre Reise 
voller Traum und ohne Kommentar! 
 
In der Wirklichkeit sind die Träume, 
die kein Physiker je beschreibt. 
Komm mit mir in meine Zwischenräume,  
wo kein Mensch die Wahrheit übertreibt. 
Komm mit mir auf meine Purzelbäume,  
wo von Wissenschaft nichts übrig bleibt. 
 
Georg Kreisler 
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Preliminary note 
For the sake of clarity and to improve readability the use of the female form was largely 
forgone in the present study (e.g. the patient is mostly referred to as “he”). Generally the 
respective wording also contains the female form. Furthermore, the author of this work was 
anxious to consider the copyright of all used texts, figures and data. 
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1 Introduction 
1.1 Pharmacoeconomics 
1.1.1 Definition 
Pharmacoeconomics is a scientific discipline which evaluates health technologies in terms of 
costs and outcomes. Health technologies encompass e.g. pharmaceutical products, health 
services or programmes [1]. As healthcare resources are limited, there is an increased interest 
in assessing and comparing the values-for-money of alternative treatment strategies [2]. For a 
meaningful comparison, it is necessary to examine additional costs and effects that one 
intervention imposes on another. Figure 1-1 illustrates this incremental approach on a four 
quadrant diagram known as the cost-effectiveness-plane. 
 
 
Figure 1-1: Cost-effectiveness-plane [3] 
The x-axis represents the difference in effect between the intervention of interest, e.g. a new 
drug, and the relevant alternative, e.g. the standard medication. The y-axis represents the 
difference in costs. If the result is in the south-east or in the north-west quadrant the choice 
between the drugs is clear. In the former case the new intervention is both more effective and 
less costly than the alternative. This means, it dominates the alternative. In the latter case the 
opposite is true. In the other two quadrants the choice depends on the maximum cost-
Cost difference
Effect  
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effectiveness ratio one is willing to accept. The slope of the line yields the cost-effectiveness 
ratio. 
1.1.2 Pharmacoeconomics in Germany and other countries 
In the light of scarce financial resources several countries implemented different cost 
containment strategies. Pharmacoeconomic evaluations of health care interventions present 
one decision-supporting approach for a rational resource allocation in health care. Important 
motives for performing pharmacoeconomic evaluations appear to be establishing value-for-
money of new drugs, to inform decisions on reimbursement and/or pricing. 
Pharmacoeconomic evaluation is sometimes referred to as “the fourth hurdle”, which suggests 
that the drug company has an additional obstacle to overcome beside the normal marketing 
authorisation requirements. Australia was the first country in 1993 that required evidence of 
cost-effectiveness on the basis of pharmacoeconomic studies from pharmaceutical companies 
beside evidence on safety, efficacy and quality of drugs. In Australia cost-effectiveness of an 
approved pharmaceutical product is a prerequisite for its listing on the pharmaceutical 
benefits schedule (PBS; positive list of pharmaceutical products). In the meantime, similar 
regulations are in force e.g. in Belgium, Austria, Norway and the Netherlands. In France, 
Switzerland and Finland the submission of clinical studies is sufficient for reimbursement 
decisions, but the results of pharmacoeconomic evaluations form the basis for price 
negotiations with pharmaceutical companies in France. In New Zealand, England/Wales and 
Sweden institutions were established which conduct their own health technology assessments 
of health care interventions [4–6]. In Germany an independent institution, the Institute for 
Quality and Efficiency in Health Care (IQWiG), was established in 2004. The legislation 
contained in the Health Care Reform GKV-WSG (statutory health insurance - act to promote 
competition) of April 2007 has extended IQWiG's responsibilities. Prior to that, the 
assessment of drugs was restricted to medical outcome. Now it could also be commissioned to 
conduct pharmacoeconomic assessments. In October 2009 the final paper on IQWiG`s 
scientific methods for evaluating costs and outcomes was published and in the meantime the 
first commissions on pharmacoeconomic evaluations have been submitted by the federal joint 
committee (G-BA) [7]. 
 
 
Introduction  5 
 
1.1.3 Pharmacoeconomic evaluations 
There are four main forms of pharmacoeconomic evaluations. 
In a cost-effectiveness analysis (CEA) the outcomes of health care interventions are measured 
in the most appropriate natural effects, such as “life year gained” or “symptom free days”. 
The results are expressed in cost-effectiveness ratios, e.g. € 5000 per life year gained. In the 
rare situations in which the relevant treatment options are identical or very similar in terms of 
health benefits and risks the evaluation is reduced to a comparison of costs only. The latter 
evaluation is known as cost-minimization analysis (CMA). In a cost-utility analysis (CUA), 
health states are valued in relation to one another through the use of health utility scores. This 
means that the quality of e.g. life years gained can be quantified, not just the number of years. 
The common measure in CUAs is the quality-adjusted life year (QALY) which enables the 
comparison of value-for-money of interventions of different fields of health care. The fourth 
evaluation is known as cost-benefit analysis (CBA). In a CBA attempts are made to value the 
outcomes of health interventions in monetary terms (e.g. willingness-to-pay approach). Thus, 
in theory, it represents the broadest form of analysis. However, assessment problems often 
limit the range of outcomes valued in monetary terms [3, 2]. 
In the present study a cost-utility analysis was chosen to evaluate the impact of 
pharmaceutical care compared to standard care on costs and outcomes of oncology patients. 
The combination of quality and quantity of life in the QALY measure is particularly useful in 
this patient group. Especially in palliative cancer patients the remaining life time should be 
accompanied with a minimum of treatment side-effects and a high quality of life.  
1.1.3.1 Study perspective 
Different study perspectives for the evaluation of costs and outcomes may be adopted in a 
pharmacoeconomic evaluation. The societal perspective is preferred by many health 
economic guidelines, but is rarely applied in practice. This perspective does not only focus on 
costs in the health care sector but also accounts for the economic consequences of e.g. lost 
productivity as a result of diseases. A health care perspective is concerned with direct 
medical costs only (see 1.1.3.2 “Costs”), as this is what the health care budget relates to. In 
case of a hospital perspective, only costs and savings that are important for the hospital are 
taken into account (e.g. less nursing time, less material). From a patient’s perspective e.g. out-
of-pocket payments or a reduced salary due to a disease are important [8]. 
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1.1.3.2 Costs 
Costs can be divided into two major categories: direct and indirect costs. 
Direct medical costs arise immediately through the treatment of a disease within the health 
care sector, e.g. costs for drugs, diagnostics, inpatient stays and physician fees. Direct non-
medical costs accrue due to the disease but beyond the treatment such as travel costs, costs for 
home help or time spent by family members providing care. The indirect non-medical costs 
result from periods of sick leave and therefore lost productivity. Indirect medical costs are 
related to health care costs which can arise in the future. For example, if a patient lives longer 
because of an intervention to prevent stroke, the future costs linked to his longer life during 
which he might develop Alzheimer can also be considered [3, 6]. 
1.1.4 Pharmacoeconomics in oncology  
Understandings of cancer biology and advances in technology have led to the development of 
a variety of new anti-cancer treatments and diagnostics. Many of these interventions are 
costly and at the same time only marginally effective [9]. In Germany a debate is going on to 
which extent pharmacoeconomic evaluations in the field of cancer should form the basis for 
resource allocation decisions. Ethical concerns are understandable given the potentially 
life-threatening condition of cancer patients. Aidelsburger et al. published a review on behalf 
of the German Cancer Society (Deutsche Krebsgesellschaft) on peculiarities associated with 
the cancer disease that should be considered in pharmacoeconomic analyses in oncology [10]. 
In clinical studies new anti-cancer drugs are often tested as second- or third-line therapy in 
cancer patients. In these patients the incremental benefit can only be marginal especially when 
gained lifetime is considered as an outcome. Add-on therapies or sequential therapy regimens 
are also common for new anti-cancer therapies. Thus, it is hard to detect their individual 
additional benefit. In case of advantages for the medication being studied, control patients 
also have the possibility to switch to the intervention arm. This leads to biased results at the 
expense of the studied drug. Pharmacoeconomic evaluations mostly require a comparison 
with standard therapies. In case of last-line therapies this is difficult as generally no definite 
approved standards exist. In many cases standard therapy means providing best supportive 
care. The factors mentioned might have consequences regarding the cost-effectiveness of new 
anti-cancer interventions [10]. Furthermore, certain oncology drugs are orphan drugs. 
Economic evaluation of orphan drugs is a domain in itself with specific characteristics and 
limitations[11]. Uyl-de Groot et al. suggest a higher cost-effectiveness threshold for cancer 
interventions in the field of gastrointestinal cancer and a more prudent price setting by 
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pharmaceutical companies [12]. An examination of NICE´s decisions based on 
pharmacoeconomic evaluations of cancer therapies by Drummond and Mason suggested that 
cancer drugs have faired quite well despite their high costs. Drummond et al. supposed that 
the seriousness of the health condition and the lack of alternative therapies in some cases led 
to mainly positive recommendations [13]. In 2008 NICE outlined a new approach for end-of-
life drugs appreciating their special role in health care. But it is problematic to set the cost-
effectiveness threshold higher for some groups of patients within a fixed budget as it results in 
other groups being denied treatment [14]. On the whole, it is important to find a balance 
between the need to promote incentives for innovation of new cancer interventions and 
potentially competing societal responsibilities [9]. Pharmacoeconomic evaluations may 
support this balancing act. 
For economic evaluations of pharmaceutical care see chapter 1.2.3 “Pharmacoeconomics in 
pharmaceutical care” and of capecitabine see chapter 1.3.4 “Pharmacoeconomics of 
capecitabine”. 
1.2 Pharmaceutical care 
1.2.1 Concept and development 
In 1990, Hepler and Strand proposed that pharmacists should deliver “pharmaceutical care”, 
just as nurses provide “nursing care” and physicians provide “medical care” [15]. They 
defined pharmaceutical care as “the responsible provision of drug therapy for the purpose of 
achieving definite outcomes that improve a patient’s quality of life”. Some years later the 
Féderation Internationale Pharmaceutique (FIP) extended the definition emphasising the 
collaborative approach and the continuous nature of the pharmaceutical care service: 
“Pharmaceutical care is the responsible provision of pharmacotherapy for the purpose of 
achieving definite outcomes that improve or maintain patients´ quality of life. It is a 
collaborative process that aims to prevent or identify and solve medicinal product and health-
related problems. This is a continuous quality improvement process for the use of medicinal 
products” [16]. In both definitions the pharmacist is not explicitly named. This indicates that 
all patient care providers including physicians and nurses can possibly deliver pharmaceutical 
care. Nevertheless, it is expected that the practitioner who will provide pharmaceutical care as 
a primary role is the pharmacist [17]. According to the FIP patient counselling and 
information becomes pharmaceutical care if the following requirements are met: systematic 
approach, setting a goal, patient-related documentation, and monitoring [16]. The SOAP-
method can be a supporting tool to meet these requirements. Subjective patient information 
8  Introduction 
(e.g. headache) and objective parameters (e.g. high blood pressure) which characterise the 
patient are analysed / assessed (e.g. stage 1 hypertension). On the basis of this analysis 
therapeutic goals (e.g. blood pressure of 120/80 mmHg) and monitoring parameters (e.g. 
blood pressure, compliance) are defined in collaboration with the prescribing physician and 
integrated in a therapeutic plan (e.g. recommendation of antihypertensive medication and 
monitoring) [18]. In the following, recommendations are implemented and monitoring 
parameters are evaluated. In certain intervals the plan is re-assessed and adapted if necessary. 
1.2.2 Pharmaceutical care for cancer patients 
Cancer patients undergoing systemic cancer therapy are at risk of multiple drug-related 
problems (DRP) as the therapy is highly toxic and particularly complex. Adverse effects, 
medication errors, drug-drug interactions and non-adherence are the most frequently reported 
DRP [19]. With his central role as being the only health care provider who may have an 
overview of all drugs prescribed and self-purchased, the pharmacist can contribute 
substantially to risk minimisation. Pharmacists have a specific drug-related knowledge which 
they can add to the clinical team [19]. In addition they can offer patient-oriented activities 
such as compounding of cytotoxic drugs considering individual patient parameters and 
therapeutic drug monitoring of critical substances [20]. The concept of pharmaceutical care 
for cancer patients offers a comprehensive approach to optimize individual drug therapy and 
solve DRP. Many studies have been conducted which show that pharmaceutical care services 
have their value in common diseases such as diabetes, hypertension, asthma, chronic pain and 
psychiatric disorders [21]. Only a few studies are published on pharmaceutical care provided 
to cancer patients [22, 23]. At the University of Bonn, department of clinical pharmacy the 
focus is on pharmaceutical care delivery to patients with breast and colorectal cancer. 
Completed projects could show significant positive impacts of pharmaceutical care on the 
adverse drug reactions nausea and emesis and on the daily compliance of patients treated with 
the oral chemotherapeutic agent capecitabine [24–27]. The present study is the first to 
investigate the cost-effectiveness of pharmaceutical care for cancer patients. 
1.2.3 Pharmacoeconomics in pharmaceutical care 
In 1998, Plumridge et al. published a review on pharmacoeconomics of pharmaceutical care. 
They only found a few articles and concluded that “there is little published research to date 
that demonstrates the pharmacoeconomic benefit of pharmaceutical care” [28]. The 
American College of Clinical Pharmacy has published summaries of the economic literature 
on pharmacy services before 1988, from 1988 through 1995, from 1996 through 2000 and the 
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latest from 2001 through 2005 [29–32]. In general they found continued evidence of the 
economic benefit of clinical pharmacy interventions. At the end of each review they 
concluded that improvements are needed in the methods used to evaluate pharmaceutical care 
services. A review by Rijdt et al. focused on pharmacoeconomic analysis of clinical pharmacy 
interventions in the hospital setting. They found pharmacoeconomic analyses of pharmacy 
practice in intensive care units, coronary care units, internal medicine wards, general medicine 
wards and emergency departments. No economic evaluation of pharmaceutical care in 
oncology could be identified. In addition, they equally concluded that most 
pharmacoeconomic evaluations of clinical pharmacy interventions exhibited limitations in 
their methodological quality and applicability to current practice [33].  
In the context of pharmacoeconomics of pharmaceutical care the question of reimbursement 
of these services arises. In Germany a first nationwide pharmaceutical care model known as 
the family pharmacy program was implemented in 2003. One year later a trilateral integrated 
care contract was signed that also included general practitioners (GP), combining the family 
physician with the family pharmacy. In this concept pharmacists are reimbursed for direct 
communication between the community pharmacist and the GP by the statutory health 
insurance company ‘BARMER Ersatzkasse’ [34]. A new reimbursed pharmaceutical service 
aims at improving the self-monitoring of blood-glucose levels in type 2 diabetes patients. The 
cognitive service can be charged twice in twelve months and is reimbursed with € 22 per 
patient by the ‘BARMER Ersatzkasse’ [35]. 
Current publications indicate that evidence of the cost-effectiveness of pharmaceutical care 
services is needed. Reliable study results will probably strengthen the position of pharmacists 
in oncology treatment teams. Furthermore, evidence on cost-effectiveness may further 
legitimate and enhance the reimbursement of pharmaceutical care services provided by 
community pharmacies. The present study tried to contribute a methodologically sound 
assessment of pharmaceutical care in the field of oncology to the available economic 
evaluations of pharmacy practice. 
1.3 Capecitabine 
All patients in the present study were treated with the chemotherapeutic agent capecitabine 
which is an orally administered prodrug of fluorouracil. There are many advantages of oral 
treatment compared to intravenous infusions as e.g. higher convenience for patients, 
avoidance of venepuncture and paravasates, and greater autonomy for the patients. Despite 
the advantages oral agents are also accompanied by many challenges. The potential toxicity of 
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anti-cancer agents, the recognition of adverse effects by the patient, the less intense contact 
between the patient and the physician as well as the importance of patients´ adherence for 
treatment success are important issues that have to be addressed. Multidisciplinary patient 
care as e.g. pharmaceutical care services and a good patient education plays a key role in a 
successful oral anti-cancer treatment [36–39]. 
1.3.1 Clinical application and drug dosing 
Capecitabine is available on the German medical market as tablets with 150 mg or 500 mg 
under the brandname Xeloda®. It is indicated for the adjuvant treatment of patients following 
surgery of stage III (Dukes' stage C) colon cancer and for the treatment of metastatic 
colorectal cancer. Furthermore, it is indicated for first-line treatment of advanced gastric 
cancer in combination with a platinum-based regimen. Xeloda® in combination with 
docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast 
cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an 
anthracycline. Xeloda® is also indicated as monotherapy for the treatment of patients with 
locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-
containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. 
[40]. 
In the present study capecitabine was also combined with other agents e.g. with paclitaxel and 
lapatinib in breast cancer patients, in combination with oxaliplatin, irinotecan, bevacizumab 
and cetuximab in colorectal cancer patients. 
Capecitabine tablets should be swallowed with water within 30 minutes after a meal in the 
morning and in the evening. One capecitabine chemotherapy cycle consists of two weeks of 
twice daily drug intake followed by seven days of break. Treatment should be discontinued if 
progressive disease or intolerable toxicity is observed. Standard and reduced dosing according 
to body surface area for a starting dose of 1250 mg/m2 twice daily are provided in table 1-1. 
In case of occurring toxicity the dose should be reduced by 25 and 50 % respectively 
depending on the severity grade (see 1.3.3 “Adverse effects”). 
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Table 1-1: Standard and reduced dosing of capecitabine according to body surface area 
for a starting dose of 1250 mg/m2 twice daily [40] 
Body 
surface area 
[m2] 
Standard 
dose (100%) 
1250 mg/m2 
[mg] 
Number of 
150 mg 
tablets  
Number of 
500 mg 
tablets 
Reduced 
dose (75%) 
950 mg/m2 
[mg] 
Reduced 
dose (50%) 
625 mg/m2 
[mg] 
≤ 1.26 1500 - 3 1150 800 
1.27 – 1.38 1650 1 3 1300 800 
1.39 – 1.52 1800 2 3 1450 950 
1.53 – 1.66 2000 - 4 1500 1000 
1.67 – 1.78 2150 1 4 1650 1000 
1.79 – 1.92 2300 2 4 1800 1150 
1.93 - 2.06 2500 - 5 1950 1300 
2.07 – 2.18 2650 1 5 2000 1300 
≥ 2.19 2800 2 5 2150 1450 
 
Capecitabine use should be carefully monitored in patients with mild to moderate liver 
dysfunction. Administration should be interrupted if treatment-related elevations in bilirubin 
of >3.0 x ULN or treatment-related elevations in aminotransferases (ALT, AST) of >2.5 x 
ULN occur. Treatment may be resumed when bilirubin decreases to ≤ 3.0 x ULN or 
aminotransferases decrease to ≤ 2.5 x ULN. In patients with mild renal impairment (CLCR = 
51-80 ml/min) no dose reduction is required, in patients with moderate renal impairment 
(CLCR = 30-50 ml/min) a dose reduction by 25 % is recommended. In case of severe hepatic 
or renal impairment (CLCR < 30 ml/min) capecitabine is contraindicated [41, 40]. 
1.3.2 Interaction with other medicinal products and food 
The following interactions of capecitabine have been described [41]: 
Coumarin-derivative anticoagulants: Altered coagulation parameters and/or bleeding were 
reported in patients taking capecitabine concomitantly with coumarin-derivative 
anticoagulants such as warfarin and phenprocoumon. Patients should be monitored regularly 
for alterations in their coagulation parameters (PT or INR) and the anticoagulant dose should 
be adjusted accordingly. 
Phenytoin: Increased phenytoin plasma concentrations resulting in symptoms of phenytoin 
intoxication in single cases were reported during concomitant use of capecitabine with 
12  Introduction 
phenytoin. Patients should be regularly monitored for increased phenytoin plasma 
concentrations. 
Folinic acid: Folinic acid enhances the toxicity of capecitabine. 
Sorivudine and analogues: A clinically significant drug-drug interaction between sorivudine 
and 5-FU, resulting from the inhibition of dihydropyrimidine dehydrogenase (DPD) by 
sorivudine, was reported. As the DPD catabolizes 5-FU its inhibition is potentially fatal. 
Therefore, capecitabine must not be administered concomitantly with sorivudine or its 
chemically related analogues, such as brivudine. There must be at least a four-week 
intermission between the end of the treatment with sorivudine or its analogues and the start of 
the capecitabine therapy. 
Food interaction: In all clinical trials, patients were instructed to administer capecitabine 
within 30 minutes after a meal. Since current safety and efficacy data are based upon 
administration with food, it is recommended that capecitabine is administered with food. The 
influence of food on the pharmacokinetics of capecitabine was evaluated by Reigner and co-
workers. Cmax as well as the AUC of capecitabine and its metabolites were reduced when the 
drug was taken within 30 minutes after consumption of a standard breakfast in comparison to 
a drug intake after an overnight fast. Thus administration with food decreases the extent of 
capecitabine absorption. The clinical significance of these findings has yet to be investigated 
[42]. 
1.3.3 Adverse effects 
Many studies show an improved safety profile of capecitabine in comparison to the 
intravenously administered 5-FU. The most frequently occurring adverse drug reactions are 
the hand-foot syndrome in 54 % of patients, followed by diarrhoea (48 %), nausea (23 %) and 
vomiting (23 %). The hand-foot syndrome and diarrhoea are the most frequent therapy 
limiting toxicities in patients treated with capecitabine. In comparison to 5-FU only the hand-
foot syndrome occurs significantly more often under therapy with capecitabine. The adverse 
effects stomatitis, diarrhoea, nausea, alopecia and neutropenia are less frequent in comparison 
to 5-FU treatment [43–45]. Concerning the immediate management of adverse effects, a dose 
reduction or therapy interruption depending on the severity grade is recommended. According 
to Cassidy et al. a dose reduction of capecitabine as a consequence of occurring toxicity does 
not lead to a reduced effectiveness of the anti-cancer treatment. No influence on the risk of 
disease progression or mortality could be observed [45]. 
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The hand-foot syndrome 
The hand-foot syndrome (HFS), also known as palmar-plantar-erythrodysesthesia (PPE), is 
the most frequent and at the same time a dose- and therapy-limiting toxicity in patients under 
treatment with capecitabine. HFS is also described under treatment with other anti-cancer 
agents like docetaxel, doxorubicin or the tyrosine kinase inhibitors sorafenib and sunitinib. 
Zuehlke was the first to describe the HFS in 1974 as adverse drug reaction of intravenous 
mitotane [46]. HFS starts with mild skin reactions at the hands and feet such as numbness, 
paraesthesia, dysesthesia, tingling and/or erythema. Painful erythema, swelling of the hands 
and feet and cracked skin as well as major skin reactions with moist desquamation, ulceration, 
blistering, bleeding and/or severe pain may follow. Depending on the severity HFS may have 
a major impact on patients´ quality of life. Activities of everyday life are impaired, patients 
are unable to work, and they have difficulty in walking and using their hands [47, 48]. 
Different classification systems for HFS exist. Table 1-2 shows the classification according to 
the “Common Terminology Criteria for Adverse Events” version 3.0 [49]. 
Table 1-2: Severity grades of HFS 
Grade 0 Grade 1 Grade 2 Grade 3 
No problems 
Minimal skin 
changes or 
dermatitis, without 
pain 
Skin changes (e.g. 
swelling, blisters, 
peeling) or pain, no 
or little impairment 
Ulcerative dermatitis 
or skin changes with 
severe pain, strong 
impairment 
 
Until today the patho-mechanism of HFS is not completely clear. An immediate toxic effect 
of the anti-cancer drug on epidermal cells is discussed. But there is no explanation for the 
local occurrence of HFS at the hands and feet [47]. Another explanation might be a higher 
accumulation of capecitabine metabolites due to the expression of the enzyme thymidine 
phosphorylase in keratinocytes of the skin. A connection between HFS and a higher 
production of sweat at the hands and feet is also assumed [48]. Furthermore, gender-specific 
differences of HFS as well as an association with different combination partners in 
chemotherapy regimens are currently being investigated [50]. As long as the patho-
mechanism remains unidentified the prevention and therapy of HFS will be limited to a relief 
of the clinical symptoms. The most important step in the treatment of HFS is the therapy 
interruption and dose reduction [51, 52]. Table 1-3 summarises a dose modification scheme 
for capecitabine. 
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Table 1-3: Dose reduction schedule depending on HFS grade [40] 
HFS severity grade Step during cycle Dose following cycle 
1  Maintain dose level 100% 
2 1st appearance Interrupt until resolved to grade 0-1 100% 
 2nd appearance Interrupt until resolved to grade 0-1 75% 
 3rd appearance Interrupt until resolved to grade 0-1 50% 
 4th appearance Discontinue treatment permanently - 
3 1st appearance Interrupt until resolved to grade 0-1 75% 
 2nd appearance Interrupt until resolved to grade 0-1 50% 
 3rd appearance Discontinue treatment permanently - 
 
Generally the treatment interruption leads to a recovery within the next days. If HFS recurs 
after interruption and dose reduction the oncologist also has the possibility to change the 
treatment cycle e.g. extend the therapy-free interval or change the cycle length [53]. 
Well-educated patients and health care professionals are crucial in the management of HFS. 
The patient should inform the health care professional immediately about a developing HFS 
and the health care professional has to identify the severity grade. The patient should know 
that therapy interruption and dose reductions due to occurring toxicity do not influence the 
effectiveness of therapy. It has to be clarified that this information does not lead to a higher 
non-adherence rate as the patient might underestimate the treatment. Ideally the patient should 
also receive written information about HFS. In addition, continuous care is recommended 
during the therapy cycle when the patient is at home, especially at the beginning of the 
treatment. Short telephone calls can help to manage HFS and other toxicities [54]. 
Several researchers focused on pharmacological strategies to handle or prevent HFS. Lin et al. 
analysed the influence of celecoxib, a selective COX-2-inhibitor, on HFS. They found a 
reduced incidence of HFS and a higher survival rate when capecitabine was combined with 
celecoxib [55]. These results are controversial as in a later randomized multi-centre study 
celecoxib neither had an effect on HFS nor on the survival rate [56]. Studies with pyridoxine 
(vitamin B6) did not show a statistically significant effect on the incidence of HFS either [57, 
58]. When capecitabine and cisplatin are used in combination, the use of vitamin B6 is not 
advised for symptomatic or secondary prophylactic treatment of HFS because of published 
reports that it may decrease the efficacy of cisplatin [41]. The supportive administration of 
vitamin E in a chemotherapy regimen with capecitabine and docetaxel was tested in a Turkish 
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case study. HFS did not worsen although the chemotherapy was administered without dose 
reduction. The authors recommended further studies to analyse the effect of vitamin E [59]. 
Aside from systemic approaches, attempts have been made with topical treatments as e.g. 
corticosteroid-containing creams. In this context skin atrophy and delayed wound healing also 
have to be considered if corticosteroids are used for a longer period of time [53]. The 
pharmacy of the University Hospital Essen, Germany reported positive findings with uridine-
containing ointments. Nevertheless, these results have to be confirmed by adequate studies 
[60]. 
Finally some empirical recommendations can be given to the patient, which he might consider 
in his everyday life. Moisturizing creams or emulsions should be applied to his hands and 
feet; he should avoid heat, pressure and rubbing of the skin. Excoriations should be padded 
softly. The skin should be aerated as often as possible to avoid excessive sweating. To relieve 
the symptoms hands and feet can be bathed in cool water; the feet should be elevated as often 
as possible [53]. 
Furthermore, it is currently being discussed whether HFS is a valuable marker to monitor the 
efficacy of capecitabine as its occurrence, at least to a low extent, might be associated with 
better clinical outcome [61, 62]. 
1.3.4 Pharmacoeconomics of capecitabine 
Some studies evaluated the cost-effectiveness of capecitabine and combinations in the 
treatment of cancer patients. Eggington et al. undertook a cost-utility analysis of capecitabine 
compared to bolus 5-FU / LV in the adjuvant treatment of colon cancer patients based on the 
results of the X-ACT trial (Xeloda® Adjuvant Chemotherapy Trial) [63]. The UK National 
Coordinating Centre for Health Technology Assessment (NCCHTA) funded the study on 
behalf of NICE. Their analysis suggested that capecitabine is expected to produce a QALY 
gain of 0.98 at lower costs per patient than the Mayo Clinic 5-FU / LV regimen, indicating 
dominance of capecitabine. The safety and tolerability profile of capecitabine was superior to 
the Mayo Clinic 5-FU / LV regimen, but it has not been compared to other less toxic 5-FU / 
LV regimens [64]. A recent analysis evaluated the cost-effectiveness of capecitabine plus 
oxaliplatin (XELOX) in comparison to 5-FU / LV and oxaliplatin (FOLFOX) in patients with 
metastatic colorectal cancer based on the results of two clinical trials. They used quality-
adjusted progression-free survival days (QAPFSD) as outcome parameter. XELOX was 
associated with a gain in QAPFSD at reduced treatment costs, demonstrating dominance over 
FOLFOX [65]. An analysis of ixabepilone plus capecitabine versus capecitabine alone in 
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metastatic breast cancer patients showed an incremental-cost-utility ratio (ICUR) of $ 359000 
per QALY gained. This result is far above the common willingness-to-pay for an additional 
QALY indicating that the combination is not a cost-effective use of health care resources 
[66]. A similar result was obtained in a cost-utility analysis of lapatinib plus capecitabine 
versus capecitabine alone in HER-2 positive advanced breast cancer patients [67]. A health 
technology assessment identified one randomized controlled trial (RCT) on capecitabine in 
combination with docetaxel versus docetaxel alone. Based on this RCT the combination 
therapy was likely to be cost-effective [68]. In conclusion, capecitabine either as monotherapy 
or in combination with oxaliplatin or docetaxel for the treatment of colorectal cancer or 
metastatic breast cancer seems to be a cost-effective use of health care resources. 
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2 Aim 
The present study aimed at setting up, conducting and evaluating the costs and outcomes of a 
pharmaceutical care service for cancer patients treated with capecitabine compared to 
standard care. 
A pharmaceutical care intervention as well as an appropriate study design, endpoints and 
infrastructure had to be developed. For the collection of data on resource use a new 
infrastructure had to be established as well. 
Endpoints within the study were direct disease-related outpatient and inpatient costs, health-
related quality of life, the adverse drug reaction hand-foot syndrome and quality-adjusted life 
years (QALYs). Further endpoints were the indirect disease-related costs, also known as loss 
of productivity, direct non-medical disease-related costs based on the patients´ need of help 
with every-day activities and the willingness-to-pay of the intervention patients for the 
pharmaceutical care service. 
A further objective was to determine the cost-effectiveness of the pharmaceutical care service 
in a cost-utility analysis. The cost-utility analysis should be based on direct disease-related 
costs and QALYs of retrospectively matched patient pairs from the control and intervention 
group.
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3 Patients and Methods 
The present project was initiated as the first study to survey the costs and outcomes of a 
pharmaceutical care service delivered to cancer patients in Germany. There was no scientific 
evidence available on pharmacoeconomics of pharmaceutical care research in oncology. 
Therefore this work was planned as a pilot study. 
3.1 Legal status of the study  
The legal classification of the study as an observational trial ensued on the basis of the 
following arguments. 
The participating physicians were not influenced with regard to their decision on diagnosis or 
the choice and implementation of therapy in the individual patient. In the field of supportive 
therapy the involved physicians were, if required, informed and advised by the participating 
clinical pharmacists according to the latest therapeutic guidelines. The physicians´ freedom of 
therapy was not limited during the study. The cooperation between the clinical pharmacists 
and the physicians was in consent with § 20 ApBetrO (Apothekenbetriebsordnung; German 
pharmacy law), which regulates the obligation of the pharmacist to give information and 
advice to patients and physicians. In the present study drugs were not tested. Instead the focus 
was on testing a service delivered to cancer patients. 
With consideration of §§ 4, 40 and 67 of the German drug law (Arzneimittelgesetz, AMG) 
and the announcement of the Federal Institute of Drugs and Medical Devices (Bundesinstitut 
für Arzneimittel und Medizinprodukte, BfArM) from 12 November 1998 (Bundesanzeiger no. 
229, 11 December 1998) the study was accomplished as an observational study.  
On 16 September 2005 the ethics committee approved the study. In 2006 two amendments to 
the study protocol on additional inclusion of breast cancer patients and pharmacoeconomic 
evaluation of pharmaceutical care were also approved by the committee. 
3.2 Participating study centres and cooperating partners 
The study was accomplished with the participation of three oncology outpatient wards and 
three oncology practices (“study centres”) which are listed in table 3-1. 
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Table 3-1: Participating study centres 
 Name of study centre 
Oncology outpatient 
wards 
University Hospital Bonn, Centre of Obstetrics and Gynaecology 
University Hospital Bonn, Department of Internal Medicine 
Johanniter Hospital Bonn, Department of Internal Medicine 
Oncology practices PD Dr. Christian M. Kurbacher, Bonn 
Dr. Peter F. Schwindt, Bonn 
Dr. Hartmud Wolter, Bonn 
 
The pharmaceutical care service was delivered by the author of this paper and another 
research scientist of the Department of Clinical Pharmacy, University of Bonn (in the 
following referred to as “study pharmacists”). The data collection and analysis was carried out 
at the Department of Clinical Pharmacy, Institute of Pharmacy of the University of Bonn (in 
the following to be called “central study office”). 
Apart from the participating study centres the study was accompanied by the following 
cooperating partners, listed with job descriptions during the study period: 
• Dr. E.S. Dietrich, director of the TK Scientific Institute for Benefit and Efficiency in 
Health Care, Hamburg (advice concerning study design and method of data analysis) 
• Dr. R. Fimmers, Institute of Medical Biometrics, Computer Sciences and Epidemiology, 
University of Bonn (statistical advice) 
• Prof. Dr. S. Hudson, Professor of Pharmaceutical Care, University of Strathclyde, 
Glasgow, Scotland (advice on pharmaceutical care of oncology patients) 
• Pharmacist K. Ruberg, Kronen-Apotheke Marxen, Wesseling (advice on pharmaceutical 
care, data collection) 
3.3 Study design 
The gold standard for pharmacoeconomic evaluations is a randomized naturalistic study 
design in which randomized patients are treated with different therapies or methods under 
realistic every-day conditions for a long time period [69]. These studies are hard to carry out 
and are very expensive. Nevertheless, it is important to define and establish standards for 
pharmacoeconomic and pharmaceutical care research in order to obtain reliable data. The 
study aimed at approaching the pharmacoeconomic gold standard as closely as possible.  
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An open, prospective, multi-centred observational cohort study with preceding control group 
was chosen as study design (figure 3-1). In each study centre the control group was studied 
before the intervention group. The control group received standard care. The intervention 
group received intensified pharmaceutical care provided by the study pharmacists. Between 
December 2006 and February 2007 all study centres switched from recruiting control patients 
to recruiting intervention patients one by one. For this three-month period control and 
intervention patients were recruited at the same time but not at the same study centre. 
Figure 3-1: Study design  
3.4 Selection of patients 
To obtain a sufficient number of patients in the study period the following inclusion and 
exclusion criteria were defined. 
Inclusion criteria: 
• Patient is diagnosed with colorectal or breast cancer. 
• Patient receiving chemotherapy with capecitabine 
• as adjuvant therapy following surgery of colorectal cancer or as mono- or 
combination chemotherapy for metastatic colorectal cancer. 
• for breast cancer as mono- or combination chemotherapy. 
• Patient starting therapy with capecitabine no longer than one week before recruitment and 
being therapy-naïve concerning orally applied chemotherapeutic agents. 
• Patient is at least 18 years old. 
• Patient gives written informed consent. 
• Patient is able to speak, read and write German. 
Control group 
 
Intervention group 
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Exclusion criteria: 
• Patient suffers from diseases or mental states which impede that he completely 
understands the information on the study provided and/or which lead to an impaired 
capability of reading and completing questionnaires (e.g. Alzheimer´s disease). 
• Patient has the intention to change his place of residence (> 100 km). 
3.5 Patient recruitment and course of the study 
The participating physician informed the patient about the pharmaceutical care project. If the 
patient was interested in the study the physician handed over a special patient information 
brochure explaining the aim and the contents of the study (appendix B). The physician 
informed the patient that his name and telephone number would be passed on to the central 
study office that would contact him during the following working-day. The physician then 
transmitted the contact details to the central study office via fax (appendix B). The study 
pharmacists usually contacted the patient the following day and arranged a meeting for a 
personal conversation. The meeting either took place in the patient’s home, at the oncology 
outpatient ward / oncology practice or at the central study office. During the first conversation 
between the study pharmacist and the patient the aim, the content and the course of the study 
were explained in detail and the patient could ask questions concerning the study. If the 
patient agreed upon participating in the study, he signed the informed consent (appendix B) 
that also allowed the study pharmacist to inspect patient records and to analyse the collected 
data in a pseudonymous manner. Then the study pharmacist documented demographic patient 
data and the patient received a special study file that contained all needed patient 
questionnaires arranged according to the chemotherapy cycles of capecitabine. The study file 
also contained postage-paid, pseudonymously coded and addressed envelopes which were 
used by the patients to send each set of questionnaires to the central study office. 
The study protocol considered a period of six months for each patient. For the whole period 
the resource utilisation was assessed. The measured resource utilisation included the 
following direct disease-related costs: costs for pharmacotherapy, oncologist fee, diagnostic 
costs, administration costs, costs for pharmacist (only in intervention group) and inpatient 
costs. Indirect disease-related costs were also assessed for six months. The measurement of 
quality of life and hand-foot syndrome were orientated at the course of the treatment with 
capecitabine. As mentioned above each chemotherapy cycle with capecitabine consisted of 14 
days with twice daily drug intake followed by a seven-day break. Before the first (t0), after the 
third (t3) and after the sixth chemotherapy cycle (t6) (each time at the first day of therapy 
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break) the questionnaire on quality of life was completed. After each cycle (each time at the 
first day of therapy break) the questionnaire on hand-foot syndrome was filled in (t1, t2, t3, t4, 
t5, t6). At the end of the study after a period of six months the questionnaires on quality of life 
and hand-foot syndrome were completed again (t7). In case of discontinuation of capecitabine 
treatment the measurements were carried out in the same intervals. In the intervention group 
the patients´ “willingness-to-pay” for the pharmaceutical care service was assessed after six 
chemotherapy cycles (t6) (figure 3-2). 
Direct non-medical disease-related costs and the current employment situation were assessed 
with a patient questionnaire before the first (t0), after the sixth cycle (t6) and after six months 
(t7) (not shown in figure 3-2). 
For the cost and outcome assessment tools mentioned see appendix A. 
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Figure 3-2: Course of treatment, cost and outcome measurement  
(HFS = hand-foot syndrome, Cap = capecitabine, EQ-5D = quality of life questionnaire, IG = 
intervention group, WTP = willingness-to-pay, t = time of measurement) 
 
3.5.1 Control group 
According to the study protocol the patients of the control group should not receive additional 
pharmaceutical care and therefore no pharmaceutical advice was given. In case of questions 
from the patients the study pharmacists advised the patients to contact their physician. Only in 
case of urgent questions the patients received short advice from the study pharmacists. To 
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minimise the contact between the study pharmacists and the patients of the control group 
during the study period, the patients received a postal reminder at the end of each 
chemotherapy cycle (appendix C). This card should remind the patients to complete the 
respective questionnaires. Only if the patient did not respond within a certain period he was 
contacted by the central study office by telephone. 
3.5.2 Intervention group 
After signing the informed consent the pharmaceutical care service started immediately 
during this first personal conversation between the study pharmacist and the patient of the 
intervention group. During this first meeting the following issues were always discussed with 
each intervention patient: 
• Medication history including all prescribed and over-the-counter (OTC) medication 
(Why? Since when? How often? Which dose? Before, with or after meal? Does it help? 
Adverse drug reactions?)  
• Education concerning capecitabine 
- Pro-drug and tumour selectivity 
- Adverse drug reactions in general 
- Administration of capecitabine (usually 14 days of twice daily drug intake 
followed by a seven-day break; to be administered with water within 30 minutes 
postprandial; dosing interval approximately twelve hours) 
• Education concerning hand-foot syndrome, e.g. 
- Prophylaxis 
- Detection 
- Treatment 
During the course of this discussion that was completed with additional issues depending on 
the patient (e.g. concerning concomitant medication beside capecitabine, questions from the 
patient) the patient received the following information material to support the pharmaceutical 
care service: 
• An information brochure on prophylaxis and treatment of certain important adverse drug 
reactions (appendix C). This brochure was developed by the Department of Clinical 
Pharmacy at the University of Bonn in cooperation with the participating physicians. 
• A patient brochure containing advice concerning prophylaxis and management of hand-
foot syndrome developed by Roche Pharma AG. 
• A patient video about the chemotherapeutic agent Xeloda® of Roche Pharma AG. 
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• Relevant “Blaue Ratgeber” developed by the ‘Deutsche Krebshilfe’ (German Cancer Aid), 
also offering the possibility to order further copies. 
All important issues of this first patient-pharmacist consultation were documented in a 
documentation sheet (appendix C). Within the next few days after that consultation the study 
pharmacist sent an individual information letter to the patient repeating important subjects in 
a written form. This letter also contained a detailed drug administration plan considering all 
current medication and the result of a computer-based interaction check (DrugDex®, DIMDI 
PharmSearch®) as well as, if necessary, other information material (appendix C). 
In case of interactions that needed further discussion with the attending physician, the study 
pharmacist contacted the physician to find a common solution. During the course of the study, 
the study pharmacist had access to the patient files at regular intervals and stayed in close 
contact with the attending physicians. The study pharmacist contacted the patient at least 
every three weeks at the end of the drug intake period of each capecitabine cycle. The 
beginning and the end of the current and next cycle were discussed. The patient was 
questioned about adverse drug events during the last cycle, new medication and he had the 
opportunity to ask questions. Advice was given and/or the attending physician was contacted 
if necessary. Discussions with the patient as well as physician were documented in a specially 
prepared documentation sheet and were based on the pharmaceutical care plan in order to 
standardise the care process (both appendix C). In case of new medication the computer-based 
interaction check was repeated, the result was documented and communicated to the patient 
and/or the attending physician if necessary. The patients of the intervention group also had the 
possibility to contact the study pharmacists at certain times during the week via phone 
(Monday till Friday from 9 a.m. to 4 p.m.) if they had specific pharmaceutical questions that 
could not wait until the next regular patient-pharmacist contact. 
3.6 Study perspectives 
For the cost-utility analysis (see 3.9 “Cost-utility analysis”) a health insurance perspective 
was used. Hence only direct medical costs were taken into account as the health insurance had 
to reimburse these costs only. The outcomes also had to reflect the health insurance 
perspective which means that outcomes had to be valuated by the community insured. In the 
following cost section (see 3.7 “Cost assessment”) not only direct medical costs were taken 
into account but also indirect and direct non-medical costs which referred to a societal 
perspective. The willingness-to-pay of intervention patients (see 3.8. “Outcome assessment”) 
referred to a patient perspective. 
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3.7 Cost assessment 
In general, costs are calculated by multiplying the used amount of resources with their 
specific unit price. In the German health care system almost all prices are administrated 
prices. These prices are influenced by different stakeholders or determined by administrative 
proceedings and do not develop due to supply and demand. The latter are called market prices 
[69]. For example prices for pharmacotherapy are partly market-based but are influenced by 
many administrative processes [70]. Physician fees or prices for diagnostic tests in the 
statutory health insurance are determined by the National Association of Statutory Health 
Insurance Physicians (NASHIP, Kassenärztliche Bundesvereinigung, KBV) in cooperation 
with the German health insurances [71]. Prices for inpatient stays are also administrated 
prices. Although administrated prices do not reflect the real price of the resource used, they 
are relevant for the health insurances as these are the prices they have to pay. 
All costs refer to 2008. More precise details are mentioned in each cost section. 
3.7.1 Direct disease-related outpatient and inpatient costs 
3.7.1.1 Costs for pharmacotherapy 
The costs for disease-related pharmacotherapy can be divided into costs for antineoplastic 
therapy, e.g. capecitabine, and supportive therapy, e.g. ondansetrone against nausea and 
emesis.  
In three study centres the resource use of disease-related pharmacotherapy was obtained from 
directly searching the patient files. The resource use was documented in the resource use 
documentation form (appendix A). In the other three study centres these resource use data 
were obtained from hardcopies of electronic patient files (appendix A). In addition, study 
patients completed a questionnaire on pharmacotherapy after each chemotherapy cycle and 
after six months. They were asked to indicate all medication they were treated with (appendix 
A). If additional disease-related pharmacotherapy which was not documented in the patient 
files could be identified in these medication overviews, this was also considered in the cost 
calculation. All resource use data were transferred into Excel®-sheets for the calculation of 
costs. 
The prices for proprietary medicinal products were obtained from the ‘Lauer-Fischer-Taxe’ 
and refer to the cut-off date 15 March 2008. The ‘Lauer-Fischer-Taxe’ is an index of all 
announced proprietary medicinal products and the standard pharmacy goods that are admitted 
for trade in Germany and their corresponding price [72]. In case of exact naming of the 
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medicinal product including dose, package size and company the corresponding price could 
be found in the ‘Lauer-Fischer-Taxe’. If only the substance with dose and package size was 
documented, the cheapest product was chosen. If, in addition, the information on dose and/or 
package size was missing the lowest dose and the biggest package size was chosen. 
Prices for sterile preparations were calculated according to the cooperating pharmacy, Kronen 
Apotheke Marxen, in Wesseling. Their calculations were in agreement with general pharmacy 
practice and the recommendations of the German ‘Hilfs-Taxe’. The purchase prices of the 
medicinal products and the corresponding excipients taken from the ‘Lauer-Fischer-Taxe’ 
formed the basis of the calculation. An additional charge of 3 % as well as labour costs of 
€ 53 in case of cytostatic drugs were added to the sum of the purchase prices. For preparations 
that do not contain CMR substances (CMR = cancerogen, mutagen, reproduction toxicity) the 
additional labour costs amounted to € 40. Finally, value-added tax of 19 % was added. A 
calculation example is shown in table 3-2.  
Table 3-2: Calculation of the sterile preparation oxaliplatin (Eloxatin®) 112 mg in 500 ml  
Glucose 5 % (as of 2008) 
Purchase price Eloxatin® 100 mg: € 517.10 
Purchase price Eloxatin® 50 mg: € 264.55 
Purchase price glucose solution 5 %: € 2.70 
Sum: € 784.35 
Additional charge 3 %: € 23.53 
Additional labour costs: € 53.00 
Sum: € 860.88 
Value-added tax 19 %: € 163.57 
Sum: € 1024.45 
 
Erythrocyte concentrates have fixed prices. Information on these prices was obtained from the 
blood donor service of the German Red Cross (Deutsches Rotes Kreuz). Prices for filtered 
erythrocyte concentrates amounted to € 81.00 as of 2008. 
Patients´ out-of-pocket payment for medicinal products and sterile preparations were 
subtracted from the assessed prices, as these did not account for the costs of the health 
insurances. This was done for patients with a statutory health insurance as well as for patients 
with a private health insurance. It was neglected if individual patients were completely 
exempted from any out-of-pocket payment. 
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3.7.1.2 Oncologist fee  
In the statutory health insurance oncologist fees as well as diagnostic and administration 
services are coded by the so called EBM-system (Einheitlicher Bewertungsmaßstab). The 
EBM-system consists of digits that code for a certain service in the health care system. The 
same is true for the private health insurance. Here the GOÄ-system (Gebührenordnung für 
Ärzte) is applied. The digits in both systems stand for a certain number of points. Each point 
has a certain value. For the EBM-system as of 2008 the value of one point was assumed to be 
3.72 cents and in the GOÄ-system 5.83 cents. In some cases the digits of the EBM-system 
code directly for a certain amount of money, e.g. laboratory tests. In case of privately insured 
patients the accounts for medical services can be charged up to 2.3-fold depending on the 
medical service. For example accounts for laboratory tests are generally multiplied by 1.15, 
accounts for oncologist consultations by 2.3. 
The EBM and GOÄ digits discounted in this study population were classified on the basis of 
their literal meaning into the three categories oncologist fee, diagnostics and administration. 
Information on the charged oncologist fees were obtained either from directly searching 
patient files followed by a documentation in the resource use documentation form, from 
hardcopies of electronic patient file cards or hardcopies of accounting files from the 
ambulatory hospital administration (appendix A). The EBM digits were searched for digits 
coding for physician fees by comparing the digits with their actual literal meaning, e.g. 01311 
stands for “Basic charge for insurants from the beginning of the 6th until the end of the 59th 
year of life” and has a value of 175 points or € 6.51. The EBM digits coding for physician 
fees were then documented in an Excel®-sheet, translated into points and the points multiplied 
by the corresponding cent value to obtain the amount of money the health insurance had to 
pay. The same procedure was carried out with the GOÄ digits unless there were patient 
accounting files available that already contained the needed information. From the same data 
source the number of oncologist visits per patient plus visits to carry out diagnostic tests (e.g. 
CT scans, if documented in the patient file) during the study period was assessed. Visits at 
other physicians e.g. general practitioners were not assessed. 
3.7.1.3 Costs for diagnostics and administration 
The same procedure as described in chapter 3.7.1.2 “Oncologist fee” was used to assess the 
costs for diagnostics and administration that had to be paid by the health insurances.  
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3.7.1.4 Costs for the pharmacists 
In the intervention group costs for pharmacists presented yet another direct disease-related 
cost category of interest. 
The time spent by the study pharmacists to deliver pharmaceutical care was used as a measure 
for pharmacist costs. The pharmacists spent time for the following tasks:  
• the first pharmacist-patient consultation,  
• the following pharmacist-patient or pharmacist-physician consultations, 
• writing individual patient letters, including medication administration plans and 
interaction checks and 
• other pharmaceutical services (e.g. literature search, contact with pharmaceutical 
companies). 
The first pharmacist-patient consultations as well as the following pharmacist-patient or 
pharmacist-physician consultations were documented on the above-mentioned documentation 
sheets (appendix C). In most cases the documented time spent for the first pharmacist-patient 
consultation not only included the total time but also differentiated between time spent on 
explaining the study and time spent on pharmaceutical care issues. Only the median of the 
latter was used as a measure for pharmacist costs. For the time spent on writing patient letters 
and other pharmaceutical services plausible estimations were used. The assessed 
pharmaceutical care time per patient was then multiplied by an hourly wage of € 22.99. This 
complies with an hourly wage of an employed pharmacist in his second to fifth year on the 
job plus associated employer outlay of 23 % (gross wage € 2991 + 23 % = € 3679, 40 hours / 
week; € 3679 / (4 x 40) = 22.99 € / hour) and is in agreement with the national collective 
wage agreement of 2008 for employed pharmacists [73, 74]. 
3.7.1.5 Direct disease-related inpatient costs 
Diagnosis related groups (DRGs) form the basis for charges of hospitalisations in the 
statutory health insurance as well as in the private health insurance since 2003. DRGs are 
used to classify hospital cases into 500 to 1000 different groups according to e.g. diagnoses, 
procedures and the presence of complications. To obtain the case-based lump sum for a 
hospitalisation the so called base rate which is a certain charge for each hospital is multiplied 
with the relative weight of the DRG. For example the University Hospital Bonn had a base 
rate of € 2728.09 in 2008. The DRG J23Z, which means “Big intervention at the breast with 
malignant growth”, had a relative weight of 1.545. The product of the base rate and the 
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relative weight equals to the case-based lump sum of € 4214.90 that had to be paid by the 
health insurance [75, 76]. 
The receipts on hospitalisations of the study patients during the study period were directly 
received from the hospital controlling centres in case of hospitalisations in cooperating 
hospitals. In case of hospitalisations in other hospitals the patients themselves requested 
receipts of their hospitalisation charges from the corresponding controlling centre and sent 
hardcopies to the central study office (appendix A). The hospitalisations were checked for 
disease-relation and those related with cancer were chosen for further evaluation. 
Hospitalisations with debatable disease-relation were discussed with the attending oncologist. 
The DRGs indicated on the receipts were used to find their relative weighting in 2008 and 
multiplied by the hospital’s base rate of 2008 to receive the corresponding case-based lump 
sum. From the same data material the number of disease-related hospitalisations per patient 
during the study period was assessed. 
The case-based lump sum that has to be paid by the health insurance covers all procedures 
during an inpatient stay including pharmacotherapy and diagnostic tests. These inpatient costs 
for pharmacotherapy and diagnostics are not to be confused with the above-mentioned 
outpatient costs for pharmacotherapy and diagnostics. 
3.7.2 Direct non-medical disease-related costs: help with every-day activities 
Direct non-medical costs are not paid by the health insurance and reflect the societal 
perspective. As an example of direct non-medical costs, the need of help with every-day 
activities and also who mostly provided the help was queried with a patient questionnaire at 
t0, t6 and t7 (appendix A). If the patient answered the question “Did you need help with every-
day activities during the last two weeks? (e.g. eating, dressing, making coffee)” with “yes” he 
should indicate who mostly provided the help: family members/friends, professional nursing 
services, voluntary organisations or others. As it is a qualitative question in which the first 
part can only be answered with yes or no, no quantitative time measurement was done. The 
received information should give an overview whether these costs play a role in the studied 
patient group. 
3.7.3 Indirect non-medical disease-related costs: loss of productivity 
The indirect disease-related costs generally reflect the perspective of the society as these costs 
result from loss of productivity. Patients were questioned about their present employment 
situation at t0, t6 and t7 (appendix A). Patients that were still employed or currently unable to 
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work were questioned in more detail at the end of their study participation about their time of 
sick leave during the last six months (absenteeism from work). If a patient was unable to work 
during the whole study period 128 days of sick leave were assumed (study period = six 
months = 180 days including 26 weekends x 2 (Saturday, Sunday) = 52 days; 180 days – 52 
days = 128 days of sick leave). The days of sick leave were valuated in money terms 
according to the human capital approach. The gross average income in Germany amounted to 
€ 3127 per month as of 2008 [77]. The number of days on sick leave was multiplied by 
€ 142.14 to estimate the indirect disease-related costs in the present study. € 142.14 resulted 
from dividing € 3127 by 22 days assuming five working days per week and 30 days per 
month minus four weekends. 
Reduced productivity at work due to the patients´ illness was not measured. 
3.8 Outcome assessment 
3.8.1 Patients´ quality of life 
Patients´ quality of life was measured with the EQ-5D questionnaire, a generic instrument that 
was developed by the EuroQol Group, at t0, t3, t6 and t7 [78]. As it can be transformed into a 
single index or utility score it has considerable potential for use in pharmacoeconomic 
analysis and thus it is used very often in that field of research. The EQ-5D questionnaire 
consists of two parts, the descriptive system and the visual analogue scale (VAS) (appendix 
A).  
The EQ-5D descriptive system 
The descriptive system defines health in terms of the following five dimensions: 
• Mobility 
• Self-care 
• Usual activities 
• Pain / discomfort 
• Anxiety / depression 
Each dimension has three response categories corresponding to no problems (=1), some 
problems (=2) and extreme problems (=3). It defines a total of 243 possible health states (35 = 
243) to which two further states were added (dead and unconscious). The level of the reported 
problem (1, 2 or 3) on each of the five dimensions determines one out of the 243 possible 
health states and can be defined by a five-digit number. For example, state 21223 would 
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indicate level two on mobility (“I have some problems…”), no problems with self-care, some 
problems with usual activities and some pain / discomfort and extreme anxiety / depression. 
From that five-digit number the EQ-5D health status index, that can be used to calculate 
QALYs, can be derived. The generated utility score lies on a scale on which full health has 
the value 1 and death has the value 0. In the present study the EQ-5D self-classified health 
states were converted to that single summary index by applying scores from the standard set 
of preference weights derived from the German population [79]. The German standard set of 
preference weights was developed between 1997 and 1998 with 339 randomly selected 
subjects. A total of 35 health states was evaluated based on the TTO method (time-trade-off, 
see 3.8.3.2 “QALYs from hand-foot syndrome questionnaire”). A linear additive model 
specification was used to value all 245 possible health states. According to this model certain 
values were subtracted from 1 (= perfect health) depending on the patient’s self-classified 
health state (see table 3-3).  
Utility scores were only calculated if no cross was missing in the EQ-5D descriptive system. 
The absolute changes in utility scores between t0 and t3, t6 and t7, respectively, were 
calculated. 
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Table 3-3: Summary of the calculation of utility scores [79] 
German TTO set 
of preference weights 
Example: 
utility score for health state 21223 
Full health (11111) = 1 Full health (11111) = 1 
At least one 2 or 3: -0.001 -0.001 
At least one 3: -0.323  -0.323 
Mobility = 2: -0.099 -0.099 
Mobility = 3: -0.327 / 
Self care = 2: -0.087  -0.000 
Self care = 3: -0.174 / 
Usual activities = 2: -0.000 -0.000 
Usual activities = 3: -0.000 / 
Pain/discomfort = 2: -0.112 -0.112 
Pain/discomfort = 3: -0.315 / 
Anxiety/depression = 2: -0.000 / 
Anxiety/depression = 3: -0.065 -0.065 
 Health state 21223 = 0.400 
The EQ-5D visual analogue scale (VAS) 
In the second part of the EQ-5D questionnaire patients were asked to mark their current health 
state on a vertical 20 cm visual analogue scale (“thermometer”) calibrated from zero (= worst 
imaginable health state) to 100 (= best imaginable health state). The VAS is generally used in 
conjunction with the 5-digit classification of the descriptive system to build an accurate 
profile of the patient’s health status. The absolute changes in VAS scores between t0 and t3, t6 
and t7, respectively, were calculated. 
The two parts of the EQ-5D questionnaire were only assessed for patients under treatment 
with capecitabine. If treatment with capecitabine was discontinued or a new antineoplastic 
therapy without capecitabine was started the completed questionnaires of that period were not 
analysed.  
3.8.2 Adverse effect hand-foot syndrome (HFS) 
HFS is a dose- and therapy-limiting toxicity in cancer patients under treatment with 
capecitabine. If not managed properly it can develop from mild skin reactions at the hands 
and feet (grade 1) to major skin reactions with bleeding, ulceration and severe pain (grade 3). 
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The HFS grade was assessed after each capecitabine cycle and after six months (t1, t2, t3, t4, t5, 
t6, t7) by a patient questionnaire (appendix A). The patients were asked to mark the particular 
grade of HFS with a cross that best characterised their current condition. The different HFS 
grades on the questionnaire were described according to the “Common Terminology Criteria 
for Adverse Events” (CTCAE) Version 3.0 of the National Cancer Institute, USA. Only those 
HFS questionnaires were evaluated in which the patient was under treatment with 
capecitabine. If treatment with capecitabine was stopped or a new antineoplastic therapy 
without capecitabine was started the completed questionnaires of that period were not 
analysed. 
3.8.3 Quality-adjusted life years (QALYs) 
QALYs present the outcome parameter in a cost-utility analysis. The background of the 
QALY is the combination of quality and quantity of life in one concept. Figure 3-3 illustrates 
the basic principle of the QALY. 
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Figure 3-3: Concept of the QALY 
 
The Y axis represents the utility score between 0 and 1 which can be considered, simply put, 
as a “quality of life” level. The X axis stands for a certain time period. The patient in 
figure 3-3 has lived for 10 years since the time of diagnosis. His average quality of life during 
these 10 years had a value of 0.8 on the scale. In terms of QALYs that means that he had 0.8 x 
10 = 8 QALYs. Each of the 10 life years had a utility score of 0.8 and the number of life 
years, in his case 10, is adjusted to their respective quality [8]. 
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3.8.3.1 QALYs from EQ-5D questionnaire  
As mentioned in chapter 3.8.1 “Patients´ quality of life”, the answers to the descriptive system 
of the EQ-5D questionnaire during treatment with capecitabine were transferred into utility 
values by the German TTO set of preference weights. These utility values were then used to 
calculate QALYs as illustrated in figure 3-4. 
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Figure 3-4: QALYs from EQ-5D questionnaire 
 
The Y axis again represents the utility score between 0 and 1. The X axis represents the time 
in days, with the four points of measurement at t0 (day 0), t3 (day 57), t6 (day 120) and t7 (day 
180). The area under the curve (AUC) corresponds to the number of quality-adjusted life days 
(QALDs). In the present study the QALDs were divided by 365 days to obtain QALYs. The 
AUC was assessed with Microsoft Excel® according to the trapezoidal method, where the area 
under the curve is defined through the function ( )xf  for the interval [ ]h,0 : 
( ) ( ) ( ) ( )∫ +⋅≈h fhfhxdxf
0 2
0   (Eq. 1) 
The best achievable QALD or QALY result was 180 QALDs or 0.49 QALYs respectively 
according to this formula and the study period of 180 days (180 days divided by 365 days = 
0.49 years). To achieve this result a patient would need a utility score of 1.000 (= perfect 
health) at all four points of measurement. 
QALDs and QALYs were only calculated for those patients whose measurement was 
available for all four points (= analysis of completers´ data). 
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3.8.3.2 QALYs from hand-foot syndrome questionnaire 
The assessed HFS grades during therapy with capecitabine (see 3.8.2 “Adverse effect hand-
foot syndrome (HFS)”) were converted into utility scores. The completed HFS questionnaires 
during periods without capecitabine treatment were not evaluated in this respect. The utility 
scores used were generated earlier in a diploma thesis at the Department of Clinical 
Pharmacy, University of Bonn [80]. In that diploma thesis a survey was conducted in a 
German community pharmacy in 2007. 53 randomly chosen subjects were introduced to the 
symptoms of HFS using cards explaining the different HFS grades by pictures of hands and 
feet, a clinical definition and citations of patients who had suffered from the particular HFS 
grade. Participants were first asked to value their own health state using the EQ-5D 
questionnaire followed by a test exercise in which the subjects had to assess a particular 
severity grade of heart failure using the VAS and the time-trade-off method (TTO). Then they 
valuated the different severity grades of HFS using the VAS and the TTO method. Both 
methods are two direct approaches to generate utility scores. The TTO method was developed 
specifically for use in health care by Torrance et al. in 1972 [81]. The application of the TTO 
technique to a chronic HFS state is illustrated in figure 3-5. 
 
Figure 3-5: TTO method to generate utility scores for HFS grades [3] 
 
During the application of the TTO technique the subject was offered two alternatives: 
• State i (current health state) for time X (here 10 years) followed by death, or 
• State 1  (perfect health state) for time Y followed by death. 
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Time Y was varied until the respondent was indifferent between the two alternatives. At this 
point the utility score was calculated using the following formula: 
X
Yhi =  (Eq. 2) 
Table 3-4 shows the HFS grades and the corresponding assessed median utility scores. 
Table 3-4: HFS grades and corresponding utility scores [80] 
HFS grade Utility score (median)  (TTO technique) 
0 1.00 
1 0.97 
2 0.72 
3 0.34 
 
The utility scores listed in table 3-4 were used to calculate QALYs according to the approach 
presented in chapter 3.8.3.1 “QALYs from EQ-5D questionnaire”. In contrast to the utility 
scores obtained from the EQ-5D questionnaire the HFS-based utilities were assessed seven 
times: at t1, t2, t3, t4, t5, t6 and t7 (days: 15, 36, 57, 78, 99, 120, 180). The utility score on day 0 
(t0) was assumed to be 1.00. If one of the first six measurement points was missing the utility 
– time - curve was plotted without that point of measurement and the QALYs were calculated. 
If the last measurement point or more than one measurement point were missing QALYs were 
not calculated for that patient. 
3.8.4 Patients´ “willingness-to-pay” for pharmaceutical care service 
The “willingness-to-pay” survey is a measurement technique often used in a cost-benefit 
analysis. Outcomes of health programmes such as the pharmaceutical care service are broadly 
defined in a cost-benefit analysis. Outcomes might comprise improvements in health status, 
the value of being better informed or the value associated with the process of care. Cost-
benefit analysis that use the “willingness-to-pay” approach can be understood as attempts to 
examine unknown markets and to measure underlying consumer demand and valuation for 
non-marketed social goods such as health care programmes [3].  
In the present study the patients of the intervention group were asked to complete the 
“willingness-to-pay” questionnaire at t6 (appendix A). This questionnaire was specifically 
developed for the study. The patients were required to imagine that there is an actual market 
existing for the pharmaceutical care service they had experienced and to reveal the maximum 
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amount of money they would be willing to pay for such a service per month. Furthermore, 
they were asked to state their household net income and size of household. 
3.9 Cost-utility analysis 
In a cost-utility analysis the outcome is measured in quality-adjusted life years (QALYs), a 
complex measure that links a time period with the patient’s quality of life during that time. 
The results can be expressed as an incremental cost-utility ratio (ICUR) in costs per QALY 
gained. 
3.9.1 Retrospective identification of matched-pairs 
To be able to compare patients of the control group with patients of the intervention group in 
a cost-utility analysis it was important to identify matched-pairs between these two patient 
groups as the patients of the present study were not randomized. The matching is an 
alternative approach to control for the effects of a covariate. It is a common technique in case-
control and cohort studies. Each member of a group is matched to one or more members of 
the other group with respect to the values of one or more covariates. However, the risk of bias 
persists as there might be unknown differences or differences difficult to determine also 
known as “confounders” [82]. 
The following main matching parameters were defined: 
• Tumour entity (breast or colorectal cancer),  
• Treatment setting (adjuvant, neoadjuvant or palliative), 
• Antineoplastic regimen at the time of inclusion (e.g. capecitabine monotherapy, 
capecitabine oxaliplatin combination therapy,…), not considering anti-estrogen therapy, 
• Treatment with bisphosphonates at the time of inclusion, 
• Type of health insurance (statutory or private health insurance). 
Only those patients were allowed to enter the matching process whose complete outpatient 
and inpatient cost data as well as EQ-5D descriptive system measurements were available. 
Also those EQ-5D questionnaires were analysed in which the patient stopped treatment with 
capecitabine or started a new antineoplastic therapy without capecitabine. If a patient died 
during the study the utility score for the following points of measurement was supposed to be 
0.000 (= dead) for that patient. 
Patients and Methods  39 
 
3.9.2 Incremental cost-utility ratio 
For the matched patient pairs the ICUR should be calculated according to the following 
formula: 
CGIG
CGIG
QALYsQALYs
CostsCosts
−
−
 (Eq. 3) 
where IG stands for intervention group and CG for control group. The mean direct disease-
related costs including outpatient and inpatient costs plus pharmacist costs were considered in 
the intervention group. The considered direct disease-related costs of the control group 
included outpatient and inpatient costs. Concerning the outcome QALYs there were two 
different QALY values available: QALYs based on the EQ-5D questionnaire and QALYs 
based on the HFS questionnaire. The ICUR should be calculated separately for both mean 
QALY values. Equation 3 leads to an estimate of the cost and effect differences. To present 
the uncertainty in that estimate a nonparametric bootstrapping was performed and a cost-
effectiveness acceptability curve was plotted. 
3.9.3 Nonparametric bootstrapping 
Bootstrapping is a resampling procedure that employs computing power to estimate the 
empirical distribution of cost-effectiveness. The approach involves a three-step procedure:  
1. Sample with replacement nCG Cost/QALY pairs from the patients in the control group 
(where nCG is the number of patients observed in the control group) and calculate the 
mean cost and effect in this bootstrap resample. 
2. Sample with replacement nIG Cost/QALY pairs from the patients in the intervention 
group (where nIG is the number of patients observed in the intervention group) and 
calculate the mean cost and effect in this bootstrap resample. 
3. Using the bootstrapped means from the steps above, calculate the difference in 
QALYs between the groups, the difference in cost between the groups and an estimate 
of the incremental cost-effectiveness. 
This three-step procedure provides one bootstrap replication of the incremental cost-utility 
[83]. This process was repeated 10000 times to generate the empirical distribution of cost-
effectiveness. 
Furthermore, a cost-effectiveness acceptability curve was drawn plotting the proportion of 
bootstrap replications whose ratios fell below a certain cost-effectiveness threshold ratio (λ). λ 
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was varied from 0 through ∞. This graphic illustrates the probability of cost-effectiveness for 
different threshold ratios (costs/QALY) [83]. 
3.9.4 Sensitivity analysis 
A sensitivity analysis is a technique to handle uncertainties in a pharmacoeconomic 
evaluation. During the analysis of cost and outcome data the author of this work identified 
critical methodological assumptions. On the basis of these the following sensitivity analyses 
were accomplished to investigate the robustness of the ICUR: 
• Two simple one way analyses:  
- Double costs for pharmacists of € 45.98/hour were assumed, as the hourly wage of 
€ 22.99 is based on the national collective wage agreement for employed pharmacists. 
If pharmacists provided the pharmaceutical care service as e.g. a freelancer they would 
have to charge more money. 
- The transformation of the EQ-5D digit into utilities was based on the UK TTO set of 
preference weights. This set is widely used in pharmacoeconomic analyses and was 
generated with more participants (n = 3235) than the German TTO set [84].  
• One analysis of extremes:  
- Following the matching process some patients had to be selected at random which is 
an established approach. Due to the limited sample size of the cost-utility analysis the 
selection of patients probably had an influence on the result of the ICUR. Therefore 
those patients leading to the best possible ICUR (best case) and those patients leading 
to the worst possible ICUR (worst case) were combined and evaluated in two separate 
sensitivity analyses.  
3.10 Study hypotheses 
The following hypotheses were investigated in the pilot study: 
• The direct disease-related outpatient costs are reduced by pharmaceutical care. 
• The direct disease-related inpatient costs are reduced by pharmaceutical care. 
• Patients´ quality of life is increased by pharmaceutical care. 
• The adverse drug reaction hand-foot syndrome is improved by pharmaceutical care. 
• More quality-adjusted life years (QALYs) are gained by pharmaceutical care. 
• Indirect disease-related costs are reduced by pharmaceutical care. 
• The need of help with every-day activities as a measure of direct non-medical disease-
related costs is reduced by pharmaceutical care. 
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• The intervention patients´ willingness-to-pay for the pharmaceutical care service is as 
high as the pharmacist costs to deliver pharmaceutical care. 
• The cost-utility analysis shows that the pharmaceutical care intervention is a cost-effective 
service. It is considered cost-effective if the additional cost per QALY lies below € 29000 
/ QALY (=₤ 20000 / QALY). This threshold is based on a review on NICE`s 
recommendations [85]. 
3.11 Statistical analysis 
For all statistical analyses the software SPSS® version 17 was used except for the 
nonparametric bootstrapping which was performed with SAS®. 
Patient characteristics 
Differences in age between control and intervention as well as between breast and colorectal 
cancer patients were tested with the parametric t-test for independent samples. Other patient 
characteristics were evaluated in respect of their absolute and relative frequency distribution. 
Differences between the control and intervention group in the other patient characteristics at 
the time of inclusion were tested with the Fisher`s exact test. 
Direct disease-related outpatient and inpatient costs 
Differences in outpatient, inpatient and total costs, in number of oncologist visits, in number 
of hospitalisations and in number of days in the study between the control and intervention 
group were tested with the nonparametric Mann-Whitney-U test for independent samples. 
Also mean, median and standard deviation were calculated. Costs for the pharmacist in the 
intervention group were evaluated descriptively. 
Direct non-medical disease-related costs: help with every-day activities 
The need of help with every-day activities in control and intervention patients at t0, t6 and t7 
was evaluated in respect of its absolute and relative frequency distribution. Differences 
between the control and intervention group at these three times were tested with the Fisher`s 
exact test for nominal data. The differences within the control and intervention group 
respectively between the first and the second measurement and between the first and the last 
measurement were tested with the McNemar test for nominal data. The answer concerning the 
help provider was evaluated regarding the absolute and relative frequency distribution. 
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Indirect non-medical disease-related costs: loss of productivity 
The current employment situation in control and intervention patients at t0, t6 and t7 was 
evaluated in respect of its absolute and relative frequency distribution. Differences between 
the control and intervention group at these three times were tested with the Fisher`s exact test. 
The differences within the control and intervention group, respectively, between the first and 
the second measurement and between the first and the last measurement were tested with the 
McNemar test for nominal data. For this test the patients were arranged in two groups: one 
group for patients that were able to work (full-time or part-time job) and one group for 
patients that were unable to work. Other categories like housewife or pensioner were not 
considered. Differences between control and intervention group concerning the days on sick 
leave and indirect costs were tested with the Mann-Whitney-U test. 
Quality of life measurement with EQ-5D questionnaire 
The results of the descriptive system of the EQ-5D questionnaire were evaluated with the help 
of relative frequency distributions at t0, t3, t6 and t7 separately for control and intervention 
patients. Mean, median and standard deviation were calculated for each of the five 
dimensions. 
Utility scores as well as EQ-5D VAS scores were evaluated descriptively calculating mean, 
median, standard deviation and interquartile range at t0, t3, t6 and t7. Differences in absolute 
changes in utility / VAS scores at t0 and t3 (t6, t7) between control and intervention patients 
were tested with the Mann-Whitney-U test. The absolute changes were illustrated as boxplots. 
Adverse effect hand-foot syndrome 
Descriptive statistics calculating median and interquartile range of hand-foot syndrome grades 
at seven different points in time (t1, t2, t3, t4, t5, t6, t7) were performed. Boxplots were chosen for 
graphical presentation. Differences between the control and intervention patients were 
analysed with the Cochran-Armitage test for trends. 
HFS-based utility scores were evaluated descriptively calculating median and interquartile 
range at t1, t2, t3, t4, t5, t6, and t7. 
Quality-adjusted life years 
QALYs and QALDs (quality-adjusted life days) were analysed descriptively by assessing 
mean, median, standard deviation and interquartile range for both patient groups. The Mann-
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Whitney-U test was used to test for statistically significant differences between the two 
patient groups. A utility-time curve was used for graphical presentation. 
Willingness-to-pay 
The willingness-to-pay (WTP) in the intervention group was analysed descriptively. It was 
tested for a correlation with the household net income as well as the net income per household 
member by applying a trend line and calculating the coefficient of determination (R2). The 
difference in WTP between patients with a statutory and a private health insurance was 
evaluated with the Mann-Whitney-U test. 
Cost-utility analysis 
Differences in outpatient and inpatient costs between the selected control group and the 
selected intervention group were tested with the nonparametric Mann-Whitney-U test for 
independent samples. Also mean, median and standard deviation were calculated. QALYs and 
QALDs (quality-adjusted life days) were analysed descriptively by assessing mean, median 
and standard deviation for both selected patient groups. The Mann-Whitney-U test was used 
to test for statistical significant differences between the two selected patient groups. 
Concerning the incremental cost-utility ratio the non-parametric bootstrapping as described in 
chapter 3.9.3 was used to estimate the empirical distribution of cost-effectiveness and a cost-
effectiveness acceptability curve was plotted. Furthermore sensitivity analyses as described in 
chapter 3.9.4 were applied. 
Study drop-outs and missing data 
Patients who dropped out of the study, e.g. because they withdrew their informed consent, 
were not analysed. All outcome data collected until then were not used for further analysis. 
This is known as a per protocol analysis (PP). 
In case of missing patient data for a certain outcome, only the available data of a patient were 
evaluated (analysis of completers´ data). Imputation methods as e.g. last observation carried 
forward (LOCF) were not used. 
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4 Results 
4.1 Patient recruitment 
Patients were recruited on three oncology outpatient wards (two Departments of Internal 
Medicine and one Department of Obstetrics and Gynaecology) and three oncology practices. 
Between May 2006 and April 2008, 100 ambulatory patients were reported to the central 
study office by the cooperating oncologists. From these 100 patients, 78 were included into 
the study and 76 were finally analysed. Figure 4-1 shows the patient recruitment in the control 
group and the intervention group in a flow diagram. 
In each patient group one patient was lost to follow-up (study drop-out). Both patients 
withdrew their informed consent. Reasons for the control patient to drop out were bad news 
from his oncologist regarding his progression of disease. In the intervention group the patient 
refused to receive pharmaceutical care. The patient wanted to receive information from his 
attending oncologist and general practitioner only. 
4.2 Patient characteristics 
As shown in figure 4-1 76 patients were analysed, 30 belonged to the control group and 46 to 
the intervention group. At the time of inclusion control patients had a mean age of 63.0 years 
(SD: 12.8; median: 64.5; IQR: 53-71.3; min.: 33; max.: 85) and intervention patients of 57.5 
years (SD: 12.5; median: 58.0; IQR: 49.8-65; min.: 28; max.: 93 years). The intervention 
patients were 5.5 years younger in the mean. This difference was not statistically significant 
(p = 0.067, t-test). At the time of inclusion breast cancer patients had a median age of 55 years 
(25 % percentile: 48; 75 % percentile: 64; minimum: 28; maximum: 80 years), while 
colorectal cancer patients showed a median of 64 years (25 % percentile: 57.5; 75 % 
percentile: 71.5; minimum: 30; maximum: 93 years). This difference observed was 
statistically significant (p = 0.001, t-test). 
The socio-demographic and disease-related patient characteristics of both groups are listed in 
table 4-1 and table 4-2.  
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Intervention Group: First patient in 12/2006, Last patient in 04/2008, Last patient out 10/2008 
Assessed for eligibility (n = 52) 
Excluded (n = 5) 
 
  Not meeting inclusion criteria (n = 4) 
 Refused to participate (n = 1)
Analysed (n = 46) 
Lost to follow-up (n = 1) 
Reason: withdrew informed 
consent 
Allocated to IG (n = 47) 
Received pharm. care (n = 47) 
Analysis 
Follow-Up 
Enrollment 
Analysis Analysed (n = 30) 
Follow-Up 
Lost to follow-up (n = 1) 
Reason: withdrew informed consent 
Assessed for eligibility (n = 48) 
Excluded (n = 17) 
 
  Not meeting inclusion criteria (n = 8) 
  Refused to participate (n = 5) 
  Other reasons (n = 4) 
Allocated to CG (n = 31) 
Received standard care (n = 31) 
Enrollment 
Control Group: First patient in 05/2006, Last patient in 02/2007, Last patient out 08/2007  
 
CG = control group, IG = intervention group 
 
Figure 4-1: Patient recruitment flow diagram 
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Table 4-1: Socio-demographic patient characteristics at the time of inclusion (control 
group n=30; intervention group n=46) 
Socio-demographic variable Control group Intervention group 
P 
value* 
  n % n %  
Age 
< 50 years old 
50-60 years old 
> 60 years old 
3 
10 
17 
10.0 
33.3 
56.7 
11 
14 
21 
23.9 
30.4 
45.7 
0.301 
Sex Female  Male 
24 
6 
80.0 
20.0 
33 
13 
71.7 
28.3 0.589 
Health insurance Statutory Private 
29 
1 
96.7 
3.3 
32 
14 
69.6 
30.4 0.003 
Marital status 
Married / partner 
Single 
Divorced 
Widow 
No answer 
19 
4 
1 
6 
0 
63.3 
13.3 
3.3 
20.0 
0.0 
39 
4 
1 
2 
0 
84.8 
8.7 
2.2 
4.3 
0.0 
0.085 
Current living 
situation 
Living alone 
With family / partner 
Living in institution 
Other 
No answer 
8 
21 
0 
1 
0 
26.7 
70.0 
0.0 
3.3 
0.0 
2 
43 
0 
1 
0 
4.3 
93.5 
0.0 
2.2 
0.0 
0.011 
Education 
Elementary school 
Secondary school 
O-levels 
Journeyman 
Master of a trade 
Bachelor 
University / College 
No answer 
8 
8 
2 
5 
1 
3 
2 
1 
26.7 
26.7 
6.7 
16.7 
3.3 
10.0 
6.7 
3.3 
11 
9 
2 
6 
1 
3 
14 
0 
23.9 
19.6 
4.3 
13.0 
2.2 
6.5 
30.4 
0.0 
0.306 
Current employment 
situation 
Full-time job 
Part-time job 
Unemployed 
Unable to work 
Pensioner 
Housewife/ -man 
Student 
No answer 
3 
2 
0 
6 
18 
1 
0 
0 
10.0 
6.7 
0.0 
20.0 
60.0 
3.3 
0.0 
0.0 
5 
4 
0 
14 
18 
5 
0 
0 
10.9 
8.7 
0.0 
30.4 
39.1 
10.9 
0.0 
0.0 
0.458 
*Fisher`s exact test (the category no answer was not considered) 
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Table 4-2: Disease-related patient characteristics at the time of inclusion (control group 
n=30; intervention group n = 46) 
Disease-related variable Control group Intervention group P value* 
  n % n %  
Tumour entity Breast cancer Colorectal cancer 
16 
14 
53.3 
46.7 
23 
23 
50.0 
50.0 0.818 
Treatment 
Curative 
(adjuvant/neoadjuvant) 
Palliative 
7 
(3/4) 
23 
23.3 
(13.3/10.0) 
76.7 
14 
(13/1) 
32 
30.4 
(28.2/2.2) 
69.6 
0.604 
Therapy 
regimen at 
inclusion1  
 
Cap 
Cap Beva 
Cap Beva Iri 
Cap Beva Ox 
Cap Cet Iri 
Cap Lap 
Cap Mil 
Cap Mit 
Cap Ox 
Cap Pac 
Cap Tras 
Cap Tras Vin 
Cap Vin 
12 
4 
1 
2 
0 
0 
0 
1 
3 
1 
3 
2 
1 
40.0 
13.3 
3.3 
6.7 
0.0 
0.0 
0.0 
3.3 
10.0 
3.3 
10.0 
6.7 
3.3 
15 
6 
2 
1 
3 
2 
1 
0 
8 
5 
3 
0 
0 
32.6 
13.0 
4.3 
2.2 
6.5 
4.3 
2.2 
0.0 
17.4 
10.9 
6.5 
0.0 
0.0 
0.387 
Time since 
diagnosis 
< ½ year 
½ year to 2 years 
> 2 years 
8 
10 
12 
26.7 
33.3 
40.0 
14 
12 
20 
30.4 
26.1 
43.5 
0.834 
Therapy setting 
Oncology outpatient 
ward 
Oncology practice 
18 
 
12 
60.0 
 
40.0 
36 
 
10 
78.3 
 
21.7 
0.121 
*Fisher`s exact test 
1Therapy regimen: Cap = capecitabine monotherapy; Cap Beva = capecitabine + bevacizumab; Cap Beva Iri = 
capecitabine + bevacizumab + irinotecan; Cap Beva Ox = capecitabine + bevacizumab + oxaliplatin; Cap Cet 
Iri = capecitabine + cetuximab + irinotecan; Cap Lap = capecitabine + lapatinib; Cap Mil = capecitabine + 
miltefosin; Cap Mit = capecitabine + mitomycin; Cap Ox = capecitabine + oxaliplatin; Cap Pac = capecitabine 
+ paclitaxel; Cap Tras = capecitabine + trastuzumab; Cap Tras Vin = capecitabine + trastuzumab + 
vinorelbin; Cap Vin = capecitabine + vinorelbin  
1Endocrine therapies (e.g. tamoxifen, exemestan, fulvestrant), treatment with bisphosphonates and radiation 
therapy are not considered. 
4.3 Direct disease-related outpatient and inpatient costs 
Direct disease-related outpatient costs 
Table 4-3 gives an overview of the different outpatient cost categories that were paid for by 
the respective health insurance in both patient groups. The number of oncologist visits during 
the study period is also shown. 
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Table 4-3: Direct disease-related outpatient costs, number of oncologist visits and study 
period 
 
Anti- 
neopl. 
therapy 
[€] 
Supp. 
therapy 
 
[€] 
Oncologist 
fee 
 
[€] 
Diagn.
cost 
 
[€] 
Admin. 
cost 
 
[€] 
No. 
visits 
 
[n] 
Study 
period
 
[days] 
Control group        
n: 30 30 30 30 30 30 30 
Sum: 
%: 
Median cost/patient: 
Mean cost/patient: 
SD: 
466949 
83.8 
8543 
15565 
19449 
63113 
11.3 
1257 
2104 
2450 
18025 
3.2 
369 
601 
637 
8521 
1.5 
238 
284 
319 
572 
0.1 
17 
19 
13 
459 
/ 
14 
15 
9 
4912 
/ 
180 
164 
38 
Intervention group        
n: 46 46 45 45 45 45 46 
Sum: 
%: 
Median cost/patient: 
Mean cost/patient: 
SD: 
691210 
84.7 
13748 
15026 
11667 
72949 
8.9 
1443 
1586 
1177 
25537 
3.1 
490 
568 
454 
26209 
3.2 
260 
582 
719 
306 
0.03 
1 
7 
10 
561 
/ 
11 
12 
6 
7631 
/ 
180 
166 
41 
P value*: 0.366 0.903 0.871 0.230 0.000 0.235 0.874 
*Mann-Whitney-U test, SD = standard deviation, Supp. = supportive, Diagn. = diagnostic, Admin. = 
administration, No. = number 
 
In both patient groups most of the money was spent on antineoplastic therapy, followed by 
supportive therapy. In the control group more money was spent on the oncologist fee than on 
diagnostics in contrast to the intervention group. In both groups administrative costs were 
negligibly small. The cost differences between control and intervention patients were not 
statistically significant except in the category administration costs. The median number of 
oncologist visits was 14 in the control and 11 in the intervention group; the difference was not 
statistically significant. The median study period was 180 days in both patient groups. 
Appendix D shows the EBM and GOÄ digits assessed in this study and their respective value 
and meaning. The digits were classified into the categories oncologist fee, diagnostics or 
administration according to their literal meaning. The direct disease-related outpatient costs 
are also shown in appendix D separately for each patient. 
Costs for pharmacist 
The first pharmacist-patient consultation lasted 78 minutes in the median (n = 46; mean: 83 
minutes, SD: 21, min.: 44, max.: 140). In 15 cases it was differentiated between the time spent 
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on explaining the study (protocol-driven time) and time spent on pharmaceutical care issues 
[3]. A median of 46 minutes were spent on explaining the study (mean: 47 minutes, SD: 15, 
min.: 19, max.: 80) and a median of 40 minutes were spent on pharmaceutical care issues 
(mean: 41 minutes, SD: 18, min.: 16, max.: 70). For the following pharmacist-patient or 
pharmacist-physician consultations a median of 131 minutes per patient were needed (mean: 
123 minutes, SD: 59, min.: 9, max.: 256). For writing individual patient letters including 
medication administration plans and interaction checks 60 minutes per patient were estimated 
as well as 15 minutes per patient for other pharmaceutical services. 
In total the study pharmacist spent 246 minutes per patient (4.1 hours) to deliver 
pharmaceutical care during the study (40 + 131 + 60 + 15 minutes). This amounted to 
pharmacist costs of € 22.99 x 4.1 hours = € 94.26 per patient for a pharmaceutical care period 
of six months or € 4335.91 for the whole patient population in a study period of six months. 
As some intervention patients received pharmaceutical care for a shorter time period since 
they died before the end of the study, the total cost for the whole intervention population 
amounted to € 3996.10 (7631 study days x € 94.26/180 days). This represented 0.41 % of 
total direct costs in the intervention group. An overview of the documented pharmacist time 
can be seen in appendix D. 
Direct disease-related inpatient costs 
Eighteen of 30 control (60 %) and 19 of 46 intervention patients (41 %) had disease-related 
inpatient stays during the study period. Twelve control (40 %) and 27 intervention patients 
(59 %) were not hospitalised.  
There was a total number of 32 hospitalisations in the control and of 30 hospitalisations in the 
intervention group. Hospitalisations were necessary in the control group due to: i.v. 
administration of chemotherapy (6), surgery (6), disease-related complications (5), 
toxicity/adverse drug reaction (4), progression (4), surgery following neoadjuvant treatment 
(4), unknown reasons (2) and diagnostic tests (1). Hospitalisations were necessary in the 
intervention group due to: disease-related complications (14), diagnostic tests (6), progression 
(6), surgery following neoadjuvant treatment (2), toxicity /adverse drug reaction (1) and i.v. 
administration of chemotherapy (1).  
The median number of inpatient stays per patient was 1.0 in the control group (mean: 1.1, SD: 
1.4) and 0.0 in the intervention group (mean: 0.7, SD: 0.9). The difference in the number of 
hospitalisations per patient was not statistically significant (p = 0.201, Mann-Whitney-U). A 
total amount of € 114327.35 was paid for inpatient stays in the control group and of 
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€ 137194.02 in the intervention group. The median inpatient costs per patient in the control 
group amounted to € 1959.13 (mean: € 3810.91, SD: € 4617.88) and to € 0.00 (mean: 
€ 2982.48, SD: € 6127.89) in the intervention group. The difference was not statistically 
significant (p = 0.112, Mann-Whitney-U).  
For more details concerning inpatient costs per patient and for an overview of cancer-related 
DRGs see appendix D. 
Total direct disease-related costs (outpatient and inpatient) 
Figure 4-2 shows the distribution of direct disease-related outpatient and inpatient costs for 
the control and intervention group as boxplots. 
In both patient groups most costs arose through the antineoplastic therapy (control group 
70 %, intervention group 73 %), followed by inpatient costs (control group 17 %, intervention 
group 14 %) and then costs for supportive therapy (control group 9 %, intervention group 
8 %). In the intervention group the oncologist fee and costs for diagnostics were equal (3 % 
and 3 %). In the control group the oncologist fee (3 %) was higher than costs for diagnostics 
(1 %). In both patient groups costs for administration were negligible small (control group 
0.1 %, intervention group 0.0 %). 
The mean total costs per patient amounted to € 22384 (median: € 16224, SD: € 20362) in the 
control group. In the intervention group the mean total cost per patient amounted to € 20726 
(median: € 20020, SD: € 12790). The difference was not statistically significant (p = 0.832, 
Mann-Whitney-U). 
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Figure 4-2: Direct disease-related outpatient and inpatient costs as boxplots 
(For reasons of clarity two extreme values in the control group were excluded (costs for 
antineoplastic therapy of € 93319 and € 51112). In the intervention group the categories 
oncologist fee, diagnostic cost and administration cost have an n of 45 because of missing 
values.) 
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4.4 Direct non-medical disease-related costs  
Help with every-day activities 
Table 4-4 shows the answers of the control and intervention patients to the question if they 
needed help with every-day activities. The question was answered three times during the 
study. 
Table 4-4: Need of help with every-day activities at three different time-points  
Time Need of help Control group Intervention group P value*
  n % n %  
t0 
Yes  
No 
Questionnaire missing
6 
24 
0 
20.0 
80.0 
0.0 
14 
32 
0 
30.4 
69.6 
0.0 
0.426 
t6 
Yes  
No 
Questionnaire missing
6 
19 
0 
24.0 
76.0 
0.0 
9 
31 
1 
22.0 
75.6 
2.4 
1.000 
t7 
Yes  
No 
Questionnaire missing
4 
18 
3 
16.0 
72.0 
12.0 
4 
29 
6 
10.3 
74.4 
15.3 
0.700 
*Fisher´s exact test 
 
At t6 five patients had died in each group (17 % control group, 11 % intervention group). At t7 
five patients were dead in the control group (17 %) versus seven in the intervention group 
(15 %).  
The differences between the control and intervention group were not statistically significant 
(see p values in table 4-4). The differences within the control group between the three time-
points showed the following p values (McNemar test): t0 versus t6: p = 1.000 (not significant); 
t0 versus t7: p = 1.000 (not significant). The differences within the intervention group between 
the three time-points showed the following p values (McNemar test): t0 versus t6: p = 1.000 
(not significant); t0 versus t7: p = 0.687 (not significant). 
In case the patients indicated that they needed help with every-day activities they were asked 
who mostly provided the help. The answers are shown in table 4-5. 
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Table 4-5: Help provider (Evaluation for t0, t6, t7 at once) 
Help provider Control group Intervention group 
 n % n % 
Family / friends  
Professional care service 
Voluntary organisation 
Others 
No answer 
12 
1 
0 
0 
3 
75.0 
6.2 
0.0 
0.0 
18.8 
26 
1 
0 
0 
0 
96.3 
3.7 
0.0 
0.0 
0.0 
 
The option “family / friends” was indicated most frequently in both patient groups (75 % in 
control group and 96 % in intervention group). “Voluntary organisations” and “others” did 
not provide help for any patient. 
4.5 Indirect non-medical disease-related costs 
Loss of productivity 
Table 4-6 shows the employment situation of control and intervention patients at three 
different time-points during the study. 
Table 4-6: Employment situation at three different time-points 
Time Employment situation Control group Intervention group P value*
  n % n %  
t0 
Full-time job 
Part-time job 
Unable to work 
Pensioner 
Housewife 
No answer / missing 
3 
2 
6 
18 
1 
0 
10.0 
6.7 
20.0 
60.0 
3.3 
0.0 
5 
4 
14 
18 
5 
0 
10.9 
8.7 
30.4 
39.1 
10.9 
0.0 
0.458 
t6 
Full-time job 
Part-time job 
Unable to work 
Pensioner 
Housewife 
No answer / missing 
1 
2 
7 
15 
0 
0 
4.0 
8.0 
28.0 
60.0 
0.0 
0.0 
7 
4 
11 
13 
5 
1 
17.1 
9.8 
26.8 
31.7 
12.2 
2.4 
0.089 
t7 
Full-time job 
Part-time job 
Unable to work 
Pensioner 
Housewife 
No answer / missing 
0 
2 
7 
15 
0 
1 
0.0 
8.0 
28.0 
60 
0.0 
4.0 
6 
5 
5 
13 
6 
4 
15.4 
12.8 
12.8 
33.3 
15.4 
10.3 
0.012 
*Fisher’s exact test (the category no answer / missing was not considered) 
 
No patient indicated “unemployed” or “student” as current employment situation at any time. 
Table 4-6 shows that from three control patients with full-time jobs at t0 no one was left after 
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six months. During the study period two control patients were working part-time. In the 
intervention group five patients were on a full-time job at t0 and six at t7. There were five 
patients with a part-time job at t7 in comparison to four at t0. A reduction took place in the 
section “unable to work” in the intervention patients from fourteen at the beginning via eleven 
in the middle and five at the end of the study. Four answers were missing at t7. The 
differences between the control and intervention group were statistically significant at t7 (see 
p value in table 4-6). 
The differences within the control patients in the groups “able to work” versus “unable to 
work” between the three points of measurements showed the following p values (McNemar): 
t0 versus t6: p = 0.500 (not significant); t0 versus t7: p = 0.625 (not significant). The 
differences within the intervention patients in the groups “able to work” versus “unable to 
work” between the three points of measurements showed the following p values (McNemar): 
t0 versus t6: p = 0.625 (not significant); t0 versus t7: p = 0.125 (not significant). 
From those patients who indicated “full-time job”, “part-time job” or “unable to work” at the 
time of inclusion the number of days on sick leave were evaluated at the end of the study. 
Nineteen control patients and 23 intervention patients had stated “pensioner” or “housewife” 
and were therefore not asked for days on sick leave. From the remaining eleven control and 
23 intervention patients, information about days on sick leave could be received from eight 
control and 17 intervention patients (three and six missing values, respectively). Four out of 
eight control patients (50 %) and eight out of 17 intervention patients (47 %) were unable to 
work during the whole study period. The results are illustrated in figure 4-3 as boxplots. 
The median number of days on sick leave amounted to 121 days in the control and 93 days in 
the intervention group. The days on sick leave were then multiplied by the average German 
gross wage per day of € 142.14. In patients that stated pensioner or housewife costs of € 0.00 
were assumed. This amounted to mean indirect costs of € 4206.29 per control patient (min: 
€ 0.00; max: € 18193.92; median: € 0.00; SD: € 7174.93) and of € 4992.67 per intervention 
patient (min: € 0.00; max: € 18193.92; median: € 0.00; SD: € 7371.50). The differences were 
not statistically significant (p = 0.464, Mann-Whitney-U). When adding the indirect costs to 
the total cost calculation indirect costs amounted to 14 % of total costs in the control and of 
17 % in the intervention group (table 4-7). 
For more information on indirect cost per patient see appendix D. 
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Figure 4-3: Days on sick leave in the control and intervention group 
 
Table 4-7: Direct costs (outpatient and inpatient costs) and indirect costs 
 Direct costs [€] 
Indirect costs 
[€] 
Control group 
Total costs: 
%: 
Median costs/patient: 
Mean costs/patient: 
SD: 
 
671527 
86 
16224 
22384 
20362 
 
113570 
14 
0 
4206 
7175 
Intervention group 
Total costs: 
%: 
Median costs/patient: 
Mean costs/patient: 
SD: 
 
953405 
83 
20020 
20726 
12790 
 
199707 
17 
0 
4993 
7372 
p value*: 0.832 0.464 
*Mann-Whitney-U 
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4.6 Patients´ quality of life 
EQ-5D descriptive system 
Table 4-8 summarises the results of the descriptive system of the EQ-5D questionnaire. A 
value of 1.0 implies “no problems”, 2.0 “some problems” and 3.0 implies “severe problems”. 
Table 4-8: Median, mean and standard deviation of the EQ-5D descriptive system at four 
different times for the control and intervention group during treatment with 
capecitabine 
EQ-5D dimension Control group Intervention group 
 t0 t3 t6 t7 t0 t3 t6 t7 
n 28 16 9 11 46 39 30 18 
Mobility 
Median 
Mean 
SD 
 
1.0 
1.43 
0.50 
 
1.0 
1.44 
0.51 
 
1.0 
1.22 
0.44 
 
1.0 
1.27 
0.47 
 
1.0 
1.46 
0.50 
 
1.0 
1.38 
0.54 
 
1.0 
1.37 
0.49 
 
1.0 
1.39 
0.50 
Self-Care 
Median 
Mean 
SD 
 
1.0 
1.21 
0.50 
 
1.0 
1.06 
0.25 
 
1.0 
1.0 
0.0 
 
1.0 
1.09 
0.30 
 
1.0 
1.15 
0.42 
 
1.0 
1.10 
0.31 
 
1.0 
1.10 
0.31 
 
1.0 
1.11 
0.32 
Usual Activities 
Median 
Mean 
SD 
 
2.0 
1.61 
0.57 
 
2.0 
1.75 
0.68 
 
1.0 
1.33 
0.50 
 
1.0 
1.45 
0.52 
 
2.0 
1.70 
0.73 
 
2.0 
1.64 
0.71 
 
2.0 
1.63 
0.62 
 
1.0 
1.33 
0.59 
Pain / Discomfort 
Median 
Mean 
SD 
 
2.0 
1.79 
0.50 
 
2.0 
1.81 
0.54 
 
2.0 
1.78 
0.67 
 
1.0 
1.55 
0.69 
 
2.0 
1.72 
0.58 
 
2.0 
1.74 
0.60 
 
2.0 
1.67 
0.48 
 
2.0 
1.78 
0.65 
Anxiety / Depression 
Median 
Mean 
SD 
 
1.0 
1.36 
0.56 
 
1.0 
1.50 
0.63 
 
1.0 
1.22 
0.44 
 
1.0 
1.27 
0.47 
 
1.0 
1.43 
0.54 
 
1.0 
1.33 
0.58 
 
1.0 
1.40 
0.56 
 
1.0 
1.28 
0.58 
SD = standard deviation 
 
At the time of inclusion the median values for all five dimensions were the same in both 
patient groups (see table 4-8). There were, however, differences in the mean values. In three 
dimensions (“mobility”, “usual activities” and “anxiety/depression”) the mean values were 
higher in the intervention group than in the control group (e.g. usual activities 1.61 vs. 1.70) 
indicating slightly more problems. In both patient groups there was no increase in median 
values at any time. In the control group there was a decrease in median values in two 
categories: in the dimension “usual activities” from 2.0 (= some problems) at t3 to 1.0 (= no 
problems) at t6 and t7 and in the dimension “pain” from 2.0 (= moderate pain) at t6 to 1.0 (= 
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none) at t7. In the intervention group there was a decrease in median value in the dimension 
“usual activities” from 2.0 (= some problems) at t6 to 1.0 (= no problems) at t7. For the 
frequency distribution of the EQ-5D scores at the four different points of measurement see 
appendix D. 
Utility scores from the EQ-5D descriptive system 
The five-digit number of the descriptive system was converted into the EQ-5D utility score. 
For these results see chapter 4.8.1 “QALYs from EQ-5D questionnaire”. 
EQ-5D VAS 
Table 4-9 shows the patients´ own assessment of their health states during treatment with 
capecitabine using the EQ-5D VAS as mean scores plus standard deviation and median scores 
plus interquartile range. 
Table 4-9: EQ-5D VAS score 
 Control group Intervention group 
 t0 t3 t6 t7 t0 t3 t6 t7 
n 29 19 11 11 46 40 29 18 
Mean 
SD 
55.9 
19.8 
58.4 
20.1 
65.0 
21.5 
69.1 
18.3 
63.2 
21.3 
59.1 
23.2 
65.3 
20.4 
69.7 
25.1 
Median 
IQR 
 
52.5 
47.5-
70.0 
60.0 
40.0-
70.0 
65.0 
50.0-
80.0 
70.0 
60.0-
80.0 
62.5 
50.0-
80.0 
60.0 
40.0-
73.8 
70.0 
52.5-
80.0 
80.0 
40.0-
90.0 
SD = standard deviation, IQR = interquartile range 
 
At the time of inclusion the intervention group started at a higher VAS score than the control 
group (not statistically significant: p = 0.133, Mann-Whitney-U test). In the intervention 
group there was a minimal deterioration of VAS scores at t3 and an improvement again at t6 
and also at t7. Figure 4-4 shows the above-mentioned data in a VAS score-time curve. 
For data on absolute changes in the VAS scores between t0 and t3, t6, t7 for control and 
intervention patients see appendix D. 
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Figure 4-4: VAS score-time curve 
(n control group: t0: 29, t3: 19, t6: 11, t7: 11; n intervention group: t0: 46, t3: 40, t6: 29, t7: 17; 
error bars = interquartile range (thick, grey = control group, thin, black = intervention 
group)) 
 
4.7 Adverse effect hand-foot syndrome 
Figure 4-5 gives an overview of HFS grades at seven different points of measurement in the 
control and intervention group. The figure summarises only the results of those HFS 
questionnaires in which the patients were under treatment with capecitabine.  
In the intervention group the median HFS grade did not exceed grade 1 at any time during the 
study period. In the control group the median HFS grade was grade 2 twice: at t5 and at t7. 
Here the differences between the intervention and control group were statistically significant 
(t5: p = 0.023, t7: p = 0.019, Cochran-Armitage test for trend). 
Concerning HFS grade 3 six out of 30 control patients (20 %) experienced HFS grade 3 at 
least once during the treatment with capecitabine versus only seven out of 46 intervention 
patients (15 %) (p = 0.588, Chi-Square test). 
For more information on the number of missing questionnaires, patients without treatment of 
capecitabine and the number of dead patients at the seven different points of measurement see 
appendix D. 
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Figure 4-5: HFS grades under treatment with capecitabine 
(CG = control group, IG = intervention group; numbers in the legend represent number of 
analysed control and intervention patients) 
 
Utility scores from the HFS questionnaire 
The patient-reported HFS grades were converted into HFS utility scores using the TTO-based 
utility scores generated earlier in the diploma thesis of D. Güney (Department of Clinical 
Pharmacy, University of Bonn). For these results see chapter 4.8.2 “QALYs from hand-foot 
syndrome questionnaire”. 
4.8 Quality-adjusted life years 
4.8.1 QALYs from the EQ-5D descriptive system  
The five-digit number of the descriptive system during treatment with capecitabine was 
converted into the EQ-5D utility score. Table 4-10 gives a summary of the generated utility 
scores in both patient groups. 
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Table 4-10: Utility scores in control and intervention group during treatment with 
capecitabine 
 Control group Intervention group 
 t0 t3 t6 t7 t0 t3 t6 t7 
n 28 16 9 11 46 39 30 18 
Mean 
SD 
0.810 
0.206 
0.789 
0.212 
0.844 
0.199 
0.866 
0.225 
0.797 
0.230 
0.781 
0.239 
0.845 
0.179 
0.796 
0.255 
Median 
IQR 
0.887 
0.723-
0.897 
0.887 
0.788-
0.897 
0.887 
0.788-
1.000 
0.999 
0.788-
1.000 
0.887 
0.788-
1.000 
0.887 
0.788-
1.000 
0.887 
0.788-
0.999 
0.887 
0.766-
1.000 
SD = standard deviation, IQR = interquartile range 
 
Intervention and control patients started at the same median utility score and nearly the same 
mean utility score at the time of inclusion. The intervention patients were stable in their 
median utility score during the whole study period. The control patients were stable in their 
median utility score until t6 and showed an improvement at t7. Figure 4-6 shows the absolute 
changes in utility scores between t0 and t3, t6, t7 for the control and intervention group. 
In the median there was no change in utility scores at any time in both patient groups. 
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Figure 4-6: Absolute changes in EQ-5D utility scores between t0 and t3, t0 and t6 and t0 and 
t7 for control and intervention patients 
(t0 and t3: control group median = 0.0, intervention group median = 0.0 (p = 0.947, Mann-
Whitney-U); t0 and t6: control group median = 0.0, intervention group median = 0.0 
(p = 0.603, Mann-Whitney-U); t0 and t7: control group median = 0.0, intervention group 
median = 0.0 (p = 0.694, Mann-Whitney-U)) 
 
In the control group QALYs based on the utility scores from the EQ-5D descriptive system 
could be calculated for eight patients (27 %). In three patients (10 %) at least one of four 
utility scores (t0, t3, t6, t7) during treatment with capecitabine was missing, in 14 patients 
(47 %) capecitabine treatment was stopped before the end of the study period for different 
reasons and five patients (17 %) died before the end of the study period and therefore QALYs 
were not calculated. In the intervention group QALYs could be calculated for 17 patients 
(37 %). In four patients (9 %) at least one of four utility scores during treatment with 
capecitabine was missing, in 18 patients (39 %) capecitabine treatment was stopped before the 
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end of the study period for different reasons and seven patients (15 %) died before the end of 
the study period and therefore QALYs were not calculated. Table 4-11 summarises the results 
of the QALY and QALD calculation per patient in both patient groups. 
Table 4-11: QALYs and QALDs in the control and intervention group 
 Control group Intervention group P value* 
n 8 17  
QALY [year] 
Median 
IQR 
Mean 
SD 
 
0.44 
0.41-0.48 
0.43 
0.07 
 
0.42 
0.37-0.47 
0.41 
0.08 
0.364 
QALD [day] 
Median 
IQR 
Mean 
SD 
 
160.0 
148.8-174.8 
155.1 
26.5 
 
154.9 
134.9-170.1 
148.6 
28.6 
0.414 
*Mann-Whitney-U test, IQR = interquartile range, SD = standard deviation,  
QALY = quality-adjusted life year, QALD = quality-adjusted life day 
 
There was nearly no difference in QALYs and QALDs between the two patient groups. The 
control group gained slightly more QALYs than the intervention group: a median of 0.44 
QALYs versus 0.42 QALYs. In terms of QALDs the control group gained 5.1 more QALDs 
in the median than the intervention group. The differences were not statistically significant.  
Figure 4-7 illustrates the utility-time curve for both patient groups. The calculation of QALDs 
and QALYs was based on the results of table 4-10. This approach also considered the 
available utility scores of those patients with at least one of four utility scores missing during 
the study period. 
64  Results 
 
Figure 4-7: Utility-time curve during treatment with capecitabine for calculation of QALDs 
and QALYs 
( n control group: t0: 28, t3: 16, t6: 9, t7: 11; n intervention group: t0: 46, t3: 39, t6: 30, t7: 18; 
AUC control group: 163.1 QALDs, AUC intervention group:: 159.7 QALDs; error bars = 
interquartile range (thick, grey = control group, thin, black = intervention group)) 
 
This approach also shows that there is nearly no difference between the control and the 
intervention group. The control group gained 0.45 QALYs and the intervention group 0.44 
QALYs. With regard to the QALDs 3.4 more QALDs were gained in the control group 
compared to the intervention group. 
4.8.2 QALYs from hand-foot syndrome questionnaire 
In the control group QALYs based on the utility scores of the HFS grades could be calculated 
for 11 patients (37 %). In 19 patients (63 %) either more than one of seven utility scores (t1, t2, 
t3, t4, t5, t6, t7) or the last utility score (t7) was missing or capecitabine treatment was stopped 
before the end of the study period and therefore QALYs were not calculated. In the 
intervention group QALYs could be calculated for 20 patients (44 %). In 26 patients (57 %) 
either more than one of seven utility scores (t1, t2, t3, t4, t5, t6, t7) or the last utility score (t7) 
was missing or capecitabine treatment was stopped before the end of the study period and 
therefore QALYs were not calculated. For more information also see appendix D, table D-19. 
Table 4-12 summarises the results of the QALY and QALD calculation per patient in both 
patient groups. 
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Table 4-12: QALYs and QALDs based on HFS utility scores in the control and intervention 
group 
 Control group Intervention group P value* 
n 11 20  
QALY [year] 
Median 
IQR 
Mean 
SD 
 
0.44 
0.40-0.47 
0.44 
0.04 
 
0.46 
0.44-0.48 
0.45 
0.04 
0.420 
QALD [day] 
Median 
IQR 
Mean 
SD 
 
162.1 
146.0-171.4 
160.4 
14.0 
 
167.5 
161.3-175.6 
164.7 
14.8 
0.420 
 *Mann-Whitney-U test, IQR = interquartile range, SD = standard deviation, QALY = quality-adjusted life year, 
QALD = quality-adjusted life day 
 
With the HFS-based approach the intervention group gained more QALYs then the control 
group: a median of 0.46 QALYs versus 0.44 QALYs. In terms of QALDs the intervention 
group gained 5.4 more QALDs in the median than the control group. The differences were not 
statistically significant.  
Figure 4-8 illustrates the HFS-based utility-time curve for both patient groups. This approach 
also considered the available utility scores of those patients with more than one of seven 
utility scores or the last utility score missing.  
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Figure 4-8: Utility-time curve and HFS-based calculation of QALDs and QALYs 
(n control group: t0: 30, t1: 29, t2: 23, t3: 18, t4: 17, t5: 11, t6: 11, t7: 11; n intervention group: 
t0: 46, t1: 44, t2: 43, t3: 40, t4: 37, t5: 34, t6: 30, t7: 21; AUC control group: 162.6 QALDs; AUC 
intervention group: 175.8 QALDs; error bars = interquartile range (thick, grey = control 
group, thin, black = intervention group)) 
 
With this approach the intervention group also gained slightly more QALYs than the control 
group: 0.48 versus 0.45 QALYs. The difference between the QALDs amounts to 13.2 more 
QALDs in the intervention group. Table 4-13 summarises the HFS utility scores that formed 
the basis for figure 4-8. 
Table 4-13: HFS utility scores in control and intervention group during treatment with 
capecitabine 
  t1 t2 t3 t4 t5 t6 t7 
CG n 29 23 18 17 11 11 11 
 median 1.000 0.970 0.970 0.970 0.720 0.970 0.720 
 IQR 0.970-1.000 
0.970-
1.000 
0.720-
0.978 
0.720-
0.970 
0.720-
0.970 
0.720-
0.970 
0.720-
0.970 
IG n 44 43 40 37 34 30 21 
 median 1.000 0.970 0.970 0.970 0.970 0.970 0.985 
 IQR 0.970-1.000 
0.720-
1.000 
0.720-
1.000 
0.720-
0.985 
0.720-
0.978 
0.720-
0.970 
0.970-
1.000 
CG = control group, IG = intervention group, IQR = interquartile range 
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4.9 Patients´ “willingness-to-pay” for pharmaceutical care service 
Thirty-two intervention patients (70 %) stated their willingness-to-pay for the received 
pharmaceutical care service on a monthly basis. 10 patients gave no answer (22 %) and 4 
patients (9 %) were already dead at the time of assessment. The median “willingness-to-pay” 
amounted to € 45.00 / month (mean: € 72.20, SD: € 99.60, min: € 5.00, max: € 500.00). 
Table 4-14 gives an overview of the corresponding median and mean “WTP” and the 
household net income. 
Table 4-14: Willingness-to-pay (WTP) per month and household net income 
Net income of 
the household 
€ 1000 -  
< 
€ 1500 
€ 1500 - 
< 
€ 2000 
€ 2000 -
< 
€ 2500 
€ 2500 -
< 
€ 3000 
€ 3000 -
< 
€ 3500 
≥ € 3500  no answer 
n 4 4 2 6 4 7 5 
WTP/month (€) 
Median 
Mean 
SD 
 
10.0 
31.3 
45.9 
 
75.0 
95.0 
75.9 
 
45.0 
45.0 
7.0 
 
17.5 
30.0 
34.8 
 
100.0 
87.5 
25.0 
 
50.0 
107.1 
175.9 
 
30.0 
87.0 
121.1 
SD = standard deviation 
 
The highest median “willingness-to-pay” per month with € 100.0 was stated by the second 
highest net income group of € 3000 to < € 3500. The lowest “willingness-to-pay” with € 10.0 
was stated by the group with the lowest net income of € 1000 to < € 1500. Concerning the 
other net income groups no linear correlation could be found. As the group sizes were small 
no statistical tests were performed. No linear correlation could be found between the 
“willingness-to-pay” and the household net income per household member (adults and 
children) (see appendix D). The patients with a statutory health insurance (n=21) were willing 
to pay a median value of € 50.0 (mean: € 86.0, SD: € 118.7) while privately insured patients 
(n=11) were willing to pay a median of € 30.0 (mean: € 45.9, SD: € 37.5). The difference was 
not statistically significant (p = 0.547, Mann-Whitney-U test). 
According to section 4.3 “Costs for pharmacists” the pharmaceutical care service provided by 
a pharmacist amounted to € 94.26 for six months. The intervention patients were willing to 
pay € 45.0 per month amounting to € 270.0 per six months thus leading to a surplus of 
€ 175.74 in six months. This showed that the benefit for the patient was higher than the 
money that had to be invested for the service when considering the costs for pharmacists only. 
68  Results 
4.10 Cost-utility analysis 
4.10.1 Matched-pairs between control and intervention group 
All outpatient and inpatient cost data as well as the EQ-5D measurements were available from 
21 out of 30 control patients (70 %) and 36 out of 46 intervention patients (78 %). Only these 
patients entered the matching process. Concerning the main matching parameters tumour 
entity, treatment setting, antineoplastic regimen at the time of inclusion, treatment with 
bisphosphonates at the time of inclusion and type of health insurance 15 intervention and 
eleven control patients were identified, resulting in eleven matched patient pairs (table 4-15): 
Table 4-15: Number of control and intervention patients in coinciding matching parameters 
Tumour 
Entity 
Treatment 
setting 
Therapy 
regimen 
Bis- 
phosphonate 
Health 
insurance 
CG 
[n] 
IG 
[n] 
Breast Adjuvant Cap Pac No Statutory 1 2 
Breast Palliative Cap Yes Statutory 4 4 
Breast Palliative Cap No Statutory 1 1 
Breast  Palliative Cap Tras Yes Private 1 1 
Colorectal Neoadjuvant Cap Ox No Statutory 1 1 
Colorectal Palliative Cap No Statutory 1 3 
Colorectal Palliative Cap Beva No Statutory 2 3 
Sum     11 15 
Therapy regimen: Cap = capecitabine monotherapy; Cap Beva = capecitabine + bevacizumab; Cap Ox = 
capecitabine + oxaliplatin; Cap Pac = capecitabine + paclitaxel; Cap Tras = capecitabine + trastuzumab 
 
Where more than one intervention patient matched with one control patient (e.g. 2:1) one 
intervention patient was selected at random to form a ratio of 1:1. Appendix D shows the 
random selection of matched patient pairs. At the time of inclusion the selected control 
patients had a mean age of 63.3 years (SD: 13.1; median: 66.0; min: 39; max: 80 years) and 
selected intervention patients of 55.8 years (SD: 10.0; median: 55.0; min: 35; max: 75 years). 
This difference was not statistically significant (p = 0.172, t-test). Concerning quality of life 
represented by the utility score at the time of inclusion there was no statistically significant 
difference between the two selected patient groups (p = 0.519, Mann-Whitney-U). Both 
groups started with a median utility score of 0.887 and a mean score of 0.813 (SD: 0.171) in 
the control and of 0.829 (SD: 0.237) in the intervention group. The socio-demographic 
characteristics of the eleven matched patient pairs at the time of inclusion are shown in 
appendix D. 
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4.10.2 Direct disease-related costs of matched-pairs 
Table 4-16 summarises the direct disease-related costs of the eleven matched patient pairs. 
Table 4-16: Direct disease-related costs of eleven matched-pairs 
 
Anti- 
neopl. 
therapy 
[€] 
Supp. 
therapy
 
[€] 
Oncol.
fee 
 
[€] 
Diagn.
cost 
 
[€] 
Admin.
cost 
 
[€] 
In- 
patient 
cost 
[€] 
Total 
direct 
costs1 
[€] 
Control group 
Sum 
% 
Median cost/patient 
Mean cost/patient 
SD 
 
104397 
59.0 
4721 
9491 
10717 
 
31780 
18.0 
1442 
2889 
3523 
 
4652 
2.6 
234 
423 
401 
 
3015 
1.7 
204 
274 
369 
 
171 
0.1 
16 
16 
13 
 
32867 
18.6 
0 
2988 
5148 
 
176879 
100.0 
15755 
16080 
11308 
Intervention group 
Sum 
% 
Median cost/patient 
Mean cost/patient 
SD 
 
122050 
71.1 
4721 
11095 
12739 
 
17896 
10.4 
1356 
1627 
1617 
 
4337 
2.5 
204 
394 
407 
 
2778 
1.6 
208 
253 
329 
 
126 
0.1 
12 
11 
10 
 
23508 
13.7 
0 
2137 
6485 
 
171662 
100.0 
9071 
15606 
13816 
p value*: 0.797 0.562 0.949 0.949 0.606 0.519 0.748 
*Mann-Whitney-U test, SD = Standard deviation, Antineopl. = antineoplastic, Supp. = supportive, Oncol. = 
oncologist, Diagn. = diagnostic, Admin. = administration 
1Total direct cost of the intervention group also contains the cost for pharmacist of € 968 (0.6 %; median: € 94; 
mean: € 88; SD: € 21). 
 
The corresponding study period of the eleven control patients was 1561 days (median: 180.0, 
mean: 141.9, SD: 53.8) and therefore shorter than of the eleven intervention patients with 
1848 days (median: 180.0, mean: 168.0, SD: 39.8). The difference was not statistically 
significant (p = 0.365, Mann-Whitney-U).  
For both patient groups most costs arose through the antineoplastic therapy, followed by 
inpatient cost, costs for supportive therapy, oncologist fee, diagnostics, and finally, with a 
very small portion, administration costs. In the intervention group costs for pharmacists were 
between costs for diagnostics and administration. In the selected control patients the costs for 
supportive therapy were nearly as high as the costs for inpatient stays (€ 31780 versus 
€ 32867). 
The main difference between both selected patient groups existed between the costs for 
antineoplastic therapy. These costs were higher in the intervention group than in the control 
group. The main reason for the difference observed was the colorectal cancer patient C 10 
who was treated with capecitabine and bevacizumab at the time of inclusion but declined the 
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treatment after one cycle and died on day 61 of the study resulting in very low costs of € 525 
for antineoplastic therapy. The treatment with bevacizumab was applied during an inpatient 
stay and was considered there. In comparison the cost for antineoplastic therapy of a matching 
intervention patient (e.g. CI 16) amounted to € 25304.  
Costs for supportive therapy were vice versa. These costs were higher in the control group 
than in the intervention group. The main reasons were the supportive treatments of the two 
control patients B 4 and B 6 and to a smaller extent B 12. B 4 and B 6 both received 
supportive therapy with Neulasta® containing the substance pegfilgrastim, a human 
granulocyte-colony-stimulating factor. Treatment with one pre-filled syringe costs about 
€ 1550. Besides, B 4 received parenteral nutrition after one and a half months in the study 
causing costs of about € 3300. B 6 received i.v. iron dextrane (Cosmofer®) for iron 
insufficiency amounting to costs of about € 710. B 12 was treated four times for 
chemotherapy-induced anaemia with Aranesp® containing darbepoetin-alpha resulting in 
costs of about € 2300. No intervention patient received any of these therapies, except for 
BI 16 who was treated with Aranesp® once. Instead of treatment with epoetin-analoga e.g. 
CI 3 and CI 20 were treated with human erythrocyte concentrates resulting in costs of € 162 
each. 
Concerning inpatient costs the costs were again higher in the control group in comparison to 
the intervention group. From the selected eleven control patients four showed inpatient stays, 
whereas only two intervention patients were hospitalised during the study period. One patient 
in the selected control group (B 12) was hospitalised due to an adverse drug reaction of the 
chemotherapy (fever under chemotherapy). No patient in the selected intervention group was 
hospitalised due to adverse drug reactions. 
Regarding oncologist fees, costs for diagnostics and administration only small differences 
were observed between the selected patient groups in relation to the cost categories discussed 
above. 
Finally, the total costs were higher in the selected control group than in the selected 
intervention group. For all details on resource-utilisation and cost calculation of the matched 
patient pairs see appendix D. 
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4.10.3 QALYs of matched-pairs 
QALYs and QALDs based on the EQ-5D questionnaire of the matched-pairs are shown in 
table 4-17. 
Table 4-17: QALYs and QALDs based on the EQ-5D questionnaire 
 Control group Intervention group 
 QALY [year] QALD [day] QALY [year] QALD [day] 
Sum 
Median/patient
Mean/patient 
SD 
3.52 
0.44 
0.32 
0.19 
1286 
160 
117 
68 
4.37 
0.45 
0.40 
0.14 
1594 
163 
145 
52 
QALY = quality-adjusted life year, QALD = quality-adjusted life day, SD = standard deviation 
 
The highest achievable sum of QALYs and QALDs were 5.39 (0.49 QALYs x 11) and 1980 
(180 QALDs x 11) respectively. The selected intervention patients led to a higher sum of 
QALYs (84 % of highest achievable score) than the control patients (65 % of highest 
achievable score). The differences were not statistically significant (p = 0.797, Mann-
Whitney-U). 
The QALYs and QALDs based on the HFS questionnaire could only be calculated for three 
control patients and for four intervention patients. In the other patients either more than one 
utility score was missing or the patients were not treated with capecitabine for the whole 
study period. Because of the small sample size these data were not used for further analysis. 
4.10.4 Incremental cost-utility ratio 
For the eleven matched patient pairs the ICUR should be calculated. There was a gain in 
QALYs at reduced costs indicating that the intervention ‘pharmaceutical care’ dominates the 
comparator ‘standard care’. Therefore the incremental cost-utility ratio (costs per QALY 
gained) was not calculated.  
• The difference in mean QALYs amounted to:  
QALYsQALYsQALYs CGIG 08.032.040.0 =−  
• The difference in mean direct costs amounted to:  
29.474€92.16079€63.15605€ −=− CGIG  
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Through the delivery of pharmaceutical care for six months to one patient 0.08 QALYs could 
be gained in comparison to not delivering that service and at the same time € 474 could be 
saved.  
4.10.5 Nonparametric bootstrapping 
Figure 4-9 shows the estimate of the empirical distribution of cost-effectiveness.  
 
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
 
Figure 4-9: Cost-effectiveness plane showing differences between intervention and control 
group after 10000 bootstrap replications 
 
The intervention group showed lower costs and more QALYs than the control group in 43 % 
of all replications (south-east quadrant); more costs and more QALYs in 44 % of all 
replications (north-east quadrant); lower costs and less QALYs in 10 % of all replications 
(south-west quadrant) and more costs and less QALYs in 3 % of all replications (north-west 
quadrant). The bootstrap results of the south-east and north-east quadrants (together 87 % of 
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all replications) were then used to plot the cost-effectiveness acceptability curve (figure 4.10). 
The highest achievable probability was therefore 87 %. 
 
 
Figure 4-10: Cost-effectiveness acceptability curve 
 
The probability that pharmaceutical care was more cost-effective than standard care was 43 % 
at a willingness to pay (WTP) for an additional QALY of € 0, reaching 62 % probability at a 
WTP of € 29000 per additional QALY. 
4.10.6 Sensitivity analysis 
Two simple one-way analyses were performed with the cost and outcome data of the eleven 
matched-pairs.  
The assumption of double cost for pharmacists of € 45.98 / hour led to the following results:  
• The difference in mean QALYs amounted to: 
QALYsQALYsQALYs CGIG 08.032.040.0 =−  
• The difference in mean direct costs amounted to: 
88.394€92.16079€04.15685€ −=− CGIG . 
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The transformation of the EQ-5D digits into utilities based on the UK TTO set of preference 
weights resulted in the following results: 
• The difference in mean QALYs amounted to: 
QALYsQALYsQALYs CGIG 07.029.036.0 =−  
• The difference in mean direct costs amounted to:  
29.474€92.16079€63.15605€ −=− CGIG  
Furthermore, an analysis of extremes was accomplished.  
By replacing the randomly selected patients BI 16 and CI 16 by the equally matching patients 
BI 21 and CI 17 the “best case”-scenario was received: 
• The difference in mean QALYs amounted to: 
QALYsQALYsQALYs CGIG 08.032.040.0 =−  
• The difference in mean direct costs amounted to: 
91.817€92.16079€01.15262€ −=− CGIG  
By replacing the randomly selected patients CI 13 and CI 1 by the also matching patients 
CI 17 and CI 20 the “worst case”-scenario was received: 
• The difference in mean QALYs amounted to: 
QALYsQALYsQALYs CGIG 09.032.041.0 =−  
• The difference in mean direct costs amounted to: 
84.1922€92.16079€76.18002€ =− CGIG  
As in the “worst case”-scenario the intervention no longer dominated the comparator, as 
money had to be invested to gain QALYs, the ICURworst case could be calculated: 
ICURworst case 
CGIG
CGIG
QALYsQALYs 32.041.0
92.16079€76.18002€
−
−=  
QALYs09.0
84.1922€=  
QALY
89.21364€= . 
The mean total costs in the “worst case” intervention patients were so high mainly because of 
a colorectal cancer patient (CI 20) who was treated with capecitabine for the first three 
months and was then switched to 5-FU, irinotecan and bevacizumab due to disease 
progression of his liver metastasis. The latter treatment resulted in costs of about € 20000. 
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The matched control patient (C 7) was treated with capecitabine only during the whole study 
period. 
For all details on resource utilisation and cost calculation of the additional patients BI 21, 
CI 17 and CI 20 see appendix D. 
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5 Discussion 
5.1 Study set-up 
The present study on pharmaceutical care used a prospective, multi-centred observational 
cohort study design with a control group. The control group received standard care and was 
studied before the intervention group which received intensified pharmaceutical care.  
Randomization is the most robust method of preventing selection bias; however a 
randomization of individual patients was not suitable to evaluate the present intervention for 
several reasons which will be discussed in the following. Pharmaceutical care must be 
regarded as a complex intervention since the service aims at both organisational and service 
modifications. At the same time it is targeted on other health care professionals with 
educational interventions in the form of e.g. supportive treatment guidelines or consideration 
of drug-drug interactions. Furthermore, pharmaceutical care has a direct influence on the 
individual patient with its behavioural aspect, the patient monitoring and education [86]. A 
recent review on economics of clinical pharmacy interventions recognized this peculiarity of 
studies on pharmaceutical care. They stated that physicians can learn from recommendations 
made by clinical pharmacists (“learning effects”) and apply these recommendations to other 
patients who are not reviewed by pharmacists. When intervention and control patients are part 
of the same ward or practice population, this may have an effect on the outcomes of the 
control group. Rijdt et al. concluded that intervention and control groups should be selected 
from different wards or practices. The populations should have similar demographic 
characteristics and a comparable severity of disease [33]. Moreover, it would have been 
unethical if the pharmacist had reviewed e.g. the supportive therapy of the intervention 
patients and made guideline-based recommendations for adjustment while control patients 
were kept on the initial supportive therapy. Furthermore, intervention patients might have 
communicated advice of the study pharmacist to control patients in the same practice. It is 
known that patients who are treated concurrently in the same ward / practice intensively 
exchange their experiences with one another. As the pharmaceutical care service somehow 
also affected the organization on the practice / ward level it was impossible to recruit control 
and intervention patients at the same time [87]. A cluster randomization of study centres 
could have minimised some of these problems by randomizing, e.g., practices and outpatient 
wards rather than individual patients. Generally speaking, studies with only a few clusters 
(less than four) per group should be avoided [88]. In the present study the number of study 
centres was limited to six by practical and also financial constraints, thus not allowing for a 
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reasonable cluster randomization. Because of the above-mentioned reasons some limitations 
with regard to the study design in the present study had to be accepted. A cost-utility analysis 
of a disease management program (DMP) for patients with asthma was conducted in the 
Netherlands [89]. The researchers also collected control group data before the implementation 
of the DMP without any randomization, thus using a similar study design as in the present 
study. Steuten et al. also had substantive arguments to justify their study design. There was a 
lack of a “fair” comparison-region as in all potential comparison-regions innovations were 
being implemented that would have biased the measure of usual care.  
The present study evaluated the contribution of two clinical pharmacists on costs and 
outcomes of cancer patients. Thus, the measured impact of pharmaceutical care depended 
on the skills and competence of the two clinical pharmacists rather than the potential of 
pharmaceutical care in general. To minimise an individual influence it was attempted to 
standardise the pharmaceutical care service. Each pharmacist-patient consultation followed a 
certain course, based on the pharmaceutical care plan. It was specified in which cases it was 
necessary to contact the attending oncologist. The pharmacists had received prior training to 
deliver a high quality service tailored to the particular needs of cancer patients treated with 
capecitabine. To promote a more sustained effect of education, the information of patients and 
physicians was not only based upon spoken words but also written material (e.g. individual 
patient letters, summaries of supportive guidelines). The study pharmacists informed patients 
and physicians according to the principles of evidence-based medicine, which is a prerequisite 
for a high quality pharmaceutical care service [90]. During the course of the study the clinical 
pharmacists received a lot of important information from the patient. These details, e.g. 
concerning self-administered medication and adverse drug effects, were mandatory for a 
successful pharmaceutical care service. This flow of information from the patient to the 
pharmacist was only possible in an atmosphere of mutual trust and was very important to 
solve and prevent drug related problems.  
The two clinical pharmacists who delivered the care service collected cost and outcome data 
and analysed the results. This procedure possibly presents a conflict of interest. It would have 
been more suitable if the pharmaceutical care service and the research and evaluation of the 
service had not been conducted by the same persons. Furthermore, it would have been more 
appropriate if the researcher who evaluated the service had been blinded in respect of the 
group identity. However, due to the method of outcome data collection in both patient groups 
via pseudonymous, questionnaires and envelopes that were sent via mail to the central study 
office, the possible influence of the pharmacist on the patients´ response behavior was 
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limited. The patients did not complete the questionnaires in the presence of the pharmacist but 
independently at home. The questionnaires in both patient groups were evaluated in the same 
way independent of the group identity. Concerning cost data the method of data collection 
and evaluation was the same in both patient groups. Hence, despite the mentioned limitations, 
everything was done to assure a reliable and sound assessment of cost and outcome data. 
According to Kennie et al. it is crucial to identify appropriate outcomes in studies evaluating 
the impact of pharmaceutical care [91]. In any evaluation of quality, the pharmacist should 
document structure (e.g. patient file), process (e.g. monitoring the drug regimen), and 
outcomes (e.g. adverse drug reactions) and evaluate these measures to provide appropriate 
care [92]. According to the Association of the Scientific Medical Societies in Germany 
(AWMF), a combination of traditional (e.g. adverse drug reactions, survival rate) and 
hermeneutic (e.g. quality of life) outcome measures should be used [93]. The selected 
measures in the present study meet those demands and are thus applicable to investigate the 
impact of pharmaceutical care. 
The studied patient population consisted of 30 control and 46 intervention patients. The 
different sample sizes were due to the longer recruiting period for intervention patients (ten 
months versus 17 months). Since this work was planned as a pilot study no sample size 
calculation was conducted. In both patient groups the tumour entities breast and colorectal 
cancer were distributed evenly (control group: 53 % breast and 47 % colorectal cancer, 
intervention group: both 50 %). Patients were recruited on three oncology outpatient wards 
and three oncology practices. Relatively more control patients were recruited in oncology 
practices than intervention patients (40 % versus 22 %). One oncology outpatient ward 
recruited a lot more intervention patients than control patients leading to the observed result. 
One reason might have been a more fluent recruitment process in that study centre after the 
oncologist became more familiar with the study. Another reason might have been their 
conviction of the benefit of the pharmaceutical care service thus leading to a higher patient 
recruitment. Between May 2006 and April 2008, 100 ambulatory patients were reported to the 
study centre by the cooperating oncologists. It is not clear whether every patient who met the 
requirements was reported to the central study office or whether the oncologists selected 
patients beforehand. It is striking that in the intervention group 30 % had a private health 
insurance compared to only 3 % in the control group. It might be possible that oncologists 
pushed the recruitment of privately insured patients for the intervention group as a special 
benefit could be expected from the pharmaceutical care service. Since private insurances 
generally pay more money for the same medical service as statutory insurances it might have 
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been of interest to the oncologists to please these patients with this service. This circumstance 
could have contributed to a selection bias. Ten percent of the German population is covered 
by a private health insurance [94]. Thus privately insured patients are underrepresented in the 
control and overrepresented in the intervention group. A similar distribution could be found 
concerning the highest level of education: 30 % of intervention patients versus only 7 % of 
control patients hold a university / college degree. It is possible that this fact had an impact on 
the capability of understanding the patient questionnaires. However, the questionnaires were 
not evaluated in this respect. Regarding the current living situation and marital status more 
intervention patients were married / with partner and living with family / partner than control 
patients. A recent study in Israel assessed the impact of marital status and gender on 
psychological distress, coping and social support in colorectal cancer patients. Married 
patients coped better with cancer than unmarried patients and women coped better than men 
[95]. As there are a higher percentage of men in the intervention group the possibly positive 
effect of the marital status might be balanced. In a study on patients with non-small cell lung 
cancer no impact of marital status on quality of life could be observed [96]. Another 
difference could be seen concerning age at the time of inclusion: intervention patients were 
6.5 years younger in the median than control patients. It is discussed in section 5.4 “Cost-
utility analysis” that age is not as important as e.g. quality of life at the time of inclusion. The 
older age of the control patients was also reflected by the higher percentage of pensioners in 
the control group compared to the intervention group (60 % versus 37 %). This probably had 
an impact on indirect costs (see section 5.2 “Cost assessment”). Regarding the therapy 
regimen at the time of inclusion most patients were treated with capecitabine monotherapy in 
both patient groups (CG: 40 %, IG: 33 %). The higher percentage of monotherapy in the 
control group could have had a positive effect on quality of life as monotherapies generally 
have less adverse effects than combination therapies. The same is true for the higher 
percentage of palliative treatments in the control group compared to the intervention group 
(77 % versus 70 %, see section 5.3 “Outcome assessment”). Concerning combination 
chemotherapy twelve different combinations were observed in the study with different 
distributions among the two patient groups. Depending on the therapy regimen different 
effects on costs and outcomes could be expected. In conclusion, heterogeneity in the 
discussed patient variables was apparent. The presented cost and outcome results of the whole 
study population need to be interpreted carefully. It was decided to find matched patient pairs 
for the cost-utility analysis based on some of the discussed parameters to limit their possible 
biasing impact (see section 5.4 “Cost-utility analysis”). 
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In the present study patients who dropped out were not analysed (study drop-outs). All 
outcome data collected until then were not used for further analysis. This stands in contrast to 
international recommendations of the intention-to-treat analysis (ITT) according to which all 
patients should be analysed as allocated to the groups [97]. However, the way of handling 
drop-outs in the present non-randomized cohort study is not as important as in a randomized 
controlled study in which the group consistency is a prerequisite for the internal validity of 
the study. The cost-utility analysis was only conducted after matching the patients of the 
control group with patients of the intervention group thus establishing consistent groups. 
Furthermore, drop-outs were not a problem in the present study, as there was only one drop-
out in each group. The same is true for missing data. There was not a substantial amount of 
missing data. This was probably because of the close contact between the central study office 
and the patients assuring an intensive follow-up of patients. 
5.2 Cost assessment 
Before discussing the results presented in the cost section of this work, the author would like 
to comment on the conditions of and her experience with data collection and cost assessment. 
It was not an easy task to receive all relevant data to assess disease-related costs. The 
establishment of an atmosphere of trust through personal relationships was obligatory to 
receive resource use data from the cooperating physicians, hospitals and their administrative 
staff. To smooth the way was hard work and took more than a year in some cases. The quality 
of resource use data was very heterogenic depending on the study centre and great effort was 
needed to transfer it into a comparable format. For future cost analysis of pharmaceutical care 
from a health insurance perspective a cooperation with, e.g., a major health insurance 
company would be recommended rather than trusting in receiving all needed data from 
cooperating study centres – here the focus should be the assessment of clinical and subjective 
outcomes and not economic ones. However, Germany is not as progressed in terms of health 
economic assessments as e.g. the UK and Sweden. Economic data are widespread between 
different parties and high data privacy protection hampers pharmacoeconomic analyses [98]. 
Concerning the direct costs in both patient groups most money was spent on costs for 
antineoplastic therapy (CG: 70 %, IG: 73 %), followed by inpatient stays (CG: 17 %, IG: 
14 %), and then costs for supportive therapy (CG: 9 %, IG: 8 %). In both groups the 
oncologist fee amounted to 3 % and costs for administration were almost 0 % of total direct 
costs. In the intervention group costs for diagnostics presented 3 % and in the control group 
1 % of total direct costs. The median costs in each category were always higher in the 
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intervention group except for the categories administration and inpatient costs. The mean 
costs in each category were higher in the control group for the categories antineoplastic and 
supportive therapy, oncologist fee, administration and inpatient costs.  
It is uncertain whether all relevant cancer-related outpatient costs could be identified, as 
patients probably did not only consult physicians in the cooperating study centres but also 
other physicians for their cancer disease. It can be assumed that this possible lack of data is 
about the same in both patient groups and therefore negligible. 
Since the patient population is heterogenic, as described in the section before, it is hard to 
draw conclusions from the cost differences between the two patient groups. In the 
intervention group a higher percentage of patients received combination chemotherapy than in 
the control group at the time of inclusion (CG: 60 %, IG: 67 %) thus leading to higher median 
costs for antineoplastic therapy. The fact that 30 % of the intervention patients and only 3 % 
of the control patients were privately insured further biased the cost results as e.g. other 
supportive therapies can be prescribed and more diagnostic tests are reimbursed by a private 
insurance company than by a statutory insurance company. For a meaningful comparison of 
costs it was obligatory to match the patients according to their therapy regimen and also their 
type of insurance, which was done for the cost-utility analysis. Concerning the percentage 
distribution of cost categories in both patient groups, the high amount of money for 
antineoplastic therapy and the relatively low amount of money for inpatient stays is striking. 
A systematic review from 2009 on cost-of-illness studies for breast-, colorectal and prostate 
cancer patients showed that inpatient stays were responsible for 50-98 % of all direct costs 
[99]. Especially in the field of colorectal cancer the latest included study analysed direct costs 
from the year 2004 in France [100]. Two highly expensive medicinal products, cetuximab and 
bevacizumab, for the treatment of advanced colorectal cancer were approved only in June of 
the analysed year and January of the following year (2005) in Europe [101, 102]. This latest 
study by Clerk et al. maybe covered a fraction of applications of cetuximab but the other 
included studies definitely did not. The application of bevacizumab could not be considered in 
any study due to the later marketing authorisation. Clerk et al. found the following cost 
distribution in a French setting for the first twelve months following diagnosis: hospitalisation 
charges 55 %, medical purchases 24 %, outpatient care 18 % and transportation 3 %. A more 
recent cost-of-illness study would probably show a different cost distribution with a higher 
percentage of medical purchases. Nevertheless, the low amount of inpatient costs in the 
present study may lead to false conclusions without further explanation. The result is probably 
due to the choice of study onset as e.g. adjuvant patients entered the study after their main 
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inpatient period with costly surgical intervention. Inpatient stays are therefore 
underrepresented in the present study. However, if the purpose of the present study had been 
the conduction of a cost-of-illness study a different observation period would have been 
needed. Despite these limitations the overwhelming amount of money that had to be paid for 
antineoplastic therapies needs to be discussed. This observation is in agreement with two 
recent publications by Garattini et al. and Danzon et al. [103, 104]. According to them, 
Germany is Europe’s largest spender on drugs, and it also has the most new drugs available. 
In case of cancer therapy this circumstance especially plays a role as in this indication very 
costly innovative drugs are used. This was the case in the present study with e.g. bevacizumab 
and cetuximab for the treatment of advanced colorectal cancer and trastuzumab for the 
treatment of HER-2/neu positive breast cancer patients. The National Institute for Health and 
Clinical Excellence (NICE) in London published a technology appraisal about bevacizumab 
and cetuximab for the treatment of metastatic colorectal cancer in 2007. On the basis of the 
available evidence they concluded that both therapies showed health outcomes in colorectal 
cancer patients. Nevertheless, according to this appraisal the assessed cost-effectiveness ratio 
was not compatible with the best use of NHS resources as the industry-set prices for the two 
medicinal products were extremely high [105, 106]. The latest major health care system 
reform in Germany in 2007 amended the social legislative code to allow insurance funds to 
set maximum drug prices and negotiate prices with the industry. It also enabled the German 
Institute for Quality and Efficiency in Health Care (IQWiG) to assess the cost-effectiveness 
ratio that could help the insurance funds with their negotiations [94]. A judgment of the 
federal constitutional court from 6 December 2005 also known as the St-Nicholas judgment, 
said that it is not in agreement with the basic human rights to exclude a statutory insured 
patient suffering from a life-threatening disease from treatment options that might cure him or 
might have a positive influence on the course of his disease [107]. On the basis of this 
decision, negotiations between insurance funds and industry in the field of cancer are 
probably not possible as insurance funds have to pay whatever price is set. Moreover, there is 
a high risk that the insurance fund sets a maximum drug price and the industry does not lower 
its price resulting in patients who are able to pay the price difference and patients who are not. 
Nevertheless, the German health care system is under pressure and rational drug prices, 
possibly also in the field of cancer [in italics: note from the author], are essential for long-
term stability of a system founded on the principle of communal responsibility [108]. 
When looking closer at inpatient costs, and keeping in mind the heterogeneity of patients 
limiting the validity, it is striking that 60 % of control patients and only 41 % of intervention 
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patients were hospitalised during the study period. There were four neoadjuvant control 
patients versus one neoadjuvant intervention patient, thus increasing the hospitalisation rate in 
the control group. But aside from these hospitalisations due to surgery following neoadjuvant 
treatments and other reasons that are hard to influence, such as inpatient i. v. administration of 
chemotherapy and disease-related complications, there were four hospitalisations (13 % of 
hospitalisations) in the control group due to drug toxicity / adverse drug reactions versus only 
one in the intervention group (3 % of hospitalisations). Maybe one or more of those inpatient 
stays in the control group could have been prevented with the help of a pharmaceutical care 
service. It is widely known that serious adverse effects may lead to hospitalisation [109, 110]. 
A recent prospective multi-centre study in the Netherlands found that from about 13000 
unplanned hospital admissions 714 (6 %) were medication-related and almost half of these 
admissions were potentially preventable drug-related problems [111]. Westfeld et al. showed 
that pharmaceutical care can contribute to a reduction of adverse effects in cancer patients 
during chemotherapy concerning nausea and vomiting [25]. The effect of pharmaceutical care 
on hospitalisation rates was not evaluated in this study. Stewart et al. showed a reduced 
hospital readmission rate for patients with congestive heart failure who received a home-
based intervention by a pharmacist and a nurse to optimize medication management [112].  
The costs for pharmacists assessed in the present study amounted to € 94 per patient for a 
period of six months. This amount was obtained by multiplying the time to deliver 
pharmaceutical care (4.1 hours) with the gross wage of an employed community pharmacist 
in his second to fifth year on the job (€ 23). The assessed time is subject to uncertainty. The 
times assumed for writing individual patient letters and for other pharmaceutical services 
were estimated as they were not documented during the study. The pharmacist fee of € 23 
might not be the correct charge for an hour of pharmaceutical care service either. This 
uncertainty was accounted for by conducting a sensitivity analysis assuming the double fee of 
€ 46 within the cost-utility analysis (see 5.4 “Cost-utility analysis”). Other publications that 
accounted for pharmacist costs also multiplied the net time spent by the pharmacist with an 
hourly wage. McMullin et al. used a mean hourly rate of $ 30 (= € 25.42, 1999 exchange rate 
1.18 $ / €) for a clinical pharmacist. Van den Bemt et al. assumed a salary of € 51 per hour 
(2002) for a hospital pharmacist indicating that pharmacist salaries vary a lot between 
countries [113–116]. Despite the mentioned uncertainties in the assumed pharmacist time, the 
assessed amount of 4.1 hours per patient to deliver pharmaceutical care for six months might 
demonstrate to some critical colleagues that a pharmaceutical care service is not as time 
consuming as they might fear. Furthermore, for possible payers of a pharmaceutical care fee 
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of about € 188 for one year of service (or € 377 if a double fee is assumed) the amount of 
money is probably a comparatively low charge. 
Indirect costs were calculated based on the human capital approach by multiplying the 
number of days on sick leave with the average German gross wage per day. They amounted to 
a mean of € 4206 per patient in the control group and € 4993 per patient in the intervention 
group (p = 0.464). As data were neither available on the number of working hours per day in 
the case of part-time jobs nor on the exact date in the case of a switch from a full-time to a 
part-time job, missing days in part-time employment situations were valued like a whole day 
missing. The percentage of part-time working patients was higher in the intervention group 
thus leading to a slight overestimation of indirect costs in intervention patients. It is frequently 
argued that the human capital approach applied in the present study overestimates the true 
cost for the society. For example, in case of short-term absences from work, losses in 
production could be compensated for by colleagues and in case of long-term absences the 
employer is likely to hire a replacement worker. Both examples probably were the case in 
some of our patients. At the same time retired patients and housewives / -men were valued 
with € 0 in terms of indirect costs although they are definitely also of value for the society [3]. 
When adding the indirect costs to the total cost calculation, indirect costs amounted to 15 % 
of total costs in the control and to 17 % in the intervention group indicating that indirect costs 
play a role in the studied patient population. The slightly higher indirect costs in the 
intervention group were probably due to the younger age of the intervention patients (58 years 
versus 64.5 years, median) thus leading to a higher risk of production losses. The higher 
percentage of pensioners in the control group at the time of inclusion emphasises this 
argument (CG: 60 % versus IG: 37 %). Lidgren et al. who studied the cost of breast cancer in 
Sweden in 2002 found significantly higher amounts of indirect costs resulting in a share of 
70 % of total costs [117]. One reason for this higher amount is that they did not only include 
days on sick leave for indirect cost calculation as in the present study but also early retirement 
and premature mortality, the latter amounting to 52 % of indirect costs. The other reason is 
that in the present study the included colorectal cancer patients were older than the included 
breast cancer patients (55 years versus 64 years), thus reducing the indirect costs as more 
patients were already retired.  
Direct non-medical costs, also known as costs for informal care, were assessed in a 
qualitative manner. In the control group 16 to 24 % of patients needed help with every-day 
activities versus 10 to 30 % in the intervention group. Most of those patients indicated that 
they received help from family members or friends (CG: 75 %, IG: 96 %). As the patients 
86  Discussion 
were not asked to state the number of hours of informal care these costs could not be valued 
in money terms as was done, e.g., in a study by Lidgren et al. for patients with breast cancer 
[118]. They multiplied the number of hours of informal care per week by the cost of leisure 
time lost, which was estimated to be 35 percent of the gross wage rate (53 Swedish kronor = 
€ 7.38). Lidgren et al. found a mean number of 3.0 hours of informal care per week for 
metastatic breast cancer patients resulting in annual costs of 8350 Swedish kronor (= € 1163). 
There was no information available on how many percent of metastatic patients needed 
informal care. In a study by Yabroff et al. approximately 99.6 % of cancer patients reported 
that they did need some informal care [119]. They interviewed patients with bladder, breast, 
colorectal, kidney and other cancers about received informal care in the two years after their 
diagnosis. In this study informal care was not only defined as help with every-day activities 
but included four different categories: emotional, instrumental, tangible and medical support. 
This is probably one reason for the much higher amount of patients that needed informal care 
compared to the present study. Here the median wage rate in 2006 ($ 16.28 = € 12.33, 2006 
exchange rate $ / € 1.32) was used to value caregiver time [113]. These two examples show 
that the valuation of leisure time is not straightforward and different methods lead to different 
approximations of informal costs. Yabroff et al. found an average caregiver time of 8.3 hours 
per day for 13.7 months for all cancers. The average value of caregiver time over two years 
after diagnosis was $ 38334 (= € 29041) for breast and $ 45699 (= € 34620) for colorectal 
cancer patients. 
5.3 Outcome assessment 
As patient outcomes, quality of life measured with the EQ-5D questionnaire, the adverse drug 
reaction hand-foot syndrome and quality-adjusted life years were assessed. Moreover, in the 
intervention group the patients´ willingness-to-pay for the pharmaceutical care service was 
evaluated. 
Both patient groups started with the same median values in all five dimensions of the EQ-5D 
descriptive system. Most problems were evident in the dimensions “usual activities” and 
“pain / discomfort”. There was no deterioration in median values at any time. There were 
improvements in both patient groups for the dimension “usual activities” and an improvement 
in the dimension “pain / discomfort” in the control group. The corresponding utility scores 
calculated on the basis of the EQ-5D descriptive system showed a stable median utility score 
of 0.887 for the intervention patients at all times. The same median utility score was assessed 
for the control patients until t6 followed by an improvement to 0.999 at t7. These results 
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indicate a very high quality of life for both patient groups throughout the course of the study. 
Only the mean utility scores showed that there was a slight deterioration in quality of life in 
both patient groups from t0 to t3 (control group: 0.810 to 0.789, intervention group: 0.797 to 
0.781). In terms of absolute changes in utility scores there was no difference at any time for 
both groups. Concerning the visual analogue scale (VAS) the intervention group started with 
a higher score than the control group (IG: 62.5 versus CG: 52.5; median). Through all times 
of measurement the median VAS score improved in both groups. The mean VAS score 
deteriorated only for the intervention patients from t0 to t3. 
The EQ-5D questionnaire was evaluated only for those patients who were under treatment 
with capecitabine. In case capecitabine treatment was stopped, the answers to the 
questionnaire were not considered. This was done in order to receive more comparable patient 
groups as quality of life under treatment with completely different chemotherapy regimens or 
even no chemotherapy at all can hardly be compared. But still patients received different 
chemotherapy regimens at the time of inclusion although all contained capecitabine. For 
example there were more intervention patients with a curative treatment than control patients 
(CG: 23 % versus IG: 30 %). Curative regimens mostly accept a higher toxicity which 
probably has a negative effect on quality of life, whereas in palliative regimens the relief of 
symptoms and an improvement or stabilisation of quality of life is most important.  
It is striking that concerning the five dimensions and utility scores there was no deterioration 
in median values and an improvement in VAS scores although chemotherapy was started. It is 
widely known that especially curative chemotherapy has a negative influence on quality of 
life. A comparable study by Westfeld et al. on pharmaceutical care of adjuvant breast and 
ovarian cancer patients showed partly similar results: in the median there were no absolute 
changes between the utility scores from t0 to t1 and from t0 to t2 [25]. In that study also “pain” 
and “usual activities”, beside “anxiety / depression” were the dimensions with the most 
predominant problems. In the course of the study there were deteriorations in the control 
group in the dimensions “mobility”, “usual activities” and “pain / discomfort” and an 
improvement in “anxiety / depression”. In the intervention group there was an improvement 
in the dimension “mobility”, “anxiety / depression” and “self care” and a deterioration in 
“usual activities”. These changes did not result in absolute changes in utility scores as already 
mentioned. The changes that Westfeld et al. observed in the descriptive system might be due 
to the solely adjuvant treatment setting resulting in higher toxicity and a higher impact on 
quality of life than in the patient group studied in this piece of work. Due to the more toxic 
chemotherapy there was probably a higher possibility of alleviating effects of pharmaceutical 
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care. The median utility scores at the time of inclusion were 0.830 for the control and 0.796 
for the intervention group which was below the utility scores of the patients of the present 
study (in both groups 0.887). This might be due to the method of utility calculation: in the 
study by Westfeld et al. the utilities were generated with the UK TTO utility set and in the 
present study with the German TTO utility set in order to represent the preferences of the 
German insured population. A sensitivity analysis in the context of the cost-utility analysis 
showed that the UK set leads to lower utility scores than the German set. Another possible 
reason is that the present study also included colorectal cancer patients thus leading to 
different utility scores. In a study by Zhou et al. quality of life was assessed with the EQ-5D 
questionnaire in patients with metastatic breast cancer under treatment with lapatinib plus 
capecitabine versus capecitabine alone [120]. Quality of life for patients in both treatment 
groups could be maintained during 24 weeks of follow-up, which is in agreement with the 
here found results. The utility index showed a mean of 0.64 versus 0.66 at baseline. Conner-
Spady et al. found a mean EQ-5D utility score of 0.770 (SD 0.16) for breast cancer patients at 
baseline prior to the beginning of high-dose chemotherapy [121]. In a study by Wilson et al. 
colon cancer patients showed a utility index of 0.824 and rectal cancer patients of 0.761 six 
weeks after hospital discharge and potentially curative surgery [122]. In all three studies the 
utility scores were based on the UK TTO utility set, providing one reason for the lower utility 
scores at baseline compared to the here found results. The VAS utility scores at the time of 
inclusion in the study by Westfeld et al. lay below the utility scores from the descriptive 
system as was the case in the present study. This is a known phenomenon as valuations of 
quality of life that are not represented in the five dimensions are also included in the VAS 
score [123]. Others found that the VAS utility score is generally lower than a utility score 
from a TTO-based approach [124]. The latter formed the basis of the UK and German utility 
set used to transfer the EQ-5D into utility scores. Unlike the here presented results the VAS 
scores in the study by Westfeld et al. showed deterioration in median values for both patient 
groups during the course of the study. In conclusion, it seems that the generic EQ-5D 
questionnaire is either not sensitive enough to display the impact of the present antineoplastic 
therapy on quality of life of the studied patient population or the applied antineoplastic 
therapy did not affect quality of life considerably considering the high portion of palliative 
treatments. If the former is true, it would be very hard to detect an effect of pharmaceutical 
care on quality of life in the studied patient population, especially in the light of the 
heterogenic population considering the fact that the effect might be biased. Westfeld et al. 
also concluded that the EQ-5D questionnaire was not able to detect differences in quality of 
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life due to pharmaceutical care between the control and intervention group. Furthermore, the 
subsequently discussed positive impact of pharmaceutical care on the occurrence of the hand-
foot syndrome showed that the EQ-5D questionnaire could not display the impact of this 
adverse drug reaction on quality of life. A solution might be the application of a disease-
specific quality of life questionnaire like the EORTC-QLQ-C30. A limitation of this 
questionnaire is that it cannot be transferred into a single quality of life index which is 
essential for the use in cost-utility analyses. It remains to be evaluated whether other 
instruments like the Short Form 6D (SF-6D) or the Health Utilities Index (HUI) that can also 
be used in cost-utility analyses are more suitable for the present patient population [125–127]. 
The hand-foot syndrome (HFS) was measured with a patient questionnaire at seven times 
during the course of the study. Both patient groups started with HFS grade 0 at t1. In the 
intervention group the median HFS grade was 1 until t6 and ended with 0.5 at t7. In the control 
group the median HFS grade was grade 2 twice: at t5 and t7, with statistically significant 
differences between the two patient groups. At the other measurements HFS reached grade 1 
in the control group. Concerning the severest HFS grade 3, six out of 30 control patients 
(20 %) experienced HFS grade 3 at least once during the treatment with capecitabine versus 
only seven out of 46 intervention patients (15 %). The HFS utility scores were lowest in the 
control group with a median of 0.720 at t5 and t7. In the intervention group the lowest median 
score was 0.970. 
As the HFS grades were characterised by the patients themselves and not by a physician the 
above-mentioned results might be biased. Patients might have confused HFS with adverse 
drug reactions of combination partners that showed similar symptoms; e.g. cetuximab leads to 
skin changes and oxaliplatin causes peripheral neuropathy, both also possibly affecting hand 
and feet. Cetuximab was only applied in intervention patients and oxaliplatin was used in a 
higher percentage in intervention patients than in control patients, thus possibly worsening the 
reported HFS grades in the intervention group. Despite this possible bias the intervention 
patients showed milder HFS grades than the control group, indicating a positive effect of 
pharmaceutical care on the occurrence of HFS in the studied patient population. The positive 
impact of pharmaceutical care is not only presented by the two statistically significant results 
at t5 and t7, but also by the reduction of the risk to develop HFS grade 3 (CG: 20 %, IG: 
15 %). Especially the latter is of great importance to patients as HFS grade 3 has a 
corresponding utility score of 0.340 indicating a major impact on patients´ quality of life. In a 
study by Cassidy et al. 17 % of colorectal cancer patients treated with capecitabine developed 
HFS grade 3 [45]. Thus the intervention patients showed less and the control patients more 
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HFS grade 3 than these patients. Walko et al. summarised safety results of capecitabine from 
three trials in breast and colorectal cancer patients. They found that the median time to HFS 
onset is 79 days but can range from 11 to 360 days [43]. In the present study a median HFS 
grade of 1 was first reported at the end of cycle two (day 36) in both patient groups. In the 
control group a median HFS grade 2 primarily occurred after the fifth chemotherapy cycle 
(day 99), then it improved again to grade 1 and finally reached grade 2 once more at t7. This 
observed phenomenon is hard to explain, especially as the capecitabine dose in the control 
group was only known at the time of inclusion. Maybe the capecitabine dose was reduced in 
cycle six in the corresponding patients. As HFS symptoms had disappeared, it was increased 
again in cycle seven and HFS got worse. However, this procedure would not have been 
according to the common recommendations of managing HFS [40]. Maybe it was just an 
artefact due to the small sample size of eleven remaining control patients under treatment with 
capecitabine at that point in the study and there is no logical explanation. A longitudinal 
model to predict HFS dynamics in patients receiving capecitabine was recently developed by 
Hénin et al. with data from two phase III trials in metastatic colorectal cancer [128]. They 
found an obvious relationship between the proportional distribution of HFS grades and the 
time of treatment and therefore the exposure to treatment with capecitabine. For example at 
treatment week 14 (= treatment for five cycles) the probabilities for the different HFS grades 
were as follows: grade 0 = 55 %, grade 1 = 15 %, grade 2 = 25 % and grade 3 = 5 %. 
Furthermore, the lower the calculated creatinine clearance at inclusion, the higher was the risk 
of HFS. In conclusion, the author wants to emphasise the importance of further research in the 
field of HFS. Hitherto no evidence-based prophylaxis and treatment strategies, except dose 
reduction and treatment stop, have been available. The observed positive results in the 
intervention group were probably due to the intense education and monitoring of the patients 
in regard to their HFS. This and a good pharmacist-physician communication probably 
resulted in a faster HFS management by the physician. Further strategies could possibly 
further reduce the occurrence of HFS grades 2 and 3. The above-mentioned dynamic model of 
HFS by Hénin et al. might be an interesting tool to develop individual treatment adaptations 
for capecitabine patients [128]. 
Quality-adjusted life years (QALYs) were calculated on the basis of the EQ-5D and HFS 
utility scores. QALYs based on the EQ-5D utility score could be calculated for eight control 
and 17 intervention patients. Both groups almost gained the same amount of QALYs: control 
patients gained a median of 0.44 QALYs and intervention patients 0.42 QALYs. On the basis 
of the utility-time curve that included all existing EQ-5D utility scores the difference was 
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even smaller: 0.45 QALYs for control and 0.44 for intervention patients. The EQ-5D VAS 
score was not used for QALY calculation as in comparison to the utility scores derived from 
the EQ-5D descriptive system the scores are said to be “inherently flawed” and should 
therefore not be used if more reliable scores are available [125]. QALYs based on the HFS 
utility score could be calculated for eleven control and 20 intervention patients and amounted 
to 0.44 QALYs for the control and 0.46 QALYs for the intervention group. On the basis of 
the HFS utility-time curve the difference between the two groups increased: 0.45 QALYs for 
the control and 0.48 QALYs for the intervention group. The difference was more obvious in 
terms of quality-adjusted life days (QALDs) resulting in 13.2 more QALDs for the 
intervention group. These two contrasting QALY results depending on the utility score used 
were not astonishing following the discussion of the EQ-5D and HFS results in the previous 
two sections. The HFS QALYs showed the positive impact of pharmaceutical care on quality 
of life that could not be detected by the EQ-5D questionnaire. Still, it might seem logical that 
HFS grades 2 and 3 have an impact on the EQ-5D dimensions “mobility”, “self-care”, “usual 
activities” and “pain”. Nevertheless, the observed differing results are in agreement with the 
familiar but still discussed problem concerning QALYs: there is a lot of evidence that 
different utility elicitation methods used in the calculation of QALYs yield different results 
[126]. The sentence “A rose is a rose is a rose is a rose…” written by Gertrud Stein as part of 
the poem Sacred Emily is obviously not transferable to “A QALY is a QALY is a QALY is a 
QALY…”. Other concerns are e.g. the utilitarian thinking behind the QALY concept and the 
smaller capacity to benefit of older, sicker or disabled patients [129]. These are some reasons 
why e.g. the IQWiG refused to accept QALYs as a single outcome parameter. It preferred 
indication-specific outcome parameters for its evaluation of costs and outcomes [7]. Despite 
the limitations, the QALY approach was used in the present study and a cost-utility analysis 
of pharmaceutical care was conducted as it also has a lot of strengths; otherwise it would not 
be in the centre of health measurement of some decision makers including the National 
Institute for Health and Clinical Excellence in the UK. One big advantage of the QALY is the 
simultaneous capture of quality and quantity gains (quality of life and mortality) and their 
combination into a single generic measure so that comparisons between studies with different 
outcomes are possible [127]. 
The maximum “willingness-to-pay” (WTP) per month for the pharmaceutical care service 
was assessed in the intervention group. The median WTP amounted to € 45 per month (min: 
€ 5, max: € 500, n = 32, € 270 per six months). There was no correlation between the WTP 
and the net income per household member. Ten intervention patients gave no answer. During 
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the conduction of the WTP assessment different problems evolved. Some patients called the 
central study office and said that they did not understand the questionnaire. After an oral 
explanation this problem could be solved and the patients stated their WTP. But the presence 
of the clinical pharmacist might have biased the results in terms of a higher WTP in these 
cases. One patient thought that he should actually pay money for the received service and he 
had to be appeased that it was a misunderstanding. Others returned the questionnaire with a 
question mark or a diagonal line; in these cases “missing answers” were assumed. It was not 
clear whether some of these patients actually meant a WTP of € 0. The described problems 
indicated that patients need to become familiar with the WTP approach and that it is not a 
trivial undertaking to pose the question in a way that it is clear to the respondent as has been 
observed by others [3]. It was not easy for some patients to imagine this theoretical payment 
situation. Nor was it easy to set the benefit they received from the pharmaceutical care service 
in relation to the benefits they might get from other goods of daily life in the context of a 
resource allocation decision. For future WTP assessments a face-to-face interview by a non-
involved investigator is recommended rather than a questionnaire format in order to prevent 
misunderstandings and to improve response rates. The results obtained in the study need to be 
interpreted carefully. The amount of € 45 per month or € 270 per six months is quite high in 
comparison to the costs for pharmacists of € 94 per six months. This result may indicate that 
the pharmaceutical care service was perceived as useful by the patients even though no 
quality of life changes were measured with the EQ-5D questionnaire. The WTP approach has 
been used in some studies to investigate the intangible benefits of pharmaceutical care 
services [130–132]. Suh et al. measured WTP for pharmacists´ services directed toward 
reducing the risk of medication-related problems [130]. They found a mean WTP from $ 4.02 
to $ 5.48 per prescription (€ 3.68 - € 5.03, 2000 exchange rate $ / € 1.09), depending on the 
level of risk reduction [113]. If the patients´ insurance covered the service they would be 
willing to pay $ 28.79 to $ 36.29 per year (€ 26.41 to € 33.29) as an extra premium. Overall, 
the average WTP for a pharmacist’s consultation was $ 5.57 (€ 5.11) and increased by $ 0.87 
(€ 0.80) as consultation time increased by 1 minute. If this last result was used to calculate the 
WTP for the delivered 246 minutes of pharmaceutical care within six months in the present 
study, it would amount to € 196.80 (246 minutes x € 0.80). Thus it would lie below the 
maximum WTP of € 270 of the intervention patients of this study. But there is a time 
difference of about eight years between the WTP assessment by Suh et al. and the present 
study. Moreover, the mixed US American patient collective in the study by Suh et al. 
probably had different preferences than a German cancer patient.  
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5.4 Cost-utility analysis 
A cost-utility-analysis was conducted for retrospectively matched patient pairs from the 
control and intervention group. Patients were matched according to the parameters tumour 
entity (breast, colorectal cancer), treatment setting (adjuvant, neoadjuvant, palliative), therapy 
regimen at the time of inclusion, treatment with bisphosphonates at the time of inclusion and 
type of health insurance (statutory or private) resulting in eleven matched patient pairs. Some 
other typical variables used in matching procedures include gender, age, socioeconomic status 
or hospital, which complies with therapy setting (outpatient ward or oncology practice) in our 
case [133]. A matching approach has also been used by Mangiapane et al. in a study on 
pharmaceutical care of asthma patients. They matched a subgroup of intervention patients 
according to gender, age, date of recruitment and amount of prescribed anti-asthmatics with 
control patients [134]. In the present study quality of life at the time of inclusion could also 
have been a considered matching parameter. The inclusion of the above-mentioned additional 
parameters would have further reduced the number of matching patient pairs possibly 
resulting in a case report. Therefore they were not applied. When comparing the eleven 
matched patient pairs regarding gender and quality of life at the time of inclusion there were 
no differences between the two groups. Concerning age the selected intervention patients 
were eleven years younger in the median than the control patients. But it is much more 
important that the groups were consistent with quality of life rather than age at the time of 
inclusion as there might be older patients who are fit and younger patients who are frail. In 
respect of the therapy setting outpatient ward versus oncology practice the distribution in both 
selected groups was almost equal. Seven control patients versus six intervention patients were 
treated on an oncology outpatient ward, thus limiting the possible bias of the slightly different 
charging modalities depending on the therapy setting. 
For the cost-utility analysis only direct costs were considered as the indirect costs were 
regarded to be too uncertain. The distribution of different cost categories in the selected 
patient groups followed the same order as the cost categories in the whole patient population 
(see section 5.2 “Cost assessment”). One peculiarity were the costs for supportive therapy in 
the selected control group as they were almost as high as the costs for inpatient stays. The 
reason was the application of several highly expensive supportive treatments in the control 
group as discussed below. Costs for antineoplastic therapy were higher in the intervention 
group than in the control group mainly because of one control patient who declined treatment 
after one cycle leading to low costs of € 525. He died on day 61 of the study. The costs of one 
matching intervention patient reached about € 25000 as he received the antineoplastic 
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treatment until the end of the study. This example reflects the problem of the small sample 
size of eleven matched-pairs. Within a larger patient group one patient would not have had 
such an immense weight in terms of cost differences. In case of costs for supportive care and 
inpatient stays it was vice versa – higher costs arose for the selected control patients. Reasons 
for the higher supportive costs were treatments with Neulasta® (pegfilgrastim), parenteral 
nutrition, Cosmofer® (iron dextrane) and Aranesp® (darbepoetin alpha). No intervention 
patient received any of these treatments, except for Aranesp® which was applied once. Two 
other intervention patients who also suffered from anaemia were treated with human 
erythrocyte concentrates instead. Especially concerning treatment with erythropoietin 
analogues for chemotherapy-induced anaemia the pharmacist-physician consultations in the 
intervention period might have influenced that result. In these consultations the pharmacist 
gave oral and written information on a technology appraisal in progress of the NICE on 
erythropoietin analogues in cancer-treatment induced anaemia. The final appraisal does not 
recommend the routine use of erythropoietin analogues as was true for the interim 
recommendations. The only exception is ovarian cancer patients receiving platinum-based 
chemotherapy and patients who cannot receive blood transfusions [135, 136]. In the selected 
intervention group one patient received transfusion with erythrocyte-concentrates instead of 
erythropoietin analogues. Whether the treatment with Cosmofer® of one control patient was 
clinically necessary or an oral iron preparation would have been sufficient cannot be tracked. 
The same is true for treatment with Neulasta®. Intensive discussions also took place regarding 
guideline compatible prophylaxis of nausea and emesis in different study centres. In both 
patient groups Kevatril® (granisetron) was used in all patients receiving treatment with 
paclitaxel / capecitabine. According to the NCCN and MASCC guidelines of 2007 only 8 mg 
of dexamethasone on day 1 would be necessary as the mentioned combination is a low emetic 
risk chemotherapy regimen [137, 138]. As the clinical pharmacist was not a real member of 
the clinical team the implementation was slow, but also because of the needed consent from 
different team members. In the meantime the implementation was successful, mainly because 
of a new clinical pharmacist who now works in one study centre and who could support the 
process. An emetic prophylaxis as recommended by the clinical pharmacist would have saved 
additional money for supportive therapy in the intervention group. Inpatient costs were higher 
in the selected control group as four control patients showed inpatient stays versus only two 
intervention patients. One selected control patient was hospitalised due to the adverse drug 
reaction “fever under chemotherapy”. No selected intervention was hospitalised due to an 
adverse drug reaction. It is hard to say whether “fever under chemotherapy” could have been 
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avoided by the pharmaceutical care service. But it is true that intervention patients receiving 
chemotherapy with a high risk of neutropenia and related fever received special information 
from the pharmacist. This information consisted of behavioural advice in case of neutropenia 
thus maybe influencing the occurrence of neutropenic fever [139]. Concerning other 
publications on impact of pharmaceutical care on hospitalisation rates see chapter 5.2 “Costs 
assessment”. 
The median quality-adjusted life years (QALYs) were almost the same in the two selected 
groups 0.44 QALYs versus 0.45 QALYs in favour of the intervention group. This advantage 
was more obvious when looking at the mean QALYs: 0.32 versus 0.40. The slightly positive 
result for the intervention group, in contrast to the result in the whole patient population (see 
5.2 “Outcome assessment”), may be due to the more comparable patients following the 
matching process. The matching parameters might have biased the QALY results in the whole 
patient group. But the result might also be an artefact due to the limited sample size of eleven 
patient pairs. In contrast to the QALYs in the whole patient population, here also those EQ-
5D utility scores were evaluated during periods without chemotherapy or regimens without 
capecitabine. When a patient died his utility score was assumed to be zero (= dead) to act as a 
counterbalance for no further costs from that period onwards. In other words the last observed 
utility score of a living patient was extrapolated to a utility score of zero at the normally 
following time of measurement. Otherwise an early death would present a cost-effective 
situation if it was not accounted for on the outcomes side. That possibility is actually the 
advantage of the QALY because it combines quality and quantity of life. In a Markov model 
based cost-utility analysis of cancer drugs in patients with advanced small-cell lung cancer a 
utility score of zero was also assigned to the state “death” [140]. QALY calculations based on 
the HFS utility scores on the other hand only make sense for those patients under treatment 
with capecitabine as it is a specific capecitabine-related side effect. Due to this prerequisite 
HFS-based QALYs could only be calculated for three control and four intervention patients 
and thus could not be used for further analysis. 
The pharmaceutical care service was associated with a gain in mean QALYs compared to 
standard care of 0.08 QALYs (0.40 QALYs ± 0.14 versus 0.32 QALYs ± 0.19) at lower mean 
costs of - € 474 (€ 15606 ± 13816 versus € 16080 ± 11308). Thus the intervention 
‘pharmaceutical care’ dominated the comparator ‘standard care’. The bootstrapping showed 
lower costs and more QALYs than the control group in 43 % of all replications; more costs 
and more QALYs in 44 % of all replications; lower costs and less QALYs in 10 % of all 
replications and more costs and less QALYs in 3 % of all replications. According to the cost-
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effectiveness acceptability curve the probability that pharmaceutical care was a cost-effective 
strategy was 43 % at a willingness-to-pay (WTP) for an additional QALY of € 0, reaching 
62 % probability at a WTP of € 29000 per additional QALY. The bootstrap results indicated 
that there was a quite high probability of the pharmaceutical care service being associated 
with a QALY gain (87 % of all replications showed a QALY gain). The cost-effectiveness 
acceptability curve indicated a moderate to high probability of the pharmaceutical care service 
to be a cost-effective service in the selected patient population. 
Due to the small sample size of 22 patients this result has limited validity as is emphasised by 
the worst and best case sensitivity analyses. In the worst case scenario € 1922.84 would have 
to be paid to gain 0.09 QALYs in one intervention patient (ICURworst case = € 21365/QALY). 
In the best case scenario €817.91 would have been saved and 0.08 QALYs would have been 
gained. But also if the ICURworst case reflected the true ratio this would probably still be 
considered cost-effective by the NICE. According to a review on NICE´s recommendations 
between 1999 and 2005, NICE requires “[…] more explicit reference to factors including the 
range of uncertainty […], the innovative nature of the technology, the particular features of 
the condition and the population receiving the technology, and where appropriate the wider 
societal costs and benefits. […]” when the cost per QALY is above ₤ 20000 (€ 29000) [85]. 
The ICURworst case still was below this threshold. The highest cost per QALY that NICE has 
accepted is an estimated ₤ 39000 (€ 57000) for riluzole to treat motor neurone disease 
indicating that the clinical situation of the patients plays a key role in the decision making. 
The two further sensitivity analyses evaluating the impact of the pharmacist costs and the 
applied utility set showed that both parameters did not change the result considerably. To the 
knowledge of the author no prospective cost-utility analysis of a pharmaceutical care service 
has been published up to now. Only one recent model-based analysis of interventions aimed 
at preventing medication errors at hospital admission was found. Pharmacist-led medicines 
reconciliation was the intervention with the highest expected net benefits and a probability of 
being cost-effective of 60 % for an additional cost per QALY of ₤ 10000 (€ 15000) [141]. 
The recent review by Rijdt et al. focused on economic effects of clinical pharmacy 
interventions in the hospital setting. The results of pharmacoeconomic analyses suggested that 
general clinical pharmacy interventions are associated with cost-savings. This trend could be 
confirmed in the present cost-utility analysis. Rijdt et al. criticized that most evaluations 
suffered from a number of methodological limitations relating to the absence of a control 
group, exclusion of pharmacist employment costs, exclusion of health outcomes, use of 
intermediate outcome measures, absence of incremental and sensitivity analyses, limited 
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scope of costs and outcomes and focus on direct health care costs only [33]. Except for the 
last point the present economic evaluation of pharmaceutical care service considered all 
recommendations mentioned. Indirect costs were assessed in the whole patient population but 
not incorporated into the cost-utility analysis for the above-mentioned reason. According to 
Rijdt et al. the present study could be classified as a study of high methodological quality but 
with one big limitation of a small sample size. 
5.5 Conclusion and perspectives 
Costs for antineoplastic therapy played a dominant role in the direct disease-related costs in 
both patient groups, followed by inpatient stays. Indirect costs have been identified as a cost 
category that should not be underestimated in the present patient population. Costs for 
pharmacists were very low compared to other cost categories in the intervention group. 
Because of the heterogenic patient population especially concerning the therapy regimen at 
the time of inclusion, conclusions regarding cost differences between the two patient groups 
were drawn for the matched patient pairs only. Pharmaceutical care showed a statistically 
significant impact on hand-foot syndrome (HFS), the most frequent and at the same time 
dose- and therapy-limiting toxicity under treatment with capecitabine, at particular points of 
time. No impact of pharmaceutical care on quality of life measured with the EQ-5D 
questionnaire could be found. In general quality of life was very high and stable. The 
intervention patients´ willingness-to-pay (WTP) per month for the pharmaceutical care 
service was quite high in comparison to the actual pharmacist costs but also in comparison to 
other reported WTP amounts. This high WTP indicated that the pharmaceutical care service 
was perceived as valuable by the intervention patients.  
The cost-utility analysis of the eleven matched patient pairs showed that in terms of common 
understanding of cost-effectiveness the pharmaceutical care service was a cost-effective 
service in the studied patient population. The very small sample size of 22 patients limits the 
validity of the observed positive result. 
For future analyses of costs and outcomes of pharmaceutical care services from a health 
insurance perspective, cooperation with a major health insurance company is recommended 
for the collection of patient-level cost data. Moreover, different quality of life instruments that 
can also be transferred into a single utility index should be investigated in a similar patient 
population to evaluate quality of life changes during chemotherapy and the impact of 
pharmaceutical care. As the WTP questionnaire had to be explained to some patients an oral 
WTP interview should be conducted by an independent interviewer to confirm the high WTP 
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of the intervention patients. For future cost-utility analyses a larger sample size is mandatory 
to investigate the cost-effectiveness of pharmaceutical care. If possible the inclusion criteria 
should be narrower in terms of acceptable therapy regimens at the time of inclusion to achieve 
better comparable patient groups. If feasible in terms of manpower, a cluster randomization of 
study centres should be conducted to control for bias followed by a retrospective matching of 
control and intervention patients. Ideally, clinical pharmacists should be integrated into the 
clinical team not only at selective points of time but during the whole study period.  
The present project was the first study to survey the costs and outcomes of a pharmaceutical 
care service delivered to cancer patients. Before, no scientific evidence was available on 
pharmacoeconomics of pharmaceutical care research in oncology. 
Despite the limitations of the present study which were discussed in detail, the used methods 
and gained results might serve as a valuable basis for future analyses of costs and outcomes 
not only of pharmaceutical care services but also of other complex interventions such as 
disease management programs (DMPs). 
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6 Summary 
Objective: The present pharmacoeconomic pilot study aimed at evaluating the costs and 
outcomes of a pharmaceutical care service delivered to cancer patients treated with 
capecitabine compared to standard care. 
Methods: An open, prospective, multi-centred cohort study with a preceding control group 
was chosen as the study design. Colorectal and breast cancer patients treated with 
capecitabine were included in the study. For a study period of six months control patients 
received standard care whereas intervention patients received intensified pharmaceutical care. 
Endpoints within the study were direct disease-related outpatient and inpatient costs, health-
related quality of life, the most frequent and at the same time dose- and therapy-limiting 
toxicity hand-foot syndrome (HFS) and quality-adjusted life years (QALYs). Further 
endpoints were the indirect disease-related costs, direct non-medical disease-related costs and 
the willingness-to-pay of the intervention patients for the pharmaceutical care service. 
Another objective was to determine the cost-effectiveness of the pharmaceutical care service 
in a cost-utility analysis. Resource use data on direct disease-related outpatient costs 
(pharmacotherapy, oncologist fee, diagnostics and administration) were retrieved from patient 
files. Data on inpatient stays during the study period were obtained from the hospital 
controlling centres. As a measure for pharmacist costs the time spent by the study pharmacists 
on delivering pharmaceutical care was used. Information on the number of days on sick leave 
were obtained from patients and used to calculate indirect costs. Quality of life was assessed 
with the EQ-5D questionnaire. HFS was assessed with a patient questionnaire after each 
chemotherapy cycle. QALYs were calculated on the basis of the EQ-5D index score and on 
the basis of HFS grade-related utility scores. The cost-utility analysis was based on direct-
disease-related costs and QALYs of retrospectively matched patient pairs from the control 
and intervention group. Matching parameters were tumour entity, treatment setting, 
antineoplastic regimen and treatment with bisphosphonates at the time of inclusion and type 
of health insurance. 
Results: Thirty patients were analysed in the control group and 46 patients in the intervention 
group. Costs for antineoplastic therapy played a dominant role in the direct costs in both 
patient groups (control group: 70 %, intervention group: 73 % of total direct costs), followed 
by costs for inpatient stays (control group: 17 %, intervention group: 14 % of total direct 
costs). Indirect costs accounted for 14 % and 17 % of total costs in the control group and 
intervention group, respectively. Costs for pharmacists were very low compared to other cost 
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categories (0.41 % of total direct costs). Because of the heterogenic patient population 
especially concerning the therapy regimen at the time of inclusion, conclusions regarding cost 
differences between the two patient groups were drawn for the matched patient pairs only. 
However, inpatient stays due to adverse drug reactions were higher in the control group 
compared to the intervention group. Furthermore, pharmaceutical care showed a statistically 
significant impact on HFS at particular points of time. No impact of pharmaceutical care on 
quality of life measured with the EQ-5D questionnaire could be monitored. In general, quality 
of life under treatment with capecitabine was very high and stable with a median utility index 
of 0.887 in both patient groups and a slight improvement in the control group for the last point 
of measurement. QALYs based on the HFS and EQ-5D questionnaire reflected the positive 
impact of pharmaceutical care on HFS and no impact on quality of life. The intervention 
patients stated a median willingness-to-pay (WTP) of € 45 per month for the pharmaceutical 
care service, thus exceeding the costs for pharmacists of € 16 per month. The retrospective 
identification of matched-pairs for the cost-utility analysis yielded eleven patient pairs. In the 
analysis 0.08 QALYs could be gained and € 474 could be saved in comparison to the selected 
control group, thus demonstrating dominance of the pharmaceutical care service. The result 
was robust to changes in pharmacist costs and the EQ-5D utility set used. It was sensitive to 
the analysis of extremes. In the worst case scenario € 1923 had to be invested to gain 0.09 
QALYs in an intervention patient resulting in an ICUR of € 21365 / QALY. In the best case 
scenario 0.08 QALYs could be gained and € 818 could be saved per intervention patient. The 
bootstrapping showed that in 87 % of all replications the pharmaceutical care service was 
associated with a gain in QALYs. According to the cost-effectiveness acceptability curve the 
probability that pharmaceutical care was a cost-effective strategy was 43 % at a WTP for an 
additional QALY of € 0, reaching 62 % probability at a WTP of € 29000 per additional 
QALY. 
Conclusion: In this pharmacoeconomic pilot study costs for antineoplastic therapy played a 
dominant role in the direct disease-related costs in both patient groups. The results of the 
study indicated that pharmaceutical care might be associated with improved HFS. The high 
WTP of the intervention patients for the pharmaceutical care service showed that the service 
was perceived as valuable by them. The results of the cost-utility analysis indicated that in 
terms of common understanding of cost-effectiveness the pharmaceutical care service was a 
cost-effective service in the studied patient population. The very small sample size of 22 
patients included in the cost-utility analysis limits the validity of the observed positive result. 
Further studies with a larger sample size are needed to confirm these findings.
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Partial funding of the study was provided by Roche Pharma AG, Basel. However, the 
researchers were entirely independent during all phases of this work. 
The central study office cooperated with Roche Pharma AG, Basel during the execution of the 
study. The clinical pharmacists were working as advisors in the context of a non-
interventional study on capecitabine treatment in metastatic breast cancer patients. 
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112  Appendix 
Inpatient costs 
Indirect costs 
Quality of life 
Hand-foot syndrome (HFS) 
Willingness-to-pay (WTP) 
Cost-utility analysis 
 
 
Appendix A  113 
Appendix A: Cost and outcome assessment tools 
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activities and current employment situation, part 1 
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Hardcopy of electronic patient file (extract) 
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Appendix B: Informed consent 
Patient information brochure (example Johanniter Hospital, Bonn) 
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Recruitment fax (example Johanniter Hospital, Bonn) 
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Consent form, part 1 
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Appendix C: Pharmaceutical care service 
Pharmaceutical care plan, part 1 
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A
ppendix C
 
 
151 
Patient brochure on adverse drug reactions 
152 
 
A
ppendix C
 
 
Appendix C  153 
Patient letter containing medication plan 
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Consultation documentation form, first patient-pharmacist consulation 
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Consultation documentation form, follow-up consultations 
(For patient-pharmacist and pharmacist-physician consultations) 
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Reminding card, control group 
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Appendix D: Results 
EBM digits 
Table D-1: EBM digits coding for oncologist fee 
EBM digit Points / € (2008) Meaning (2008) 
01311 175 
Grundpauschale für Versicherte ab 
Beginn des 6. bis zum vollendeten 59. 
Lebensjahr 
01312 205 Grundpauschale für Versicherte ab Beginn des 60. Lebensjahr 
01510 1420 Zusatzpauschale für ambulante Beobachtung und Betreuung, > 2 h 
01511 2700 Zusatzpauschale für ambulante Beobachtung und Betreuung, > 4 h 
01512 3970 Zusatzpauschale für ambulante Beobachtung und Betreuung, > 6 h 
02100 160 Infusion, mind. 10 min Dauer 
02101 445 
Infusionstherapie, 
obligat: i.v. Zytostatika, Virustatika, 
Antimykotika und/oder Antimykotika 
mit konsumierender Erkrankung, mind. 
60 min Dauer 
02110 600 
Erste Transfusion der ersten 
Blutkonserve/ Blutpräparation/ 
Frischblut 
02111 240 Jede weitere Transfusion im Anschluss an die Position 02110 
02341 330 Punktion II (z.B. Mammae, Knochenmark, Leber, Pankreas) 
02343 725 Entlastungspunktion des Pleuraraums und/oder nichtoperative Pleuradrainage 
02511 30 
Elektrotherapie unter Anwendung 
niederfrequenter und/oder 
mittelfrequenter Ströme 
03115 35 Konsultationskomplex 
08215 (only 2007) 50 
Konsultationskomplex, weiterer 
persönlicher oder anderer Arzt-
Patientenkontakt (=frauenärztliche 
Grundleistung) 
08220 (only 2007) 235 
Beratung, Erörterung und/oder 
Abklärung, mind. 10 min Dauer 
(=frauenärztliche Grundleistung) 
08345 (not 2007) 540 
Zusatzpauschale Behandlung und/oder 
Betreuung eines Patienten mit einer 
gesicherten onkologischen Erkrankung 
bei laufender Therapie oder Betreuung 
im Rahmen der Nachsorge 
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EBM digit Points / € (2008) Meaning (2008) 
13215 (only 2007) 50 
Konsultationskomplex, weiterer 
persönlicher oder anderer Arzt-
Patientenkontakt (=internistische 
Grundleistung) 
13220 (only 2007) 235 
Beratung, Erörterung und/oder 
Abklärung, mind. 10 min Dauer 
(=internistische Grundleistung) 
13491 865 
Grundpauschale für Versicherte ab 
Beginn des 6. bis zum vollendeten 59. 
Lebensjahr (Hämato-/Onkologie) 
13492 905 
Grundpauschale für Versicherte ab 
Beginn des 60. Lebensjahrs (Hämato-
/Onkologie) 
13500 540 
Zusatzpauschale Behandlung einer 
laboratoriumsmedizinisch oder 
histologisch/zytologisch gesicherten, 
primär hämatologischen und/oder 
onkologischen und/oder 
immunologischen Systemerkrankung 
13502 540 
Zusatzpauschale intensive, 
aplasieinduzierende und/oder 
toxizitätsadaptierte antiproliferative 
Behandlung  
16215 (only 2007) 50 
Konsultationskomplex, weiterer 
persönlicher oder anderer Arzt-
Patientenkontakt (=neurologische 
Grundleistung) 
16220 (only 2007) 235 
Beratung, Erörterung und/oder 
Abklärung, mind. 10 min Dauer 
(=neurologische Grundleistung) 
30400 210 Massagetherapie (z.B. manuelle Lymphdrainage) 
30420 265 Krankengymnastik (Einzelbehandlung), mind. 15 min Dauer 
80111 175 
Grundpauschale für Versicherte ab 
Beginn des 6. bis zum vollendeten 59. 
Lebensjahr, Gemeinschaftspraxis und 
MVZ 
80112 205 
Grundpauschale für Versicherte ab 
Beginn des 60. Lebensjahr, 
Gemeinschaftspraxis und MVZ 
86503 € 25.56 Behandlung solider Tumoren 
86505 € 255.65 Intravasale Polychemotherapie pro Behandlungsfall 
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Table D-2: EBM digits coding for diagnostics (laboratory parameter / blood test) 
EBM digit Charge [€] (2008) Meaning (2008) 
32030 € 0.50 Orientierende Untersuchung 
32031 € 0.25 Mikroskopische Untersuchung des Harns 
32042 € 0.25 BSG (Blutkörperchensenkungs- geschwindigkeit) 
32056 € 0.25 Gesamteiweiß 
32057 € 0.25 Glucose 
32058 € 0.25 Bilirubin gesamt 
32059 € 0.40 Bilirubin direkt 
32060 € 0.25 Cholesterin gesamt 
32061 € 0.25 HDL-Cholesterin 
32063 € 0.25 Triglyceride 
32064 € 0.25 Harnsäure 
32065 € 0.25 Harnstoff 
32066 € 0.25 Kreatinin (Jaffé-Methode) 
32067 € 0.40 Kreatinin enzymatisch 
32068 € 0.25 Alkalische Phosphatase 
32069 € 0.25 GOT 
32070 € 0.25 GPT 
32071 € 0.25 Gamma-GT 
32072 € 0.40 Alpha-Amylase 
32073 € 0.40 Lipase 
32074 € 0.25 Creatinkinase (CK) 
32075 € 0.25 LDH 
32081 € 0.25 Kalium 
32082 € 0.25 Calcium 
32083 € 0.25 Natrium 
32084 € 0.25 Chlorid 
32085 € 0.25 Eisen 
32086 € 0.40 Anorganisches Phosphat 
32094 € 4.00 HbA1 und/oder HbA1c 
32101 € 3.00 Quantitative Bestimmung mittels Immunoassay, Thyrotropin (TSH) 
32103 € 0.60 Gesamt-IgA 
32104 € 0.60 Gesamt-IgG 
32105 € 0.60 Gesamt-IgM 
32107 € 0.75 Elektrophoretische Trennung von Proteinen oder Lipoproteinen im Serum 
32110 € 0.75 Blutungszeit 
32112 € 0.60 Partielle Thromboplastinzeit (PTT) 
32113 € 0.60 Quick, Thromboplastinzeit (TPZ) aus Plasma 
32115 € 0.75 Thrombingerinnungszeit (TZ) 
32116 € 0.75 Fibrinogen 
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EBM digit Charge [€] (2008) Meaning (2008) 
32120 € 0.50 
Bestimmung von mind. 2 der folgenden 
Parameter: Erythrozytenzahl, 
Thrombozytenzahl, Leukozytenzahl, 
Hämoglobin, Hämatokrit, mechanisierte 
Retikulozytenzählung 
32122 € 1.10 
Vollständiger Blutstatus mittels 
automatisierter Verfahren (obligater 
Leistungsinhalt: Erythrozytenzahl, 
Thrombozytenzahl, Leukozytenzahl, 
Hämoglobin, Hämatokrit, mechanisierte 
Zählung der Neutrophilen, Eosinophilen, 
Basophilen, Lymphozyten und Monozyten) 
32123 € 0.40 
Zuschlag zu 32121 oder 32122 bei 
nachfolgender mikroskopischer 
Differenzierung 
32169 € 15.30 
Vergleichende hämatologische 
Begutachtung von mikroskopisch 
differenzierten Ausstrichen des 
Knochenmarks und des Blutes einschl. 
Dokumentation 
32248 € 1.40 Magnesium 
32324 € 4.90 CEA (Carcinoembryonales Antigen) 
32325 € 4.90 Ferritin 
32354 € 5.60 LH (Lutropin) 
32355 € 5.10 Prolaktin 
32356 € 5.10 Östradiol 
32357 € 4.60 Progesteron 
32390 € 9.70 CA 125 
32391 € 8.20 CA 15-3 
32392 € 9.20 CA 19-9 
32395 € 19.90 NSE (Neuronenspezifische Enolase) 
32426 € 4.60 Gesamt-IgE 
32435 € 6.90 Albumin 
32446 € 8.70 Kappa-Ketten 
32447 € 8.70 Lambda-Ketten 
32448 € 10.20 Immunglobulin A, G oder M im Liquor 
32460 € 5.40 CRP (C-reaktives Protein) 
32494 € 7.70 Antimitochondriale Antikörper (AMA), auch Subtypen, z. B. AMA-M2 
32540 € 9.20 Nachweis der Blutgruppenmerkmale A, B, 0 und Rh-Faktor D 
32542 € 7.20 Coombs-Test 
32545 € 7.20 Antikörper-Suchtest 
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Table D-3: EBM digits coding for diagnostics (CT / MRT) 
EBM digit Points / € (2008) Meaning (2008) 
34311 2100 CT von Teilen der Wirbelsäule 
34330 1865 CT Thorax 
34340 1875 CT Oberbauch 
34341 2315 CT Abdomen 
34342 1875 CT Becken 
34345 545 CT-Zuschlag bei Kontrastmitteleinbringungen 
34411 3430 MRT von Teilen der Wirbelsäule 
34421 3430 MRT Schädelbasis 
34440 3430 MRT Oberbauch 
34441 3430 MRT Abdomen 
34442 3430 MRT Becken 
 
Table D-4: EBM digits coding for diagnostics (other) 
EBM digit Points / € (2008) Meaning (2008) 
01741 4325 Koloskopischer Komplex 
01756 215 Histologische Untersuchung eines durch Biopsie gewonnenen Materials 
13251 565 Belastungs-EKG 
13422 2645 Zusatzpauschale (Teil-) Koloskopie (inklusive Kolon transversum) 
17311 1860 Ganzkörperszintigraphische Untersuchung 
17312 475 Zuschlag zu 17311 
17362 1900 Zuschlag SPECT 
27320 225 EKG 
32045 € 0.25 Mikroskopische Untersuchung eines Körpermaterials 
32687 € 5.10 Kulturelle mykologische Untersuchung 
32722 € 7.70 Stuhluntersuchung 
32749 € 12.80 Nachweis bakterieller Toxine 
32750 € 2.60 Differenzierung gezüchteter Bakterien mittels mono- oder polyvalenter Seren 
32760 € 4.10 Bakterienreinkultur-Differenzierung, bis zu 3 Reaktionen 
33011 245 
Sonographie der Gesichtsweichteile 
und/oder Halsweichteil und/oder 
Speicheldrüsen 
33020 760 
Echokardiographische Untersuchung 
(Sonographie) mittels M-Mode und B-
Mode Verfahren 
33040 360 Sonographie Thorax 
33041 465 
Sonographische Untersuchung einer oder 
beider Brustdrüsen mittels B-Mode-
Verfahren, ggf. einschl. der regionalen 
Lymphknoten, je Sitzung 
33042 445 Sonographische Untersuchung des Abdomens 
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EBM digit Points / € (2008) Meaning (2008) 
33044 400 Sonographie der weiblichen Genitalorgane 
34220 270 Röntgenaufnahme des knöchernen Thorax 
34221 430 Röntgenaufnahme von Teilen der Wirbelsäule (mind. 2 Ebenen) 
34234 210 Röntgenaufnahme des Beckens und/oder dessen Weichteile 
34241 430 Röntgenaufnahme der Brustorgane (2 Ebenen) 
 
Table D-5: EBM digits coding for administration 
EBM digit Points / € (2008) Meaning (2008) 
01430 35 
Verwaltungskomplex (z.B. Ausstellung 
von Wiederholungsrezepten ohne 
persönlichen Arzt-Patientenkontakt) 
01600 110 Ärztlicher Bericht über das Ergebnis einer Patientenuntersuchung 
01601 210 
Ärztlicher Brief in Form einer 
individuellen schriftlichen Information des 
Arztes an einen anderen Arzt über den 
Gesundheitsstatus des Patienten 
01602 35 Mehrfertigung (z.B. Kopie) eines Berichtes oder Briefes 
01610 40 Bescheinigung zur Feststellung der Belastungsgrenze 
01620 85 
Kurze Bescheinigung oder kurzes Zeugnis, 
nur auf besonderes Verlangen der 
Krankenkasse 
01621 125 
Krankheitsbericht, nur auf besonderes 
Verlangen der Krankenkasse oder 
Ausstellung der vereinbarten Vordrucke 
nach den Mustern 11, 53 oder 56 
01622 235 Schriftlicher Kurplan / Gutachten, auf besonderes Verlangen der Krankenkasse 
32008 / Kennnummer, Abrechnungsscheine sind damit zu kennzeichnen 
32012 / 
Kennnummer „Tumorerkrankung unter 
parenteraler tumorspezifischer Behandlung 
oder progrediente Malignome unter 
Palliativbehandlung“, Abrechnungsscheine 
sind damit zu kennzeichnen 
32019 / 
Kennnummer “Erkrankungen unter 
systematischer Zytostatikatherapie 
und/oder Strahlentherapie” 
Abrechnungsscheine sind damit zu 
kennzeichnen 
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EBM digit Points / € (2008) Meaning (2008) 
32022 / 
Kennnummer “Manifester Diabetes 
Mellitus” 
Abrechnungsscheine sind damit zu 
kennzeichnen 
40120 € 0.55 
Kostenpauschale für die Versendung bzw. 
den Transport von Briefen und/oder 
schriftlichen Unterlagen bis 20g oder 
Übermittlung Telefax 
40144 € 0.13 
Kostenpauschale für fotokopierte oder 
EDV-technisch reproduzierte 
Befundmitteilungen, Berichte, Arztbriefe, 
je Seite 
80032 / Patient ist von Zuzahlungen befreit (auch Praxisgebühr) 
90909 / 
Praxisbesonderheitsziffer “orale und 
parenterale Chemotherapie bei 
Tumorpatienten einschließlich 
zugelassener Hormonanaloga, Zytokine 
und Interferone sowie Rezepturen” 
90914 / 
Kennzeichungsziffer “Substitution von 
Plasmafaktoren bei 
Faktormangelkrankheiten” 
90916 / 
Praxisbesonderheitsziffer 
“Schmerztherapie mit Opioiden und mit 
dazugehörigen Laxantien” 
90925 / 
Praxisbesonderheitsziffer 
“Antithrombotische Mittel (nur Heparin 
und Heparinoide, parenteral)” 
90929 / 
Praxisbesonderheitsziffer “Bisphosphonate 
und selekitve 
Östrogenrezeptormodulatoren bei 
Osteoporsose” 
99970 / 
Versicherter wünscht explizit keinen 
Bericht. Abrechnungen sind damit zu 
kennzeichnen. 
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GOÄ digits 
Table D-6: GOÄ digits coding for oncologist fee: 
GOÄ digit Points Rate in € (2008) Meaning (2008) 
1 80 Basic: € 4.66 2.3: € 10.72 
Beratung – auch mittels 
Fernsprecher 
3 150 Basic: € 8.74 2.3: € 20.11 
Eingehende Beratung, mind. 10 
Min – auch mittels Fernsprecher 
31 450 Basic: € 26.23 2.3: € 60.33 Homöopathische Folgeanamnese 
34 300 Basic: € 17.49 2.3: € 40.22 
Erörterung der Auswirkungen 
einer Krankheit (mind. 20 Min.) 
45 70 Basic: € 4.08 2.3: € 9.38 Visite im Krankenhaus 
60 120 Basic: € 6.99 2.3: € 16.09 Konsiliarische Erörterung 
78 180 Basic: € 10.49 2.3: € 24.13 
Behandlungsplan für die 
Chemotherapie und/oder 
schriftlicher Nachsorgeplan 
250 40 Basic: € 2.33 1.8: € 4.20 
Blutentnahme mittels Spritze, 
Kanüle oder Katheter aus der 
Vene 
252 40 Basic: € 2.33 2.3: € 5.36 
Injektion, subkutan, submukös, 
intrakutan oder intramuskulär 
261 30 Basic: € 1.75 2.3: € 4.02 
Einbringung von Arzneimitteln 
in einen parenteralen Katheter 
265 60 Basic: € 3.50 2.3: € 8.04 
Auffüllung eines subkutanen 
Medikamentenreservoirs oder 
Spülung eines Ports 
271 120 Basic: € 6.99 2.3: € 16.09 
Infusion, intravenös, bis zu 30 
Min. Dauer 
272 180 Basic: € 10.49 2.3: € 24.13 Infusion, intravenös, > 30 Min. 
275 360 Basic: € 20.98 2.3: € 48.26 
Dauertropfinfusion von 
Zytostatika, > 90 Min. 
297 45 Basic: € 2.62 2.3: € 6.03 
Entnahme und Aufbereitung von 
Abstrichmaterial zur 
zytologischen Untersuchung 
506 120 Basic: € 6.99 1.8: € 12.59 
Krankengymnastische 
Ganzbehandlung als 
Einzelbehandlung 
1103 185 Basic: € 10.78 2.3: € 24.80 
Probeexzision aus dem 
Gebärmutterhals/ Muttermund 
/Vaginalwand 
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Table D-7: GOÄ digits coding for diagnostics (laboratory parameter / blood test) 
GOÄ digit Points Rate in € (2008) Meaning (2008) 
3502 120 Basic: € 6.99 1.15: € 8.04 
Differenzierung des Blutausstrichs, 
mikroskopisch 
3503 70 Basic: € 4.08 1.15: € 4.69 Hämatokrit 
3512 70 Basic: € 4.08 1.15: € 4.69 Alpha-Amylase 
3513 70 Basic: € 4.08 1.15: € 4.69 Gamma-Glutamyltranspeptidase 
3514 70 Basic: € 4.08 1.15: € 4.69 Glukose 
3515 70 Basic: € 4.08 1.15: € 4.69 GOT (ASAT, AST) 
3516 70 Basic: € 4.08 1.15: € 4.69 GPT (ALAT, ALT) 
3517 70 Basic: € 4.08 1.15: € 4.69 Hämoglobin 
3518 70 Basic: € 4.08 1.15: € 4.69 Harnsäure 
3519 70 Basic: € 4.08 1.15: € 4.69 Kalium 
3520 70 Basic: € 4.08 1.15: € 4.69 Kreatinin 
3550 60 Basic: € 3.50 1.15: € 4.02 Blutbild und Blutbildbestandteile 
3551 20 Basic:  € 1.17 1.15: € 1.34 Differenzierung der Leukozyten 
3555 40 Basic: € 2.33 1.15: € 2.68 Calcium 
3556 30 Basic: € 1.75 1.15: € 2.01 Chlorid 
3557 30 Basic: € 1.75 1.15: € 2.01 Kalium 
3558 30 Basic: € 1.75 1.15: € 2.01 Natrium 
3560 40 Basic: € 2.33 1.15: € 2.68 Glukose 
3570 30 Basic: € 1.75 1.15: € 2.01 Albumin, photometrisch 
3573 30 Basic: € 1.75 1.15: € 2.01 Gesamt-Protein im Serum oder Plasma 
3574 200 Basic: € 11.66 1.15: € 13.41 Proteinelektrophorese im Serum 
3580 40 Basic: € 2.33 1.15: € 2.68 Anorganisches Phosphat 
3581 40 Basic: € 2.33 1.15: € 2.68 Bilirubin, gesamt 
3583 40 Basic: € 2.33 1.15: € 2.68 Harnsäure 
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3584 40 Basic: € 2.33 1.15: € 2.68 Harnstoff 
3585 40 Basic: € 2.33 1.15: € 2.68 Kreatinin 
3587 40 Basic: € 2.33 1.15: € 2.68 Alkalische Phosphatase 
3588 50 Basic: € 2.91 1.15: € 3.35 Alpha Amylase 
3592 40 Basic: € 2.33 1.15: € 2.68 
Gamma-GT (Gamma-
Glutamyltranspeptidase) 
3594 40 Basic: € 2.33 1.15: € 2.68 GOT (Glutamatoxalazetattransaminase) 
3595 40 Basic: € 2.33 1.15: € 2.68 GPT (Glutamatpyruvattransaminase) 
3597 40 Basic: € 2.33 1.15: € 2.68 LDH (Laktatdehydrogenase) 
3598 50 Basic: € 2.91 1.15: € 3.35 Lipase 
3605 50 Basic: € 2.91 1.15: € 3.35 PTT (Partielle Thromboplastinzeit) 
3607 50 Basic: € 2.91 1.15: € 3.35 TPZ (Thromboplastinzeit) 
3620 40 Basic: € 2.33 1.15: € 2.68 Eisen im Serum oder Plasma 
3652 35 Basic: € 2.04 1.15: € 2.35 Streifentest im Urin 
3711 40 Basic: € 2.33 1.15: € 2.68 
Blutkörperchensenkungsgeschwindigkeit 
(BSG, BKS) 
3741 200 Basic: € 11.66 1.15: € 13.41 CRP (C-reaktives Protein) 
3742 250 Basic: € 14.57 1.15: € 16.76 Ferritin, Ligandenassay 
3901.H3 450 Basic: € 26.23 1.15: € 30.16 CA 15-3, Ligandenassay 
3902 300 Basic: € 17.49 1.15: € 20.11 CA 19-9 
3905 250 Basic: € 14.57 1.15: € 16.76 CEA (Carcinoembryonales Antigen) 
4021 250 Basic: € 14.57 1.15: € 16.76 
FSH (Hormonbestimmung mittels 
Ligandenassay) 
4026 250 Basic: € 14.57 1.15: € 16.76 
LH (Luteinisierendes Hormon) 
(Hormonbestimmung mittels 
Ligandenassay) 
4030 250 Basic: € 14.57 1.15: € 16.76 
TSH (Hormonbestimmung mittels 
Ligandenassay) 
4039 350 Basic: € 20.40 1.15: € 23.46 
Estradiol  (Hormonbestimmung mittels 
Ligandenassay) 
4040 350 Basic: € 20.40 1.15: € 23.46 
Progesteron  (Hormonbestimmung 
mittels Ligandenassay) 
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4062 480 Basic: € 27.98 1.15: € 32.17 
Untersuchungen mit ähnlichem 
methodischen Aufwand 
 
Table D-8: GOÄ digits coding for diagnostics (CT / MRT / PET) 
GOÄ digit Points Rate in € (2008) Meaning (2008) 
5371 2300 Basic: € 134.06 1.8: € 241.31 
CT Hals- und/oder 
Thoraxbereich 
5372 2600 Basic: € 151.55 1.8: € 272.78 CT Abdomen 
5488 6000 Basic: € 349.72 1.8: € 629.50 PET 
5700 4400 Basic: € 256.46 1.8: € 461.64 MRT Bereich Kopf 
5705 4200 Basic: € 244.81 1.8: € 440.65 MRT Bereich Wirbelsäule 
5715 4300 Basic: € 250.64 1.8: € 451.14 MRT Bereich Thorax 
5720 4400 Basic: € 256.46 1.8: € 461.64 
MRT Bereich Abdomen 
und/oder Becken 
5730 4000 Basic: € 233.15 1.8: € 419.67 
MRT einer oder mehrerer 
Extremitäten 
 
Table D-9: GOÄ digits coding for diagnostics (other) 
GOÄ digit Points Rate in € (2008) Meaning (2008) 
2 30 Basic: € 1.75 1.8: € 3.15 Messung von Körperzuständen  
5 80 Basic: € 4.66 2.300: € 10.72 Symptombezogene Untersuchung 
7 160 Basic: € 9.33 2.3: € 21.45 
Vollständige körperliche 
Untersuchung mind. eines der 
folgenden Organe: Hautorgan, Stütz- 
und Bewergungsorgane, 
Brustorgane, Bauchorgane, weibl. 
Genitaltrakt 
11 60 Basic: € 3.50 2.3: € 8.04 
Digitaluntersuchung des Mastdarms 
und/ oder Prostata 
401 400 Basic: € 23.31 
Zuschlag zu den sonographischen 
Leistungen nach den Numnern 410-
418 bei zusätzlicher Anwendung des 
Duplex-Verfahrens 
403 150 Basic. € 8.74 1.8: € 15.74 
Zuschlag zu den sonographischen 
Leistungen bei transkavitärer 
Untersuchung 
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404 250 Basic: € 14.57 
Zuschlag zur Doppler-
sonographischen Leistung bei 
zusätzlicher 
Frequenzspektrumanalyse 
405 200 Basic: € 11.66 Zuschlag zu den Leistungen 415 oder 424 – cw Dopplerzuschlag 
406 200 Basic: € 11.66 Zuschlag zu der Leistung 424 – bei zusätzlicher Farbkodierung 
410 200 Basic: € 11.66 2.3: € 26.81 
Ultraschalluntersuchung eines 
Organs (Leber) 
420 80 Basic: € 4.66 2.3: € 10.72 
Ultraschalluntersuchung von bis zu 
drei weiteren Organen (Gallenblase, 
Niere, Milz) 
424 700 Basic: € 40.80 2.3: € 93.84 
Zweidimensionale Doppler-
echokardiographische Untersuchung 
651 253 Basic: € 14.75 1.8: € 26.54 
Elektrokardiographische 
Untersuchung 
4851 130 Basic: € 7.58 1.8: € 13.64 
Zytologische Untersuchung zur 
Krebsdiagnostik 
5030 360 Basic: € 20.98 1.8: € 37.77 
Röntgenaufnahme Oberarm, 
Unterarm, Ellenbogengelenk, 
Oberschenkel, Unterschenkel,… 
jeweils in 2 Ebenen 
5120 260 Basic: € 15.15 1.8 fach: € 27.28 
Strahlendiagnostik  Rippen einer 
Thoraxhälfte, Schulterblatt oder 
Brustbein in einer Ebene 
5121 140 Basic: € 8.16 1.8 fach: € 14.69 Ergänzende Ebene(n) 
5137 450 Basic: € 26.23 1.8: € 47.21 
Brustorgane-Übersicht, 
gegebenenfalls einschließlich 
Breischluck und Durchleuchtungen-, 
in mehreren Ebenen (= Röntgen 
Thorax) 
5330 750 Basic: € 43.72 1.8: € 78.69 Venographie einer Extremität 
 
Table D-10: GOÄ digits coding for administration 
GOÄ digit Points Rate in € (2008) Meaning (2008) 
2 30 Basic: € 1.75 1.8: € 3.15 
Ausstellung von Rezept/ 
Überweisung/ Befund/ 
Anordnung auch mittels 
Fernsprecher 
70 40 Basic: € 2.33 2.3: € 5.36 
Kurze Bescheinigung oder kurzes 
Zeugnis, 
Arbeitsunfähigkeitsbescheinigung
75 130 Basic: € 7.58 2.3: € 17.43 
Ausführlicher schriftlicher 
Krankheits- und Befundbericht 
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Table D-11: Direct disease-related outpatient costs of the control patients 
Patient 
Anti- 
neoplastic
therapy 
[€] 
Supp. 
therapy 
 
[€] 
Oncologist
fee 
 
[€] 
Diagn. 
cost 
 
[€] 
Admin. 
cost 
 
[€] 
No. 
visits 
 
[n] 
Study 
period
 
[days] 
B 1 1049.10 1807.67 211.28 278.96 16.72 12 180 
B 2 5072.71 3384.66 725.07 308.73 12.45 26 180 
B 3 27677.38 4729.38 1150.24 150.90 19.87 17 180 
B 4 7611.07 8066.81 913.23 90.20 11.14 16 81 
B 5 34967.39 3886.19 1049.77 280.44 15.62 25 180 
B 6 4296.84 10488.42 926.41 26.50 17.09 14 180 
B 7 35572.82 3705.90 439.73 1321.41 0.00 11 180 
B 8 1049.10 1442.31 67.69 41.52 8.36 8 98 
B 9 8042.81 2116.21 469.03 411.94 23.43 18 180 
B 10 1049.10 31.84 64.62 84.48 8.36 2 61 
B 11 3711.24 3367.17 524.09 373.34 45.16 21 180 
B 12 9585.79 3600.73 234.12 18.70 25.08 10 180 
B 13 4328.70 3501.59 697.60 233.60 43.03 26 180 
B 14 20144.61 151.45 234.13 67.45 8.36 10 180 
B 15 31069.92 94.02 297.20 52.60 28.98 13 180 
B 16 2121.61 213.17 98.01 69.08 12.45 9 180 
C 1 15396.24 755.08 1.86 155.87 15.62 3 180 
C 2 20374.30 703.43 1449.86 306.13 25.08 25 180 
C 3 14796.51 1379.52 924.99 406.96 56.32 21 180 
C 4 93318.49 3639.58 1264.36 1370.01 31.24 28 180 
C 5 51111.80 1588.65 3101.99 575.99 19.32 42 180 
C 6 9042.78 1133.41 148.78 303.21 0.00 10 180 
C 7 4720.95 36.84 96.14 271.69 23.43 12 180 
C 8 16013.13 845.87 195.26 294.14 0.00 15 180 
C 9 18316.82 1018.61 278.76 242.09 4.09 15 180 
C 10 524.55 130.26 51.79 288.99 15.62 3 61 
C 11 524.55 344.16 178.54 37.30 16.54 4 180 
C 12 2098.20 0.00 195.84 111.30 34.74 22 180 
C 13 3098.26 906.97 895.62 142.90 16.72 14 111 
C 14 20262.03 63.39 1139.20 204.15 16.72 10 180 
Sum: 
(%): 
Median: 
Mean: 
SD: 
466948.80
(83.8)
8542.80
15564.96
19448.64
63133.29
(11.3) 
1256.47
2104.44
2450.10
18025.22
(3.2)
368.47
600.84
636.45
8520.58 
(1.5) 
237.85 
284.02 
319.32
571.54 
(0.1) 
16.72 
19.05 
13.28 
459 
/ 
14 
15 
9 
4912 
/ 
180 
164 
38 
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Patient 
Anti- 
neoplastic
therapy 
[€] 
Supp. 
therapy 
 
[€] 
Oncologist
fee 
 
[€] 
Diagn. 
cost 
 
[€] 
Admin. 
cost 
 
[€] 
No. 
visits 
 
[n] 
Study 
period
 
[days] 
BI 1 3671.85 52.46 91.30 145.58 14.32 11 180 
BI 2 41408.63 4411.40 472.14 1216.57 0.00 10 180 
BI 3 18749.81 2909.26 504.65 798.47 3.15 16 180 
BI 4 16158.43 1950.75 674.75 3094.72 17.43 24 180 
BI 5 1049.10 1356.25 38.69 31.20 8.18 6 48 
BI 6 34889.82 3534.95 1703.72 104.29 2.40 12 180 
BI 7 11284.61 2488.63 298.34 19.50 4.09 11 180 
BI 8 4720.95 3440.09 203.64 123.11 24.54 9 180 
BI 9 21317.76 337.24 489.74 364.16 0.00 15 180 
BI 10 2126.18 1210.53 0.00 0.00 0.00 0 18 
BI 11 3185.71 2204.33 186.74 208.24 0.00 8 180 
BI 12 3147.30 2182.00 104.88 1451.91 17.43 5 180 
BI 13 3192.36 2383.57 137.64 203.31 0.00 8 162 
BI 14 22820.91 1763.13 missing missing missing missing 180 
BI 15 1208.84 448.32 8.74 255.19 0.00 3 62 
BI 16 10432.25 3131.06 299.65 105.18 1.10 11 180 
BI 17 5943.01 2700.05 109.00 224.54 0.00 14 180 
BI 18 3621.75 2432.76 96.91 54.78 0.00 8 169 
BI 19 3845.44 2475.70 350.14 2101.44 10.72 16 180 
BI 20 22575.78 4436.22 187.86 260.49 0.00 11 180 
BI 21 10259.76 1856.73 175.58 24.15 0.55 11 180 
BI 22 12110.26 1261.19 815.34 259.96 35.41 11 180 
BI 23 9110.55 1387.32 459.21 153.76 4.25 20 118 
CI 1 2622.75 127.98 108.41 34.40 25.67 6 180 
CI 2 16455.08 1497.74 876.20 1452.89 0.00 21 180 
CI 3 3404.26 367.79 509.42 264.00 19.88 13 180 
CI 4 29880.87 2768.38 1045.28 935.36 0.00 16 180 
CI 5 13380.53 744.54 1119.30 143.60 0.00 18 180 
CI 6 9004.36 1781.67 936.19 417.55 0.00 12 180 
CI 7 22109.75 1188.52 1125.26 437.34 0.00 14 180 
CI 8 524.55 0.00 0.00 0.00 0.00 0 34 
CI 9 15051.45 1863.47 272.71 2065.30 0.00 11 180 
CI 10 18183.12 199.19 264.17 1107.85 3.15 11 180 
CI 11 2622.75 279.52 68.27 1088.57 3.15 10 180 
CI 12 47228.59 2405.67 795.12 304.90 0.00 26 180 
CI 13 20306.74 18.42 1172.50 209.95 12.27 9 180 
CI 14 15160.36 1259.42 621.50 610.89 0.00 18 180 
CI 15 14115.50 759.93 630.22 65.80 8.74 7 180 
CI 16 25304.31 86.31 1145.53 215.10 19.71 12 180 
CI 17 23195.06 85.01 1119.68 233.05 10.76 13 180 
CI 18 17411.20 754.42 744.61 506.23 0.00 10 180 
CI 19 34316.34 2511.99 1254.03 2056.25 0.00 22 180 
CI 20 21887.16 605.33 1399.23 269.35 25.67 25 180 
CI 21 21226.37 690.99 1148.51 513.99 0.00 17 180 
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Patient 
Anti- 
neoplastic
therapy 
[€] 
Supp. 
therapy 
 
[€] 
Oncologist
fee 
 
[€] 
Diagn. 
cost 
 
[€] 
Admin. 
cost 
 
[€] 
No. 
visits 
 
[n] 
Study 
period
 
[days] 
CI 22 38115.96 1513.63 1105.90 1909.06 33.51 18 180 
CI 23 12872.07 1085.15 665.96 167.00 0.00 12 180 
Sum: 
(%): 
Median: 
Mean: 
SD: 
691210.19
(84.69)
13748.02
15026.31
11666.85
72949.01
(8.94) 
1442.53
1585.85
1176.92
25536.66
(3.13)
489.74
567.48
453.95
26208.98 
(3.20) 
259.96 
582.42 
718.88
306.08 
(0.03) 
0.55 
6.80 
10.01 
561 
/ 
11 
12 
6 
7631 
/ 
180 
166 
41 
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Table D-13: Pharmacist time spent for intervention patients 
Patient-
code First consultation 
Follow-up 
consultations 
 
Total time  
 
[min] 
Protocol driven 
time 
[min] 
Time for 
pharmaceutical care 
[min] 
Time 
 
[min] 
BI 1 44 n.d. n.d. 27 
BI 2 60 n.d. n.d. 45 
BI 3 140 n.d. n.d. 90 
BI 4 115 n.d. n.d. 132 
BI 5 70 n.d. n.d. 166 
BI 6 105 n.d. n.d. 203 
BI 7 72 n.d. n.d. 30 
BI 8 65 n.d. n.d. 48 
BI 9 81 65 16 173 
BI 10 55 n.d. n.d. 15 
BI 11 60 n.d. n.d. 148 
BI 12 66 n.d. n.d. 150 
BI 13 75 n.d. n.d. 121 
BI 14 60 n.d. n.d. 99 
BI 15 106 n.d. n.d. 95 
BI 16 70 50 20 180 
BI 17 105 46 59 256 
BI 18 77 n.d. n.d. 243 
BI 19 97 40 57 212 
BI 20 85 58 27 154 
BI 21 73 n.d. n.d. 139 
BI 22 70 n.d. n.d. 95 
BI 23 50 32 18 163 
CI 1 100 n.d. n.d. 147 
CI 3 85 n.d. n.d. 135 
CI 2 80 n.d. n.d. 148 
CI 4 90 n.d. n.d. 188 
CI 5 70 n.d. n.d. 64 
CI 6 105 36 69 154 
CI 7 90 n.d. n.d. 61 
CI 8 80 n.d. n.d. 9 
CI 9 110 65 45 168 
CI 10 75 n.d. n.d. 140 
CI 11 107 n.d. n.d. 90 
CI 12 55 n.d. n.d. 56 
CI 13 70 n.d. n.d. 43 
CI 14 72 n.d. n.d. 130 
CI 15 90 49 41 121 
CI 16 120 80 40 107 
CI 17 120 n.d. n.d. 149 
CI 18 101 46 55 41 
CI 19 75 n.d. n.d. 181 
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Patient-
code First consultation 
Follow-up 
consultations 
CI 20 70 36 34 125 
CI 21 89 19 70 177 
CI 22 64 37 27 121 
CI 23 79 40 39 114 
Median 78 46 40 131 
Mean 83 47 41 123 
SD 21 15 18 59 
Min 44 19 16 9 
Max 140 80 70 256 
n.d. = not documented 
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Table D-14: Base rates of relevant hospitals 2006 until 2008 according to AOK 
Hospital Base rate 2006 [€] 
Base rate 
2007 [€] 
Base rate 
2008 [€] 
University Bonn 2990.99 2822.36 2728.09 
Johanniter Bonn 2506.74 2546.13 2605.07 
St. Marien Bonn 2369.68 2541.14 2591.11 
St. Antonius Schleiden Not known Not known 2715.95 
Malteser Bonn 2671.18 2648.98 2677.36 
University Cologne 2954.89 2778.39 2672.10 
Waldkrankenhaus Bonn 2446.65 2507.81 2593.24 
 
Table D-15: Inpatient costs in the individual control patients 
Patient No. stay Hospital Reason DRG 
Relative 
weight 
DRG 
costs 
[€] 
Other 
costs 
[€] 
B 1 1 University 
Bonn 
Progression E71B 0.597 1628.67 140.2 
 2 „ Surgery J11A 1.187 3238.24 153.97 
 3 „ Not known I65B 1.119 3052.73 -2057.08 
 4 „ DRC E73B 0.861 2348.89 -1340.11 
 5 „ Not known I65B 1.119 3052.73 -2057.08 
     Total: 8161.16 
B 8 1 University 
Bonn 
Progression B15Z 3.866 10546.80 300.98 
 2 „ Progression B66B 1.360 3719.20 148.66 
     Total: 14706.64 
B 9 1 Johanniter 
Bonn 
Surgery J11A 1.187 3092.22 77.94 
     Total: 3170.16 
B 12 1 University 
Bonn 
Toxicity T62B 0.574 1565.92 189.75 
     Total: 1755.67 
B 13 1 University 
Bonn 
Toxicity F71B 0.797 2174.29 189.75 
     Total: 2364.04 
B 14 1 University 
Bonn 
Surgery following 
neoadjuvant treatment 
J23Z 1.545 4214.90 195.15 
     Total: 4410.05 
B 15 1 University 
Bonn 
Surgery following 
neoadjuvant treatment 
J23Z 1.545 4214.90 195.15 
     Total: 4410.05 
B 16 1 University 
Bonn 
Surgery following 
neoadjuvant treatment 
J16Z 2.369 6462.85 238.27 
     Total: 6701.12 
C 1 1 Johanniter 
Bonn 
Application of i.v. 
chemotherapy 
G60B 0.421 1096.73 903.2 
 2 „ Application of i.v. 
chemotherapy 
G60B 0.421 1096.73 903.2 
 3 „ Application of i.v. 
chemotherapy 
G60B 0.421 1096.73 903.2 
 4 „ Application of i.v. 
chemotherapy 
G60B 0.421 1096.73 903.2 
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Patient No. stay Hospital Reason DRG 
Relative 
weight 
DRG 
costs 
[€] 
Other 
costs 
[€] 
 5 „ Application of i.v. 
chemotherapy 
G60B 0.421 1096.73 903.2 
 6 " Application of i.v. 
chemotherapy 
G60B 0.421 1096.73 903.2 
     Total: 11999.61 
C 3 1 Johanniter 
Bonn 
Toxicity F74Z 0.405 1055.05 59.46 
 2 St. Marien 
Bonn 
Surgery H01Z 4.577 11859.51 675.45 
     Total: 13649.47 
C 4 1 Johanniter 
Bonn 
Surgery H61B 0.651 1695.90 40.17 
     Total: 1736.07 
C 5 1 Johanniter 
Bonn 
DRC H41A 2.035 5301.32 114.43 
     Total: 5415.75 
C 6 1 University 
Bonn 
DRC G67D 0.457 1246.74 167.65 
     Total: 1414.39 
C 8 1 University 
Bonn 
Surgery following 
neoadjuvant treatment 
G17Z 3.077 8394.33 1242,69 
 
 2 " Surgery G60B 0.421 1148.53 -424.56 
     Total: 10360,99 
C 9 1 University 
Bonn 
Progression G18Z 2.652 7234.89 401.23 
 2 St. Antonius 
Schleiden 
Toxicity G67B 0.580 1575.25 2571.81 
     Total: 11783.19 
C 10 1 Johanniter 
Bonn 
Diagnostic test G46C 1.051 2737.93 1516.67 
 2 " DRC G60A 0.654 1703.72 82.98 
     Total: 6041.29 
C 11 1 St. Marien 
Bonn 
Surgery G07C 1.320 3420.27 664.85 
     Total: 4085.12 
C 13 1 Johanniter 
Bonn 
DRC G60B 0.421 1096.73 1065.86 
     Total: 2162.59 
DRC = Disease-related complication 
 
Table D-16: Inpatient costs in the individual intervention patients 
Patient No. stay Hospital Reason DRG
Relative 
weight 
DRG 
costs [€] 
Other 
costs 
[€] 
BI 3 1 Johanniter Bonn Progression J18Z 1.771 4613.58 145.33 
     Total:  4758.91 
BI 4 1 Johanniter Bonn Diagnostic test J62B 0.565 1471.86 135.42 
     Total:  1607.28 
BI 5 1 Malteser Bonn DRC K62Z 0.685 1833.99 59,46 
     Total: 1893,45 
BI 7 1 University Bonn Toxicity E75C 0.545 1486.81 1129.85 
     Total: 2616.66 
BI 13 1 University Bonn DRC H61B 0.651 1775.99 946.02 
  2 " DRC Z65Z 0.599 1634.13 121.36 
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Patient No. stay Hospital Reason DRG
Relative 
weight 
DRG 
costs [€] 
Other 
costs 
[€] 
  3 " DRC J62B 0.565 1541.37 118.57 
     Total: 6137.43 
BI 15 1 University Bonn Progression B66D 0.761 2076.08 123.71 
     Total: 2199.79 
BI 18 1 University Bonn DRC E71A 1.230 3355.55 129.57 
  2 " DRC A13B 10.309 28123.88 501.37 
     Total: 32110.37 
BI 19 1 
University 
Cologne Progression I65C 0.729 1947.96 -845.25 
  2 
University. 
Cologne Progression I08C 2.325 6212.63 348.34 
     Total: 7663.68 
BI 23 1 Johanniter Bonn Progression J62A 1.251 3258.94 4456.61 
  2 " DRC J62B 0.565 1471.86 104.42 
     Total: 9291.84 
CI 3 1 University Bonn 
Surgery following 
neoadjuvant treatment G16B 3,969 10827,79 329,39 
  2 " 
Surgery following 
neoadjuvant treatment H09A 3,753 10238,52 218,78 
     Total: 21614.48 
CI 4 1 Johanniter Bonn Diagnostic test G60B 0.421 1096.73 73.27 
     Total: 1170.00 
CI 5 1 Johanniter Bonn 
Application of i.v. 
chemotherapy G60B 0.421 1096.73 1969.17 
  2 " Diagnostic test Z64B 0.394 1026.40 -376.83 
     Total: 3715.47 
CI 8 1 Johanniter Bonn DRC G13Z 1.908 4970.47 1388.27 
     Total: 6358.74 
CI 9 1 Johanniter Bonn DRC E64A 1.324 3449.11 627.36 
  2 " Diagnostic test G46B 1.350 3516.84 262.38 
  3 " DRC E64A 1.324 3449.11 -1524.78 
     Total: 9780.03 
CI 12 1 Johanniter Bonn Diagnostic test G60B 0.421 1096.73 74.27 
     Total: 1171.00 
CI 14 1 Johanniter Bonn DRC G65Z 0.520 1354.64 -922.03 
  2 " DRC G18B 2.480 6460.5 -3519.74 
     Total: 3373.44 
CI 19 1 University Bonn DRC G18B 2.480 6765.66 79.24 
     Total: 6844.90 
CI 20 1 
Waldkrankenhaus 
Bonn Diagnostic test G48C 0.796 2064.22 96.61 
     Total: 2160.83 
CI 21 1 Johanniter Bonn Progression G07C 1.320 3438.69 138.09 
  2 " DRC G02Z 3.423 8917.15 231.76 
     Total: 12725.7 
DRC = Disease-related complication 
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Indirect costs 
Table D-17: Indirect costs in the control and intervention group 
Control 
patient 
Days on 
sick leave 
[days] 
Indirect 
costs 
[€] 
 Intervention patient 
Days on 
sick leave 
[days] 
Indirect 
costs 
[€] 
B 1   missing missing BI 1   0 0.00 
B 2   41 5827.74 BI 2   n. a. 0.00 
B 3   n. a. 0.00 BI 3   n. a. 0.00 
B 4   n. a. 0.00 BI 4   n. a. 0.00 
B 5   missing missing BI 5   n. a. 0.00 
B 6   n. a. 0.00 BI 6   n. a. 0.00 
B 7   114 16203.96 BI 7   128 18193.92 
B 8   n. a. 0.00 BI 8   15 2132.10 
B 9   n. a. 0.00 BI 9   128 18193.92 
B 10   44 6254.16 BI 10   n. a. 0.00 
B 11   n. a. 0.00 BI 11   missing missing 
B 12   128 18193.92 BI 12   n. a. 0.00 
B 13   n. a. 0.00 BI 13   n. a. 0.00 
B 14   128 18193.92 BI 14   128 18193.92 
B 15   128 18193.92 BI 15   43 6112.02 
B 16   missing missing BI 16   93 13219.02 
C 1   n. a. 0.00 BI 17   43 6112.02 
C 2   n. a. 0.00 BI 18   n. a. 0.00 
C 3   n. a. 0.00 BI 19   128 18193.92 
C 4   n. a. 0.00 BI 20   n. a. 0.00 
C 5   128 18193.92 BI 21   n. a. 0.00 
C 6   n. a. 0.00 BI 22   128 18193.92 
C 7   n. a. 0.00 BI 23   n. a. 0.00 
C 8   88 12508.32 CI 1   n. a. 0.00 
C 9   n. a. 0.00 CI 2   missing missing 
C 10   n. a. 0.00 CI 3   n. a. 0.00 
C 11   n. a. 0.00 CI 4   missing missing 
C 12   n. a. 0.00 CI 5   n. a. 0.00 
C 13   n. a. 0.00 CI 6   n. a. 0.00 
C 14   n. a. 0.00 CI 7   18 2558.52 
   CI 8   n. a. 0.00 
   CI 9   n. a. 0.00 
   CI 10   n. a. 0.00 
   CI 11   n. a. 0.00 
   CI 12   missing missing 
   CI 13   n. a. 0.00 
   CI 14   128 18193.92 
   CI 15   35 4974.90 
   CI 16   73 10376.22 
   CI 17   n. a. 0.00 
   CI 18   missing missing 
   CI 19   n. a. 0.00 
   CI 20   61 8670.54 
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Control 
patient 
Days on 
sick leave 
[days] 
Indirect 
costs 
[€] 
 Intervention patient 
Days on 
sick leave 
[days] 
Indirect 
costs 
[€] 
   CI 21   missing missing 
   CI 22   128 18193.92 
   CI 23   128 18193.92 
Sum: 
Median: 
Mean: 
SD: 
 
113569.86 
0.00 
4206.29 
7174.93 
 
199706.70 
0.00 
4992.67 
7371.50 
n. a. = not applicable 
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Quality of life 
Table D-18: EQ-5D frequency distribution during treatment with capecitabine 
EQ-5D dimension Control group Intervention group 
 t0 t3 t6 t7 t0 t3 t6 t7 
n 28 16 9 11 46 39 30 18 
Mobility 
No problems % 
Some problems % 
Confined to bed % 
 
57.1 
42.9 
0.0 
 
56.2 
43.8 
0.0 
 
77.8 
22.2 
0.0 
 
72.7 
27.3 
0.0 
 
54.3 
45.7 
0.0 
 
46.1 
33.3 
2.6 
 
63.3 
36.7 
0.0 
 
61.1 
38.9 
0.0 
Self-Care 
No problems % 
Some problems % 
Unable to % 
 
82.1 
14.3 
3.6 
 
93.7 
6.3 
0.0 
 
100.0 
0.0 
0.0 
 
90.9 
9.1 
0.0 
 
87.0 
10.9 
2.1 
 
89.7 
10.3 
0.0 
 
90.0 
10.0 
0.0 
 
88.9 
11.1 
0.0 
Usual Activities 
No problems % 
Some problems % 
Unable to % 
 
42.9 
53.5 
3.6 
 
37.5 
50.0 
12.5 
 
66.7 
33.3 
0.0 
 
54.5 
45.5 
0.0 
 
45.7 
39.1 
15.2 
 
48.7 
38.5 
12.8 
 
43.3 
50.0 
6.7 
 
72.2 
22.2 
5.6 
Pain / Discomfort 
None % 
Moderate % 
Extreme % 
 
25.0 
71.4 
3.6 
 
25.0 
68.7 
6.3 
 
33.3 
55.6 
11.1 
 
54.5 
36.4 
9.1 
 
34.8 
58.7 
6.5 
 
33.3 
59.0 
7.7 
 
33.3 
66.7 
0.0 
 
33.3 
55.6 
11.1 
Anxiety / Depression 
None % 
Moderate % 
Extreme % 
 
67.9 
28.6 
3.6  
 
56.2 
37.5 
6.3 
 
77.8 
22.2 
0.0 
 
72.7 
27.3 
0.0 
 
58.7  
39.1 
2.2  
 
71.8 
23.1 
5.1 
 
63.4 
33.3 
3.3 
 
77.8 
16.7 
5.5 
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Figure D-1: Absolute changes in VAS scores 
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Hand-foot syndrome (HFS) 
Table D-19: Median HFS and information on number of missing questionnaires, number of 
patients not treated with capecitabine and number of dead patients 
  t1 t2 t3 t4 t5 t6 t7 
CG n 29 23 18 17 11 11 11 
 
n missing  
n no Cap 
n dead 
1 
0 
0 
2 
5 
0 
1 
9 
2 
0 
10 
3 
1 
14 
4 
0 
14 
4 
0 
13 
5 
 median HFS 0.0 1.0 1.0 1.0 2.0 1.0 2.0 
 IQR 0.0-1.0 0.0-1.0 0.75-2.0 1.0-2.0 1.0-2.0 1.0-2.0 1.0-2.0 
IG n 44 43 40 37 34 30 21 
 
n missing 
n no Cap 
n dead 
2 
0 
0 
0 
2 
1 
0 
3 
3 
1 
4 
4 
0 
8 
4 
2 
10 
4 
1 
17 
7 
 median HFS 0.0 1.0 1.0 1.0 1.0 1.0 0.5 
 IQR 0.0-1.0 0.0-2.0 0.0-2.0 0.5-2.0 0.75-2.0 1.0-2.0 0.0-1.0 
CG/IG p-value* 0.440 0.607 0.646 0.383 0.023 0.592 0.019 
CG = control group, IG = intervention group, IQR = interquartile range, no Cap = no treatment with 
capecitabine, missing = missing questionnaire but patient treated with capecitabine, *Cochran-Armitage test for 
trend 
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Willingness-to-pay (WTP) 
 
Figure D-2: WTP and net income per household member 
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Cost-utility analysis 
Table D-20: Randomly selected matched patient pairs 
Tumour 
entity 
 
Treatment 
setting 
 
Therapy 
regimen 
 
Bis- 
phosphonate 
 
Health 
insurance 
 
IG 
 
 
CG 
 
 
Breast Adjuvant Cap Pac No Statutory BI 16 B 12 
Breast Palliative Cap Yes Statutory 
BI 5 
BI 8 
BI 11 
BI 17 
B 4 
B 6 
B 11 
B 8 
Breast Palliative Cap No Statutory BI 1 B 10 
Breast  Palliative Cap Tras Yes Private BI 2 B 7 
Colorectal Neoadjuvant Cap Ox No Statutory CI 3 C 8 
Colorectal Palliative Cap No Statutory CI 1 C 7 
Colorectal Palliative Cap Beva No Statutory CI 16 CI 13 
C 10 
C 14 
CG = control group, IG = intervention group,  Therapy regimen: Cap = capecitabine monotherapy; Cap Beva 
= capecitabine + bevacizumab; Cap Ox = capecitabine + oxaliplatin; Cap Pac = capecitabine + paclitaxel; 
Cap Tras = capecitabine + trastuzumab 
 
Table D-21: Best and worst selected matched patient pairs for sensitivity analysis 
Tumour 
entity 
 
Treatment 
setting 
 
Therapy 
regimen 
 
Bis- 
phososphonate
 
Health 
insurance
 
IG 
best 
case 
IG 
worst 
case 
CG 
 
 
Breast Adjuvant Cap Pac No Statutory BI 21 BI 16 B 12
Breast Palliative Cap Yes Statutory 
BI 5 
BI 8 
BI 11 
BI 17 
BI 5 
BI 8 
BI 11 
BI 17 
B 4 
B 6 
B 11 
B 8 
Breast Palliative Cap No Statutory BI 1 BI 1 B 10
Breast  Palliative Cap Tras Yes Private BI 2 BI 2 B 7 
Colorectal Neoadjuvant Cap Ox No Statutory CI 3 CI 3 C 8 
Colorectal Palliative Cap No Statutory CI 1 CI 20 C 7 
Colorectal Palliative Cap Beva No Statutory CI 13 CI 17 
CI 16 
CI 17 
C 10 
C 14
CG = control group, IG = intervention group, Therapy regimen: Cap = capecitabine monotherapy; Cap Beva = 
capecitabine + bevacizumab; Cap Ox = capecitabine + oxaliplatin; Cap Pac = capecitabine + paclitaxel; Cap 
Tras = capecitabine + trastuzumab 
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Table D-22: Socio-demographic patient characteristics of eleven randomly matched-pairs 
at the time of inclusion 
Socio-demographic variable Control group Intervention group 
  n % n % 
Age 
< 50 years old 
50-60 years old 
> 60 years old 
1 
4 
5 
9.1 
36.4 
54.5 
2 
3 
6 
18.2 
27.3 
54.6 
Sex Female  Male 
9 
2 
81.8 
18.2 
9 
2 
81.8 
18.2 
Marital status 
Married / partner 
Single 
Widow 
9 
1 
1 
81.8 
9.1 
9.1 
9 
1 
1 
81.8 
9.1 
9.1 
Current living 
situation 
Living alone 
With family / partner 
Other 
2 
8 
1 
18.2 
72.7 
9.1 
1 
10 
0 
9.1 
90.9 
0.0 
Education 
Elementary school 
Secondary school 
O-levels 
Journeyman 
Master of a trade 
Bachelor 
No answer 
4 
2 
1 
1 
1 
1 
1 
36.4 
18.2 
9.1 
9.1 
9.1 
9.1 
9.1 
4 
4 
0 
2 
0 
1 
0 
36.4 
36.4 
0.0 
18.2 
0.0 
9.1 
0.0 
Current 
employment 
situation 
Full time job 
Part time job 
Unable to work 
Pensioner 
Housewife/ -man 
1 
0 
3 
6 
1 
9.1 
0.0 
27.3 
54.5 
9.1 
1 
2 
1 
4 
3 
9.1 
18.2 
9.1 
36.4 
27.3 
Therapy setting 
Oncology outpatient 
ward 
Oncology practice 
7 
 
4 
63.6 
 
36.4 
6 
 
5 
54.5 
 
45.5 
It was tested for statistically significant differences between the selected control group and the selected 
intervention group (Fisher`s exact test): 
age range: p = 1.000; sex: p = 1.000; marital status: p = 1.000, current living situation: p = 0.586, education: 
p = 0.852, current employment situation: p = 0.518, therapy setting: p = 1.000 
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Tables D-23 – D-47:  
Tables D-23 – D-47 contain details on resource utilisation and cost calculation of the eleven 
randomly matched patient pairs and three additional patients (BI 21, CI 17, CI 20), separately 
for each patient. In case of a charge in euro [€] for an EBM or GOÄ digit or a medication, the 
amount of money was multiplied by the resource us (number of units) to calculate costs. In 
case of points for an EBM digit instead of a charge in euro [€] the points were multiplied by 
3.72 cents and then by the resource use (number of units) to calculate costs.  
 
Table D-23: BI 1, study period 09.01.-09.07.2007 
Digit / Medication Points / € Resource use 
Costs 
(€) Sum (€) 
1. Oncologist fee     
13500 540 2 40.18  
86503 25.56 € 2 51.12 91.30 
2. Diagnostics     
2.1 Laboratory parameter     
32068 0.25 € 3 0.75  
32058 0.25 € 3 0.75  
32057 0.25 € 3 0.75  
32460 5.40 € 3 16.20  
32071 0.25 € 3 0.75  
32069 0.25 € 3 0.75  
32070 0.25 € 3 0.75  
32081 0.25 € 3 0.75  
32075 0.25 € 3 0.75  
32083 0.25 € 3 0.75  
32084 0.25 € 3 0.75  
32067 0.40 € 3 1.20  
32064 0.25 € 3 0.75  
32123 0.40 € 3 1.20  
32122 1.20 € 3 3.60  
32324 4.90 € 2 9.80  
32391 8.20 € 2 16.40  
32120 0.50 € 6 3.00 59.65 
2.2 MRT/CT/PET     
34330 1865 1 69.38 69.38 
2.3 Other     
33042 445 1 16.55 16.55 
3. Administration     
01430 35 5 6.51  
32012 0 1 0.00  
01601 210 1 7.81 14.32 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 7 3741.85 3741.85 
    -70.00 
Patient`s co-payment 10.00 € 7 70.00 3671.85 
4.2 Supportive     
 0.00 €  0.00 0.00 
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Digit / Medication Points / € Resource use 
Costs 
(€) Sum (€) 
4.3 Supportive (patient 
documentation)     
Hexobion 100 100St 14.21 € 5 71.05  
Imodium KAP 10St 11.41 € 1 11.41  
Equizym MCA 49.20 € 1 49.20 131.66 
Patient`s co-payment 5.00 € 6 30.00 -79.20 
Patient`s co-payment 49.20 € 1 49.20 52.46 
 
Table D-24: BI 2, study period 17.01.-17.07.2007 
Digit / Medication Points / € Resource use Costs (€) 
Sum 
(€) 
1. Oncologist fee     
275 48.26 € 8 386.08  
78 24.13 € 1 24.13  
250 4.20 € 9 37.80  
272 24.13 € 1 24.13 472.14 
2. Diagnostics     
2.1 Laboratory parameter     
3905 16.76 € 3 50.28  
3901 30.16 € 3 90.48  
3550 4.02 € 9 36.18  
3551 1.34 € 9 12.06  
3558 2.01 € 9 18.09  
3557 2.01 € 9 18.09  
3555 2.68 € 9 24.12  
3585 2.68 € 9 24.12  
3583 2.68 € 9 24.12  
3581 2.68 € 9 24.12  
3594 2.68 € 9 24.12  
3595 2.68 € 9 24.12  
3592 2.68 € 9 24.12  
3587 2.68 € 9 24.12  
3597 2.68 € 9 24.12  
3560 2.68 € 9 24.12  
3741 13.41 € 9 120.69 587.07 
2.2 MRT/CT/PET     
5488 629.50 € 1 629.50 629.50 
2.3 Other     
 0.00 € 0 0.00 0.00 
3. Administration     
 0.00 € 0 0.00 0.00 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 8 4276.40  
Trastuzumab Roche 612mg 500ml NaCl0.9% 4019.59 € 9 36176.31 41598.63 
Aromasin 25mg 100 St 572.96 € 2 1145.92 -190.00 
Patients Payment 10.00 € 19 190.00 41408.63 
4.2 Supportive     
Hexobion 100 100St 14.21 € 4 56.84  
Remergil TAB 30mg N3 178.74 € 2 357.48  
Remergil TAB 30mg N2 94.37 € 1 94.37  
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Digit / Medication Points / € Resource use Costs (€) 
Sum 
(€) 
Perfalgan10mg/ml 12x100ml BristolMyers 43.11 € 1 43.11  
Pantozol 40mg 100 St 128.42 € 3 385.26  
Bondronat 6mg x 5 N1 1.652.08 € 2 3304.16  
Patient`s co-payment 10.00 € 7 70.00 4241.22 
Patient`s co-payment 9.44 € 1 9.44 -104.44 
Patient`s co-payment 5.00 € 5 25.00 4136.78 
4.3 Supportive (patient documentation)     
Wobenzym N 800 St 129.95 € 1 129.95  
Selenase 300 100St 54.32 € 1 54.32  
Lektinol 0,5ml 25 AMP 235.73 € 1 235.73  
Equziym MCA 100St 49.20 € 4 196.80  
Patient`s co-payment 5.43 € 1 5.43  
Patient`s co-payment 129.95 € 1 129.95 616.80 
Patient`s co-payment 10.00 € 1 10.00 -342.18 
Patient`s co-payment 49.20 € 4 196.80 274.62 
 
Table D-25: BI 5, study period: 08.02.–27.03.2007 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 5 9.30  
13220 235 2 17.48  
02100 160 2 11.90 38.69 
2. Diagnostics     
2.1 Laboratory parameter     
32068 0.25 € 2 0.50  
32056 0.25 € 2 0.50  
32107 0.75 € 2 1.50  
32066 0.25 € 1 0.25  
32082 0.25 € 2 0.50  
32057 0.25 € 1 0.25  
32075 0.25 € 2 0.50  
32324 4.90 € 2 9.80  
32391 8.20 € 2 16.40  
32120 0.50 € 2 1.00 31.20 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
 0 0 0.00 0.00 
3. Administration     
01600 110 2 8.18 8.18 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 2 1069.10 1069.10 
    -20.00 
Patient`s co-payment 10.00 € 2 20.00 1049.10 
4.2 Supportive     
MCP AL Tropfen 100ml 12.25 € 1 12.25  
Bondronat 6mg N1 343.91 € 2 687.82  
Fraxiparin 0,3 x 10 FS 47.47 € 1 47.47  
Palladon 16mg RetKAP 20 St 129.07 € 1 129.07  
194  Curriculum vitae 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
Palladon 2,6mg KAP 20 St 41.29 € 1 41.29  
Palladon 24mg RetKAP 20 St 187.89 € 1 187.89  
Ibuprofen 800 TAB 50St 14.77 € 1 14.77 1120.56 
Patient`s co-payment 5.00 € 3 15.00 -65.00 
Patient`s co-payment 10.00 € 5 50.00 1055.56 
4.3 Supportive (patient documentation)     
MCP AL Tropfen 100ml 12.25 € 1 12.25  
Novalgin TRO 50ml 14.21 € 1 14.21  
Novaminsulfon TRO 100ml 16.72 € 1 16.72  
Ibu 800 CT 100St 21.11 € 1 21.11  
Celldolor 100/8mg 50St 43.98 € 1 43.98  
Omeprazol 20mg 60St 31.25 € 1 31.25  
MST 100mg 50St 140.42 € 1 140.42  
Movicol-Beutel 50St 34.86 € 1 34.86  
Laxoberal TRO 17.90 € 1 17.90  
Lactulose Sirup 500ml 9.44 € 1 9.44  
Furosemid 40mg 100St 13.55 € 1 13.55 355.69 
Patient`s co-payment 10.00 € 1 10.00 -55.00 
Patient`s co-payment 5.00 € 9 45.00 300.69 
 
Table D-26: BI 8, study period 16.04.-16.10.2007 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 7 13.02  
13220 235 2 17.48  
02100 160 7 41.66  
13502 540 2 40.18  
13500 540 2 40.18  
86503 25.56 € 2 51.12 203.64 
2. Diagnostics     
2.1 Laboratory parameter     
32068 0.25 € 5 1.25  
32058 0.25 € 5 1.25  
32065 0.25 € 5 1.25  
32057 0.25 € 5 1.25  
32082 0.25 € 5 1.25  
32066 0.25 € 5 1.25  
32071 0.25 € 5 1.25  
32069 0.25 € 5 1.25  
32070 0.25 € 5 1.25  
32081 0.25 € 5 1.25  
32075 0.25 € 5 1.25  
32083 0.25 € 5 1.25  
32056 0.25 € 5 1.25  
32072 0.40 € 5 2.00  
32064 0.25 € 5 1.25  
32324 4.90 € 5 24.50  
32391 8.20 € 5 41.00  
32460 5.40 € 5 27.00  
32120 0.50 € 4 2.00 114.00 
Curriculum vitae  195 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
33011 245 1 9.11 9.11 
3. Administration     
01430 35 6 7.81  
01601 210 2 15.62  
40120 0.55 € 2 1.10  
90909 0.00 € 2 0.00  
90929 0.00 € 2 0.00 24.54 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 9 4810.95 4810.95 
    -90.00 
Patient`s co-payment 10.00 € 9 90.00 4720.95 
4.2 Supportive     
Bondronat 6mg/6ml N1 5x6ml 1.652.08 € 2 3304.16  
Omeprazol STADA 40mg 30St 38.38 € 1 38.38  
Pantozol 40mg 30St TMR 43.68 € 1 43.68 3386.22 
Patient`s co-payment 5.00 € 1 5.00 -25.00 
Patient`s co-payment 10.00 € 2 20.00 3361.22 
4.3 Supportive (patient documentation)     
Equizym MCA 49.20 € 2 98.40  
Pantozol 40mg 30St TMR 43.68 € 2 87.36  
Lefax Kautabletten 20St 5.31 € 1 5.31  
Patient`s co-payment 49.20 € 2 98.40 191.07 
Patient`s co-payment 3.80 € 1 3.80 -112.20 
Patient`s co-payment 5.00 € 2 10.00 78.87 
 
Table D-27: BI 11, study period: 27.06.-27.12.2007 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
01311 175 2 13.02  
08220 235 4 34.97  
08345 540 2 40.18  
30420 265 10 98.58 186.74 
2. Diagnostics     
2.1 Laboratory parameter     
32081 0.25 € 1 0.25  
32082 0.25 € 1 0.25  
32083 0.25 € 1 0.25  
32066 0.25 € 1 0.25  
32122 1.20 € 1 1.20  
32120 0.50 € 4 2.00  
32391 8.20 € 2 16.40  
32356 5.10 € 1 5.10  
32390 9.70 € 1 9.70  
32354 5.60 € 1 5.60  
32357 4.60 € 1 4.60  
32355 5.10 € 1 5.10 50.70 
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Digit / Medication Points / € Resource use Costs (€) Sum (€) 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
17311 1860 1 69.19  
17312 475 1 17.67  
17362 1900 1 70.68 157.54 
3. Administration     
32019 0 0 0.00 0.00 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120St 534.55 € 5 2672.75 3245.71 
Aromasin 25mg 100St 572.96 € 1 572.96 -60.00 
Patient`s co-payment 10.00 € 6 60.00 3185.71 
4.2 Supportive     
Bondronat 50mg 84St 1.101.00 € 2 2202.00  
Neuro ratio 100St 12.85 € 1 12.85  
Berberil N TRO 4.41 € 1 4.41  
Patient`s co-payment 5.00 € 1 5.00 2219.26 
Patient`s co-payment 10.00 € 2 20.00 -29.38 
Patient`s co-payment 4.38 € 1 4.38 2189.88 
4.3 Supportive (patient documentation)     
Diclofenac 100mg 100St 16.80 € 1 16.80 24.45 
Euphrasia AT 10ml 7.65 € 1 7.65 -10.00 
Patient`s co-payment 5.00 € 2 10.00 14.45 
 
Table D-28: BI 16, study period: 31.10.2007-01.05.2008 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
08345 540 2 40.18  
08220 235 9 78.68  
01311 175 2 13.02  
02101 445 10 165.54 299.65 
2. Diagnostics     
2.1 Laboratory parameter     
32120 0.50 € 2 1.00  
32122 1.20 € 9 10.80  
32058 0.25 € 5 1.25  
32064 0.25 € 3 0.75  
32065 0.25 € 3 0.75  
32066 0.25 € 6 1.50  
32069 0.25 € 5 1.25  
32070 0.25 € 5 1.25  
32071 0.25 € 4 1.00  
32081 0.25 € 6 1.50  
32082 0.25 € 6 1.50  
32083 0.25 € 6 1.50  
32068 0.25 € 3 0.75  
32391 8.20 € 1 8.20  
32460 5.40 € 1 5.40  
32392 9.20 € 1 9.20  
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Digit / Medication Points / € Resource use Costs (€) Sum (€) 
32324 4.90 € 1 4.90  
32086 0.40 € 1 0.40  
32248 1.40 € 1 1.40  
32073 0.40 € 2 0.80  
32072 0.40 € 1 0.40  
32075 0.25 € 2 0.50  
32074 0.25 € 1 0.25  
32057 0.25 € 1 0.25  
32085 0.25 € 1 0.25  
32325 4.90 € 1 4.90  
32056 0.25 € 1 0.25  
32113 0.60 € 1 0.60  
32112 0.60 € 1 0.60  
32115 0.75 € 1 0.75  
32116 0.75 € 1 0.75  
32390 9.70 € 1 9.70 74.30 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
33044 400 1 14.88  
34241 430 1 16.00 30.88 
3. Administration     
40120 0.55 € 2 1.10 1.10 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 3 1603.65  
Paclitaxel 99,23mg 250ml NaCl0.9% 677.66 € 10 6776.60 10582.25 
Ibandronat 50mg 84St 1.101.00 € 2 2202.00 -150.00 
Patient`s co-payment 10.00 € 15 150.00 10432.25 
4.2 Supportive     
Tavegil 5AMP 11.50 € 2 23.00  
Granisetron 2mg 5TAB 100.29 € 2 200.58  
Ranitidin 50mg 5AMP 14.48 € 2 28.96  
Dexamethason 4mg 100ml NaCl0.9% 52.29 € 10 522.90  
Kevatril 1mg 100ml NaCl0.9% 69.91 € 10 699.10  
NaCl0.9% 250ml x10 23.40 € 1 23.40  
NaCl0.9% 10ml x20 10.22 € 1 10.22  
Heparin Calcium 7500 10 FS 25.50 € 1 25.50  
MCP Tropfen 100ml 12.25 € 1 12.25  
Aranesp 300µg 1 FS 0,6ml 856.49 € 1 856.49  
Vagiflor Zäpfchen 12St 22.90 € 1 22.90  
Ferrosanol duodenal KAP N3 26.58 € 1 26.58  
Patient`s co-payment 10.00 € 1 10.00  
Patient`s co-payment 5.00 € 10 50.00 2451.88 
Patient`s co-payment 5.23 € 10 52.30 -182.20 
Patient`s co-payment 6.99 € 10 69.90 2269.68 
4.3 Supportive (patient documentation)     
Ferrosanol duodenal 100mg 100St 26.58 € 2 53.16  
Mar Meerwassernasenspray 20ml 4.85 € 1 4.85  
Vit B6 ratiopharm 40mg 100St 7.59 € 1 7.59  
Granisetron 2mg 5TAB 100.29 € 8 802.32  
Folsan 5mg 100St 18.31 € 1 18.31  
Vitasprint B12 Trinkampullen 10St 26.43 € 1 26.43  
198  Curriculum vitae 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
Deumavan Salbe 20ml 14.48 € 1 14.48  
Multi-Gyn-Liquid Gel 9.95 € 1 9.95  
Patient`s co-payment 4.85 € 1 4.85  
Patient`s co-payment 26.43 € 1 26.43  
Patient`s co-payment 9.95 € 1 9.95 937.09 
Patient`s co-payment 14.48 € 1 14.48 -75.71 
Patient`s co-payment 5.00 € 4 20.00 861.38 
 
Table D-29: BI 17, study period 30.11.2007-30.05.2008 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
08345 540 3 60.26  
01311 175 2 13.02  
02100 160 6 35.71 109.00 
2. Diagnostics     
2.1 Laboratory parameter     
32120 0.50 € 1 0.50  
32122 1.20 € 4 4.80  
32058 0.25 € 3 0.75  
32065 0.25 € 1 0.25  
32066 0.25 € 6 1.50  
32069 0.25 € 4 1.00  
32070 0.25 € 4 1.00  
32071 0.25 € 4 1.00  
32081 0.25 € 3 0.75  
32082 0.25 € 8 2.00  
32083 0.25 € 3 0.75  
32068 0.25 € 1 0.25  
32391 8.20 € 2 16.40  
32075 0.25 € 3 0.75  
32112 0.60 € 2 1.20  
32115 0.75 € 2 1.50  
32390 9.70 € 1 9.70  
32391 8.20 € 1 8.20 52.30 
2.2 MRT/CT/PET     
34330 1865 1 69.38  
34340 1875 1 69.75 139.13 
2.3 Other     
33042 445 2 33.11 33.11 
3. Administration     
32019 0 0 0.00 0.00 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 4 2138.20  
Navelbine 20mg KAP 4St 363.62 € 4 1454.48  
Navelbine 20mg KAP 1St 86.89 € 2 173.78  
Navelbine 30mg KAP 4St 547.73 € 4 2190.92  
Navelbine 30mg KAP 1St 133.01 € 1 133.01 6090.39 
Patient`s co-payment 10.00 € 13 130.00 -147.38 
Patient`s co-payment 8.69 € 2 17.38 5943.01 
Curriculum vitae  199 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
4.2 Supportive     
Bondronat 6mg/6ml Infusion 100ml NaCl0,9% 385.56 € 7 2698.92  
Sab simplex TRO 30ml 6.72 € 1 6.72 2705.64 
Patient`s co-payment 10.00 € 7 70.00 -75.00 
Patient`s co-payment 5.00 € 1 5.00 2630.64 
4.3 Supportive (patient documentation)     
Pantozol 20mg 60St 56.16 € 1 56.16  
Imodium lingual 100St 16.60 € 1 16.60  
MCP Stada TRO 100ml 12.27 € 1 12.27 85.03 
Patient`s co-payment 5.00 € 2 10.00 -15.62 
Patient`s co-payment 5.62 € 1 5.62 69.41 
 
Table D-30: BI 21, study period: 07.04.-07.10.2008 
Digit / Medication Points / € 
Resource 
use Costs (€) Sum (€) 
1. Oncologist fee     
01311 175 1 6.51  
02101 445 9 148.99  
08345 540 1 20.09 175.58 
2. Diagnostics     
2.1 Laboratory parameter     
32068 0.25 € 6 1.50  
32058 0.25 € 5 1.25  
32071 0.25 € 4 1.00  
32069 0.25 € 5 1.25  
32070 0.25 € 5 1.25  
32081 0.25 € 6 1.50  
32082 0.25 € 6 1.50  
32083 0.25 € 6 1.50  
32073 0.40 € 2 0.80  
32064 0.25 € 2 0.50  
32065 0.25 € 3 0.75  
32066 0.25 € 5 1.25  
32122 1.20 € 8 9.60  
32120 0.50 € 1 0.50 24.15 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
 0 0 0.00 0.00 
3. Administration     
40120 0.55 € 1 0.55 0.55 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 3 1603.65  
Paclitaxel 130,2mg 250ml NaCl0.9% 975.19 € 1 975.19  
Paclitaxel 129,6mg 250ml NaCl0.9% 866.05 € 9 7794.45  
Tamoxifen 20mg 100St 21.47 € 1 21.47 10394.76 
Patient`s co-payment 10.00 € 13 130.00 -135.00 
Patient`s co-payment 5.00 € 1 5.00 10259.76 
4.2 Supportive     
Tavegil 5AMP 11.50 € 2 23.00  
200  Curriculum vitae 
Digit / Medication Points / € 
Resource 
use Costs (€) Sum (€) 
Granisetron beta 2mg 5St N1 100.29 € 3 300.87  
Ranitidin 50mg 5AMP 14.48 € 2 28.96  
Dexamethason 4mg 100ml NaCl0.9% 52.29 € 10 522.90  
Kevatril 1mg 100ml NaCl0.9% 69.91 € 10 699.10  
NaCl0.9% 250ml x10 23.40 € 1 23.40  
NaCl0.9% 10ml x20 10.22 € 1 10.22  
Heparin Calcium 7500 10 FS 25.50 € 1 25.50  
Bepanthen Augen-und Nasensalbe 3.24 € 1 3.24  
Pantozol 40mg 100St 128.42 € 1 128.42  
Berberil N AT 4.41 € 1 4.41  
Linocab direkt Kombipackung 16.78 € 1 16.78  
Clexane 60 172.20 € 1 172.20  
Tepilta  43.13 € 1 43.13  
Patient`s co-payment 4.38 € 1 4.38  
Patient`s co-payment 5.23 € 10 52.30  
Patient`s co-payment 6.99 € 10 69.90  
Patient`s co-payment 2.70 € 1 2.70 2002.13 
Patient`s co-payment 10.00 € 2 20.00 -194.28 
Patient`s co-payment 5.00 € 9 45.00 1807.85 
4.3 Supportive (patient documentation)     
Ferrosanol duodenal 100St 26.58 € 1 26.58 58.88 
Pantozol 20mg 30St 32.30 € 1 32.30 -10.00 
Patient`s co-payment 5.00 € 2 10.00 48.88 
 
Table D-31: CI 1, study period: 11.12.2006–11.06.2007 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 1 1.86  
80112 205 2 15.25  
13500 540 2 40.18  
86503 25.56 € 2 51.12 108.41 
2. Diagnostics     
2.1 Laboratory parameter     
32068 0.25 € 2 0.50  
32058 0.25 € 2 0.50  
32057 0.25 € 2 0.50  
32460 5.40 € 2 10.80  
32071 0.25 € 2 0.50  
32069 0.25 € 2 0.50  
32070 0.25 € 2 0.50  
32081 0.25 € 2 0.50  
32075 0.25 € 2 0.50  
32083 0.25 € 2 0.50  
32084 0.25 € 2 0.50  
32067 0.40 € 2 0.80  
32064 0.25 € 2 0.50  
32123 0.40 € 2 0.80  
32122 1.20 € 2 2.40  
32324 4.90 € 1 4.90  
32392 9.20 € 1 9.20 34.40 
Curriculum vitae  201 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
 0 0 0.00 0.00 
3. Administration     
01430 35 1 1.30  
01610 40 1 1.49  
01620 85 3 9.49  
01621 125 1 4.65  
01622 235 1 8.74 25.67 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 5 2672.75 2672.75 
    -50.00 
Patient`s co-payment 10.00 € 5 50.00 2622.75 
4.2 Supportive     
Omep 40mg N3 109.97 € 1 109.97 109.97 
Patient`s co-payment 0.00 € 1 0.00 0.00 
    109.97 
4.3 Supportive (patient documentation)     
Hexobion 100 100St 14.21 € 1 14.21 28.01 
Ibuprofen 600mg 50St 13.80 € 1 13.80 -10.00 
Patient`s co-payment 5.00 € 2 10.00 18.01 
 
Table D-32: CI 3, study period: 26.02.2007 - 26.08.2007 
Digit / Medication Points / € Resource-use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 11 20.46  
13220 235 8 69.94  
01510 1420 5 264.12  
02341 330 1 12.28  
02110 600 1 22.32  
02111 240 1 8.93  
13500 540 2 40.18  
13502 540 1 20.09  
86503 25.56 € 2 51.12 509.42 
2. Diagnostics     
2.1 Laboratory parameter     
32068 0.25 € 6 1.50  
32058 0.25 € 6 1.50  
32065 0.25 € 6 1.50  
32057 0.25 € 6 1.50  
32082 0.25 € 6 1.50  
32066 0.25 € 6 1.50  
32460 5.40 € 6 32.40  
32071 0.25 € 7 1.75  
32069 0.25 € 7 1.75  
32070 0.25 € 7 1.75  
32081 0.25 € 6 1.50  
32075 0.25 € 6 1.50  
202  Curriculum vitae 
Digit / Medication Points / € Resource-use Costs (€) Sum (€) 
32083 0.25 € 6 1.50  
32056 0.25 € 6 1.50  
32072 0.40 € 6 2.40  
32064 0.25 € 6 1.50  
32120 0.50 € 9 4.50  
32460 4.90 € 3 14.70  
32392 9.20 € 3 27.60  
32112 0.60 € 1 0.60  
32113 0.60 € 1 0.60  
32169 15.30 € 1 15.30 119.85 
2.2 MRT/CT/PET     
34441 3430 1 127.60 127.60 
2.3 Other     
33042 445 1 16.55 16.55 
3. Administration     
01602 35 1 1.30  
01430 35 1 1.30  
32012 0 12 0.00  
01601 210 2 15.62  
40120 0.55 € 3 1.65 19.88 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 2 1069.10 3464.26 
Oxaliplatin 85mg Mayne 500ml Glu 5% 598.79 € 4 2395.16 -60.00 
Patient`s co-payment 10.00 € 6 60.00 3404.26 
4.2 Supportive     
Erythrozytenkonzentrat 81.00 € 2 162.00  
Voltaren 50 DRAG 50 St 19.83 € 1 19.83 199.79 
Tilidin ratio plus TRO 50ml 17.96 € 1 17.96 -5.00 
Patient`s co-payment 5.00 € 1 5.00 194.79 
4.3 Supportive (patient documentation)     
Questionnaire cycle 4 missing     
Pantozol 20mg 88.37 € 2 176.74  
Locacorten Creme  18.94 € 1 18.94 195.68 
Patient`s co-payment 8.84 € 2 17.68 -22.68 
Patient`s co-payment 5.00 € 1 5.00 173.00 
 
Table D-33: CI 13, study period: 24.07.2007-24.01.2008 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 7 13.02  
01510 1420 9 475.42  
80112 205 1 7.63  
13492 905 1 33.67  
13500 540 2 40.18  
13502 540 2 40.18  
86503 25.56 € 2 51.12  
86505 255.65 € 2 511.30 1172.50 
2. Diagnostics     
2.1 Laboratory parameter     
Curriculum vitae  203 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
32068 0.25 € 9 2.25  
32058 0.25 € 9 2.25  
32065 0.25 € 9 2.25  
32057 0.25 € 9 2.25  
32082 0.25 € 9 2.25  
32066 0.25 € 9 2.25  
32460 5.40 € 9 48.60  
32071 0.25 € 9 2.25  
32069 0.25 € 9 2.25  
32070 0.25 € 9 2.25  
32081 0.25 € 9 2.25  
32075 0.25 € 9 2.25  
32083 0.25 € 9 2.25  
32056 0.25 € 9 2.25  
32072 0.40 € 9 3.60  
32064 0.25 € 8 2.00  
32324 4.90 € 8 39.20  
32392 9.20 € 9 82.80  
32120 0.50 € 9 4.50 209.95 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
 0 0 0.00 0.00 
3. Administration     
01430 35 3 3.91  
80032 0 1 0.00  
90909 0 1 0.00  
32012 0 2 0.00  
01601 210 1 7.81  
40120 0.55 € 1 0.55 12.27 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 4 2138.20  
Avastin 300mg 250ml NaCl 0.9% 1.646.94 € 1 1646.94 20436.74 
Avastin 470mg 250ml NaCl 0.9% 2.081.45 € 8 16651.60 -130.00 
Patient`s co-payment 10.00 € 13 130.00 20306.74 
4.2 Supportive     
Dexahexal 8mg/2ml 5x2 AMP N2 14.21 € 2 28.42  
Vitamin B Komplex Ratio 60 St KAP 8.38 € 1 8.38 36.80 
Patient`s co-payment 8.38 € 1 8.38 -18.38 
Patient`s co-payment 5.00 € 2 10.00 18.42 
4.3 Supportive (patient documentation)     
 0.00 € 0 0.00 0.00 
 
Table D-34: CI 16, study period: 20.08.2007-20.02.2008 
Digit / Medication Points / € Resource-use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 11 20.46  
13220 235 3 26.23  
01510 1420 6 316.94  
204  Curriculum vitae 
Digit / Medication Points / € Resource-use Costs (€) Sum (€) 
01511 2700 1 100.44  
80111 175 1 6.51  
13491 865 1 32.18  
13500 540 2 40.18  
13502 540 2 40.18  
86503 25.56 € 2 51.12  
86505 255.65 € 2 511.30 1145.53 
2. Diagnostics     
2.1 Laboratory parameter     
32068 0.25 € 9 2.25  
32058 0.25 € 9 2.25  
32065 0.25 € 9 2.25  
32057 0.25 € 9 2.25  
32082 0.25 € 9 2.25  
32066 0.25 € 9 2.25  
32460 5.40 € 9 48.60  
32071 0.25 € 9 2.25  
32069 0.25 € 9 2.25  
32070 0.25 € 9 2.25  
32081 0.25 € 9 2.25  
32075 0.25 € 9 2.25  
32083 0.25 € 9 2.25  
32056 0.25 € 9 2.25  
32072 0.40 € 9 3.60  
32064 0.25 € 9 2.25  
32324 4.90 € 9 44.10  
32392 9.20 € 9 82.80  
32120 0.50 € 9 4.50 215.10 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
 0 0 0.00 0.00 
3. Administration     
01430 35 2 2.60  
80032 0 1 0.00  
90909 0 2 0.00  
32012 0 2 0.00  
32022 0 1 0.00  
01601 210 1 7.81  
01622 235 1 8.74  
40120 0.55 € 1 0.55 19.71 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 9 4810.95 25464.31 
Avastin 580mg 250ml NaCl 2.950.48 € 7 20653.36 -160.00 
Patient`s co-payment 10.00 € 16 160.00 25304.31 
4.2 Supportive     
Hexobion 100 20 St Dra N1 3.80 € 1 3.80  
Dexahexal 8mg/2ml 5x2 AMP N2 14.21 € 1 14.21  
Polyspectran 5g ASO N1 15.98 € 1 15.98  
Betaisodona Salbe 30g N1 5.07 € 1 5.07 39.06 
Patient`s co-payment 5.00 € 3 15.00 -18.80 
Patient`s co-payment 3.80 € 1 3.80 20.26 
Curriculum vitae  205 
Digit / Medication Points / € Resource-use Costs (€) Sum (€) 
4.3 Supportive (patient documentation)     
Orthomol immun Trinkfl 30 St 60.95 € 5 304.75  
Hexobion Vit B6 100mg 100 St 14.21 € 5 71.05 375.80 
Patient`s co-payment 60.95 € 5 304.75 -309.75 
Patient`s co-payment 5.00 € 1 5.00 66.05 
 
Table D-35: CI 17, study period: 21.09.2007-21.03.2008 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 7 13.02  
01510 1420 8 422.59  
80112 205 1 7.63  
13492 905 1 33.67  
13500 540 2 40.18  
13502 540 2 40.18  
86503 25.56 € 2 51.12  
86505 255.65 € 2 511.30 1119.68 
2. Diagnostics     
2.1 Laboratory parameter     
32068 0.25 € 9 2.25  
32058 0.25 € 9 2.25  
32065 0.25 € 9 2.25  
32057 0.25 € 9 2.25  
32082 0.25 € 9 2.25  
32066 0.25 € 9 2.25  
32460 5.40 € 9 48.60  
32071 0.25 € 9 2.25  
32069 0.25 € 9 2.25  
32070 0.25 € 9 2.25  
32081 0.25 € 9 2.25  
32075 0.25 € 9 2.25  
32083 0.25 € 9 2.25  
32056 0.25 € 9 2.25  
32072 0.40 € 9 3.60  
32064 0.25 € 9 2.25  
32324 4.90 € 9 44.10  
32392 9.20 € 9 82.80  
32120 0.50 € 9 4.50  
32248 1.40 € 1 1.40 216.50 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
33042 445 1 16.55 16.55 
3. Administration     
01602 35 1 1.30  
90909 0 1 0.00  
32012 0 1 0.00  
01601 210 1 7.81  
40120 0.55 € 3 1.65 10.76 
4. Drugs     
206  Curriculum vitae 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 6 3207.30 23335.06 
Avastin 580mg 250ml NaCl 2.515.97 € 8 20127.76 -140.00 
Patient`s co-payment 10.00 € 14 140.00 23195.06 
4.2 Supportive     
Dexahexal 8mg/2ml 5x2 AMP N2 14.21 € 2 28.42  
Pantozol 40mg 60St TMR N3 79.55 € 1 79.55  
Omeprazol STADA 40mg 60St KMR N3 68.69 € 1 68.69  
Imodium 50St KAP N3 14.59 € 1 14.59 107.97 
Patient`s co-payment 5.00 € 3 15.00 -22.96 
Patient`s co-payment 7.96 € 1 7.96 85.01 
4.3 Supportive (patient documentation)     
Equizym MCA 49.20 € 1 49.20  
Lachsöl Kapseln Omega 3 Fettsäuren 120 St 14.85 € 1 14.85 64.05 
Patient`s co-payment 49.20 € 1 49.20 -64.05 
Patient`s co-payment 14.85 € 1 14.85 0.00 
 
Table D-36: CI 20, study period: 08.11.2007-08.05.2008 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 8 14.88  
01510 1420 3 158.47  
01511 2700 4 401.76  
02101 445 5 82.77  
02110 600 1 22.32  
02111 240 1 8.93  
13492 905 2 67.33  
13500 540 2 40.18  
13502 540 2 40.18  
86503 25.56 € 2 51.12  
86505 255.65 € 2 511.30 1399.23 
2. Diagnostics     
2.1 Laboratory parameter     
32068 0.25 € 18 4.50  
32058 0.25 € 18 4.50  
32065 0.25 € 18 4.50  
32057 0.25 € 18 4.50  
32082 0.25 € 18 4.50  
32324 4.90 € 14 68.60  
32066 0.25 € 18 4.50  
32460 5.40 € 18 97.20  
32071 0.25 € 18 4.50  
32069 0.25 € 18 4.50  
32070 0.25 € 18 4.50  
32081 0.25 € 18 4.50  
32120 0.50 € 12 6.00  
32075 0.25 € 18 4.50  
32083 0.25 € 18 4.50  
32056 0.25 € 18 4.50  
32072 0.40 € 18 7.20  
Curriculum vitae  207 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
32064 0.25 € 18 4.50  
32123 0.40 € 2 0.80  
32122 1.20 € 5 6.00  
32094 4.00 € 1 4.00 252.80 
2.2 MRT/CT/PET     
/ 0 0 0.00 0.00 
2.3 Other     
33042 445 1 16.55 16.55 
3. Administration     
01430 35 1 1.30  
01610 40 1 1.49  
01620 85 3 9.49  
01621 125 1 4.65  
01622 235 1 8.74 25.67 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500mg 120 St 534.55 € 4 2138.20  
Irinotecan 340mg in 250ml NaCl 0.9% 991.80 € 6 5950.80  
Folinsäure 800mg in 250ml NaCl 0.9% 441.99 € 6 2651.94  
5-FU 800mg in 250ml NaCl 0.9% 72.67 € 6 436.02  
5-FU 4500mg 46h Pumpe 192.03 € 6 1152.18  
Avastin 360mg in 250ml NaCl 0.9% 1.646.94 € 6 9881.64 22210.78 
Patient`s co-payment 10.00 € 28 280.00 -323.62 
Patient`s co-payment 7.27 € 6 43.62 21.887.16 
4.2 Supportive     
Omeprazol 20mg 1A Pharma 60St KMR 31.25 € 5 156.25  
Erythrozytenkonzentrat 81.00 € 2 162.00  
Novaminsulfon Rat 500mg/ml 50ml Trp 13.60 € 1 13.60  
Prednisolon AL 20mg Tabl. 50St 15.98 € 2 31.96  
Movicol Beutel 50 St Pulver 34.86 € 2 69.72  
Spiro Comp Forte Rat 100/20 50St LTA  28.62 € 1 28.62  
Ondansetron STADA 8mg 5St Amp 79.80 € 2 159.60  
Dexahexal 8mg/2ml 5x2ml Amp 14.21 € 2 28.42  
Kalinor BTA 15St 7.59 € 1 7.59 657.76 
Patient`s co-payment 5.00 € 9 45.00 -60.96 
Patient`s co-payment 7.98 € 2 15.96 596.80 
4.3 Supportive (patient documentation)     
MCP Hexal 100ml 12.27 € 1 12.27  
Imodium 10 St 11.41 € 1 11.41  
MAR Plus Pflegespray 5.15 € 1 5.15 23.68 
Patient`s co-payment 5.00 € 2 10.00 -15.15 
Patient`s co-payment 5.15 € 1 5.15 8.53 
 
Table D-37: B 4, study period: 12.05.–31.07.2006 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
08215 50 17 31.62  
08220 235 8 69.94  
01511 2700 4 401.76  
02343 725 3 80.90  
208  Curriculum vitae 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
80112 205 1 7.63  
86503 25.56 € 1 25.56  
86505 255.65 € 1 255.65  
13500 540 1 20.09  
13502 540 1 20.09 913.23 
2. Diagnostics     
2.1 Laboratory parameter     
32122 1.10 € 10 11.00  
32069 0.25 € 8 2.00  
32070 0.25 € 8 2.00  
32071 0.25 € 8 2.00  
32068 0.25 € 8 2.00  
32066 0.25 € 8 2.00 21.00 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
33041 465 4 69.19 69.19 
3. Administration     
01430 35 5 6.51  
01600 110 1 4.09  
40120 0.55 € 1 0.55 11.15 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500 mg 120 FTA 534.55 € 2 1069.10  
Xeloda 150 mg 60 FTA 88.75 € 1 88.75  
Navelbine 55,2 mg in 250 ml NaCl 318.10 € 1 318.10  
Fareston Emra-Med 60 mg Tbl. 30 St. 55.07 € 1 55.07  
Avastin 6 mg/kg= 446,4 mg in 250 ml NaCl 2051.48 € 3 6154.44  
Patient`s co-payment 10.00 € 6 60.00 7685.46 
Patient`s co-payment 8.88 € 1 8.88 -74.39 
Patient`s co-payment 5.51 € 1 5.51 7.611.07 
4.2 Supportive     
Zofran Zydis Lingual, 10St 113.67 € 1 113.67  
Pantozol 40mg, 30St 43.68 € 1 43.68  
Bondronat 6 mg in 250 ml NaCl 385.82 € 3 1157.46  
Kevatril 2mg, 5St 133.73 € 2 267.46  
Kevatril Amp. 1 mg 5 St. 100.59 € 1 100.59  
Neulasta  6 mg FS N1 1548.13 € 2 3096.26  
Oliclinomel 3,4% GF-E (1OP: 4x1500ml) 640,55 4 2562,20  
NaCl 0,9% Braun 20x10 ml 9,63 2 19,26  
Soluvit N 10AMP 155,07 2 310,14  
Vitalipid Adult 10AMP 112,63 2 225,26  
Addel N 20x 10ml 162,95 1 162,95  
Novalgin, Erw. Supp. 10St. 13,01 1 13,01  
NaCl 0,9% Braun 10x1000ml 17,11 2 34,22  
Sterofundin 15,14 2 30,28 8136.44 
Patient`s co-payment 10,00 18 180,00 -210.00 
Patient`s co-payment 5,00 6 30,00 7926.44 
4.3 Supportive (patient documentation)     
Tromcardin forte, 100St 18.16 € 1 18.16  
Ibuprofen, 600mg 50St 13.80 € 1 13.80  
Pantozol, 40mg, 100St 128.42 € 1 128.42 160.38 
Patient`s co-payment 5.00 € 2 10.00 -20.00 
Curriculum vitae  209 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
Patient`s co-payment 10.00 € 1 10.00 140.38 
 
Table D-38: B 6, study period: 27.05.-27.11.2006 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
08215 50 16 29.76  
08220 235 10 87.42  
01510 1420 3 158.47  
80112 205 2 15.25  
86503 25.56 € 2 51.12  
13500 540 2 40.18  
13502 540 2 40.18  
10215 50 1 1.86  
01511 2700 5 502.20 926.44 
2. Diagnostics     
2.1 Laboratory parameter     
32122 1.10 € 9 9.90  
32069 0.25 € 9 2.25  
32071 0.25 € 9 2.25  
32068 0.25 € 9 2.25  
32070 0.25 € 9 2.25  
32066 0.25 € 9 2.25 21.15 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
32045 0.25 € 1 0.25  
32687 5.10 € 1 5.10 5.35 
3. Administration     
01430 35 10 13.02  
01600 110 1 4.09 17.11 
4. Drugs     
4.1 Antineoplastic     
Xeloda 150 mg Tbl. 60 St. 88.75 € 1 88.75  
Xeloda 500 mg Tbl. 120 St. 534.55 € 4 2138.20  
Ixoten 50 mg MTA 50 St. 325.36 € 7 2277.52 4415.72 
Patient`s co-payment 8.88 € 1 8.88 -118.88 
Patient`s co-payment 10.00 € 11 110.00 4.296.84 
4.2 Supportive     
Zometa 4 mg in 250 ml NaCl 401.83 € 9 3616.47  
Neulasta 6 mg FS N1 1.548.13 € 4 6192.52  
Cosmofer 175 mg in 250 ml NaCl 141.00 € 5 705.00  
Tannolact Badezusatz 100 g 11.97 € 2 23.94  
Linola sept 5.85 € 3 17.55  
Hexobion 100 Drg 100 St. 14.21 € 1 14.21  
Cefasel 300 Tbl. 5x 20 St. 55.56 € 1 55.56  
Gabapentin 300mg, 50St 28.52 € 1 28.52  
Patient`s co-payment 10.00 € 18 180.00 10653.77 
Patient`s co-payment 5.56 € 1 5.56 -215.56 
Patient`s co-payment 5.00 € 6 30.00 10438.21 
4.3 Supportive (patient documentation)     
210  Curriculum vitae 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
Cefasel 300 Tbl. 5x 20 St. 55.56 € 1 55.56  
Orthomol immun, 30St, x4 223.80 € 1 223.80 279.36 
Patient`s co-payment 223.80 € 1 223.80 -229.36 
Patient`s co-payment 5.56 € 1 5.56 50.00 
 
Table D-39: B 7, study period: 27.06.-27.12.2006 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
271 16.09 € 9 144.81  
261 4.02 € 9 36.18  
250 4.20 € 7 29.40  
1 10.72 € 5 53.60  
60 16.09 € 1 16.09  
31 60.33 € 2 120.66  
Zusatz A 4.08 € 2 8.16  
297 6.03 1 6.03  
1103 24.08 1 24.08 439.01 
2. Diagnostics     
2.1 Laboratory parameter     
3905 16.76 € 3 50.28  
3901 30.16 € 3 90.48  
3550 4.02 € 9 36.18  
3551 1.34 € 9 12.06  
3558 2.01 € 10 20.10  
3557 2.01 € 9 18.09  
3555 2.68 € 9 24.12  
3585 2.68 € 9 24.12  
3583 2.68 € 9 24.12  
3581 2.68 € 9 24.12  
3594 2.68 € 9 24.12  
3595 2.68 € 9 24.12  
3592 2.68 € 9 24.12  
3587 2.68 € 9 24.12  
3597 2.68 € 9 24.12  
3560 2.68 € 9 24.12  
3741 13.41 € 9 120.69  
4026 16.76 € 1 16.76  
4021 16.76 € 1 16.76  
4039 23.46 € 1 23.46  
4040 23.46 € 1 23.46  
4062 32.17 € 1 32.17  
3652 2.35 € 1 2.35 704.04 
2.2 MRT/CT/PET:     
5700 461.64 € 1 461.64 461.64 
2.3 Other:     
4851 13.64 € 1 13.64  
410 26.81 € 1 26.81  
420 10.72 € 3 32.16  
403 15.74 € 1 15.74  
11 8.04 € 1 8.04  
Curriculum vitae  211 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
7 21.45 € 1 21.45  
401 23.31 € 1 23.31  
404 14.57 € 1 14.57 155.72 
3. Administration:     
 0.00 € 0 0.00 0.00 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500 mg 120 FTA 534.55 9 4810.95  
Trastuzumab 680 mg in 250 ml NaCl 4019.59 1 4019.59  
Trastuzumab 510 mg in 250 ml NaCl 3229.08 6 19374.48  
Trastuzumab 504 mg in 250 ml NaCl 3229.08 1 3229.08  
Trastuzumab 495 mg in 250 ml NaCl 3229.08 1 3229.08  
Femara 100St 564.12 1 564.12 35772.82 
Zoladex 3,6mg 3FS 545.52 1 545.52 -200.00 
Patient`s co-payment 10.00 € 20 200.00 35572.82 
4.2 Supportive     
Bondronat 6 mg in 500 ml NaCl 0.9% 386.16 9 3475.44  
NaCl0.9% 250mlx10 23.40 1 23.40 3498.84 
Patient`s co-payment 5.00 € 1 5.00 -95.00 
Patient`s co-payment 10.00 € 9 90.00 3403.84 
4.3 Supportive (patient documentation)     
Pantozol 40mg, 60St 79.55 4 318.20  
Neuro ratio 100mg, 100St 12.85 2 25.70 343.90 
Patient`s co-payment 5.00 € 2 10.00 -41.84 
Patient`s co-payment 7.96 € 2 31.84 302.06 
 
Table D -40: B 8, study period: 07.06.-12.09.2006 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
08220 235 7 61.19  
01311 175 1 6.51 67.70 
2. Diagnostics     
2.1 Laboratory parameter     
32122 1.10 € 1 1.10  
32058 0.25 € 1 0.25  
32064 0.25 € 1 0.25  
32065 0.25 € 3 0.75  
32066 0.25 € 1 0.25  
32069 0.25 € 1 0.25  
32070 0.25 € 1 0.25  
32071 0.25 € 1 0.25  
32435 6.90 € 1 6.90  
32083 0.25 € 3 0.75  
32081 0.25 € 3 0.75  
32082 0.25 € 3 0.75  
32068 0.25 € 1 0.25  
32120 0.50 € 1 0.50 13.25 
2.2 MRT/CT/PET     
/ 0  0.00 0.00 
2.3 Other     
212  Curriculum vitae 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
33040 360 1 13.39  
34231 400 1 14.88 28.27 
3. Administration     
01601 210 1 7.81  
40120 0.55 € 1 0.55 8.36 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500 mg 120 FTA 534.55 € 2 1069.10 1069.10 
    -20.00 
Patient`s co-payment 10.00 € 2 20.00 1049.10 
4.2 Supportive     
Kevatril 2mg TAB 133.73 € 1 133.73  
Vomex A 150mg 10 SUPP 8.95 € 1 8.95  
Riopan Gel 10St 7.69 € 1 7.69  
Capval Dragees 12.50 € 1 12.50  
Bondronat 6mg 250ml NaCl 385.82 € 3 1157.46  
Patient`s co-payment 4.57 € 1 4.57 1320.33 
Patient`s co-payment 10.00 € 4 40.00 -54.57 
Patient`s co-payment 5.00 € 2 10.00 1265.76 
4.3 Supportive (patient documentation)     
Pantozol, 40mg, 60St 79.55 € 2 159.10  
Vomex A 150mg 10 SUPP 8.95 € 1 8.95  
Imbun retard 800mg 100St 30.37 € 1 30.37  
Novaminsulfon-ratio 500mg 50St 14.80 € 1 14.80  
Neuro-ratiopharm 50St 9.25 € 1 9.25  
Patient`s co-payment 15.00 € 1 15.00 222.47 
Patient`s co-payment 5.00 € 3 15.00 -45.92 
Patient`s co-payment 7.96 € 2 15.92 176.55 
 
Table D-41: B 10, study period: 02.08.-02.11.2006 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
80111 175 1 6.51  
13500 540 1 20.09  
86503 25.56 € 1 25.56  
13215 50 2 3.72  
13220 235 1 8.74 64.62 
2. Diagnostics     
2.1 Laboratory parameter     
32120 0.50 € 1 0.50  
32066 0.25 € 1 0.25  
32064 0.25 € 1 0.25  
32057 0.25 € 1 0.25  
32071 0.25 € 1 0.25  
32068 0.25 € 1 0.25  
32075 0.25 € 1 0.25  
32324 4.90 € 1 4.90  
32391 8.20 € 1 8.20 15.10 
2.2 MRT/CT/PET     
34330 1865 1 69.38 69.38 
Curriculum vitae  213 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
2.3 Other     
 0 0 0.00 0.00 
3. Administration     
01601 210 1 7.81  
40120 0.55 € 1 0.55 8.36 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500 mg FTA 120 St. 534.55 2 1069.10 1069.10 
Patient`s co-payment 10.00 € 2 20.00 -20.00 
    1.049.10 € 
4.2 Supportive     
Prednisolon  50 mg Tbl. 50 St. 29.99 1 29.99 41.84 
Lorazepam ratio  1 mg Tbl. 20 St. 11.85 1 11.85 -10.00 
Patient`s co-payment 5.00 2 10.00 31.84 
4.3 Supportive (patient documentation)     
Nobilin Plus Kps., 4x60St 15.40 1 15.40  
Nobilin Lyco Kps., 4x60St 68.88 1 68.88  
Nobilin Q10 Multivitamin, 240St 73.90 1 73.90  
Patient`s co-payment 15.40 1 15.40 158.18 
Patient`s co-payment 68.88 1 68.88 -158.18 
Patient`s co-payment 73.90 1 73.90 0.00 
 
Table D-42: B 11, study period: 11.07.2006-11.01.2007 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 20 37.20  
13220 235 4 34.97  
02100 160 3 17.86  
02101 445 13 215.20  
01312 205 1 7.63  
01510 1420 4 211.30 524.15 
2. Diagnostics     
2.1 Laboratory parameter     
32120 0.50 € 17 8.50  
32066 0.25 € 7 1.75  
32064 0.25 € 1 0.25  
32068 0.25 € 2 0.50  
32069 0.25 € 1 0.25  
32071 0.25 € 5 1.25  
32058 0.25 € 1 0.25  
32083 0.25 € 7 1.75  
32081 0.25 € 7 1.75  
320 0.40 € 1 0.40  
32070 0.25 € 4 1.00  
32075 0.25 € 4 1.00  
32324 4.90 € 4 19.60  
32391 8.20 € 8 65.60  
32112 0.60 € 4 2.40  
32113 0.60 € 4 2.40  
32110 0.75 € 3 2.25  
32065 0.25 € 1 0.25  
214  Curriculum vitae 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
32082 0.25 € 2 0.50  
32460 5.40 € 1 5.40  
32122 1.10 € 1 1.10 118.15 
2.2 MRT/CT/PET     
34330 1865 1 69.38  
34341 2315 1 86.12  
34345 645 1 23.99 179.49 
2.3 Other     
32760 4.10 € 4 16.40  
32722 7.70 € 3 23.10  
32749 12.80 € 1 12.80  
32750 2.60 € 9 23.40 75.70 
3. Administration     
01600 110 2 8.18  
01601 210 3 23.44  
40120 0.55 € 1 0.55  
01430 35.00 10 13.02 45.19 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500 mg 120 FTA 534.55 € 4 2138.20 3861.24 
Epirubicin 20mg in 250ml Glu 5% 156.64 € 11 1723.04 -150.00 
Patient`s co-payment 10.00 € 15 150.00 3711.24 
4.2 Supportive     
Bondronat 6 mg in 250 ml NaCl 385.82 8 3086.56 3086.56 
Patient`s co-payment 10.00 8 80.00 -80.00 
    3006.56 
4.3 Supportive (patient documentation)     
Hexobion 100mg 100St 14.21 2 28.42  
Pantozol, 40mg, 30St 43.68 2 87.36  
Pantozol, 40mg, 60St 79.55 1 79.55  
MCP AL TRO 12.25 1 12.25  
Vomex A, 50mg, N1 6.40 2 12.80  
Perenterol 50mg 32.82 1 32.82  
Kalinor N3 45.59 1 45.59  
Imbun 800mg retard, N2  20.56 1 20.56  
Omeprazol STADA, 40mg, 60St 68.69 1 68.69  
Imodium (Janssen-cilag), 2mg, 50St 16.60 1 16.60  
Diclofenac 100 retard, 50St 13.17 1 13.17  
Kalinor Brause 30St 15.20 1 15.20  
Patient`s co-payment 10.00 2 20.00  
Patient`s co-payment 7.96 1 7.96 433.01 
Patient`s co-payment 5.00 7 35.00 -72.40 
Patient`s co-payment 9.44 1 9.44 360.61 
 
Table D-433: B 12, study perspective: 27.09.2006-27.03.2007 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
08220 235 9 78.68  
02101 445 9 148.99  
01311 175 1 6.51 234.17 
2. Diagnostics     
Curriculum vitae  215 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
2.1 Laboratory parameter     
32122 1.10 € 7 7.70  
32058 0.25 € 4 1.00  
32066 0.25 € 4 1.00  
32065 0.25 € 4 1.00  
32069 0.25 € 4 1.00  
32070 0.25 € 4 1.00  
32071 0.25 € 4 1.00  
32075 0.25 € 3 0.75  
32083 0.25 € 3 0.75  
32081 0.25 € 3 0.75  
32082 0.25 € 3 0.75  
32068 0.25 € 4 1.00  
32120 0.50 € 2 1.00 18.70 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
 0 0 0.00 0.00 
3. Administration     
01601 210 3 23.44  
40120 0.55 € 3 1.65 25.09 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500 mg 120 FTA 534.55 € 3 1603.65  
Paclitaxel 105,9 mg   862.10 € 3 2586.30  
Paclitaxel 108 mg   862.10 € 1 862.10  
Paclitaxel 109 mg   862.10 € 1 862.10  
Paclitaxel 81,5 mg   677.66 € 1 677.66  
Paclitaxel 64,4 mg   677.66 € 1 677.66  
Paclitaxel 54,67 mg   677.66 € 1 677.66  
Paclitaxel 54,34 mg   677.66 € 1 677.66 9725.79 
Bondronat 50 mg 84 Stück 1.101.00 € 1 1101.00 -140.00 
Patient`s co-payment 10.00 € 14 140.00 9.585.79 
4.2 Supportive     
Kevatril 1 mg in 100 ml NaCl  69.91 € 9 629.19  
Dexamethason 4 mg in 100 ml NaCl 52.08 € 9 468.72  
Aranesp 150 1 Amp. s.c.  486.53 € 3 1459.59  
Aranesp 300 1 Amp. s.c. 856.50 € 1 856.50  
Ferro sanol duodenal Kps. N3 26.58 € 1 26.58  
Bepanthen Salbe 100 g 10.02 € 1 10.02  
Sic-ophthal Trpf. N1 4.26 € 1 4.26  
Mundspüllösung 1.71 € 1 1.71  
Pantozol 40 N1 26.24 € 1 26.24  
Tavegil 5AMP 11.50 € 2 23.00  
Ranitidin 50mg 5AMP 14.48 € 2 28.96  
NaCl0.9% 250ml x10 23.40 € 1 23.40  
NaCl0.9% 10ml x20 10.22 € 1 10.22  
Heparin Calcium 7500 10 FS 25.50 € 1 25.50  
Patient`s co-payment 6.99 € 9 62.91  
Patient`s co-payment 5.21 € 9 46.89  
Patient`s co-payment 10.00 € 4 40.00  
Patient`s co-payment 5.00 € 7 35.00  
Patient`s co-payment 10.02 € 1 10.02 3593.89 
Patient`s co-payment 4.05 € 1 4.05 -200.58 
216  Curriculum vitae 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
Patient`s co-payment 1.71 € 1 1.71 3393.31 
4.3 Supportive (patient documentation)     
Pantozol, 40mg, 60St 79.55 € 2 159.10  
MCP-Tropfen, 100ml 12.25 € 1 12.25  
Juice plus, KAP 29.40 € 1 29.40  
Ferro sanol duodenal, 100St 26.58 € 1 26.58  
Unacid PD oral, 10St 28.73 € 1 28.73  
Ciprofloxacin, 500mg, 10St 16.68 € 1 16.68  
Patient`s co-payment 5.92 € 1 5.92 272.74 
Patient`s co-payment 5.00 € 6 30.00 -65.32 
Patient`s co-payment 29.40 € 1 29.40 207.42 
 
Table D-44: C 7, study period: 24.07.2006-24.01.2007 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 6 11.16  
86503 25.56 € 2 51.12  
13500 500 1 18.60  
80112 205 2 15.25 96.13 
2. Diagnostics     
2.1 Laboratory parameter     
32122 1.20 € 7 8.40  
32123 0.40 € 7 2.80  
32083 0.25 € 7 1.75  
32081 0.25 € 7 1.75  
32084 0.25 € 7 1.75  
32067 0.40 € 7 2.80  
32064 0.25 € 7 1.75  
32058 0.25 € 7 1.75  
32069 0.25 € 7 1.75  
32070 0.25 € 7 1.75  
32071 0.25 € 7 1.75  
32068 0.25 € 7 1.75  
32075 0.25 € 7 1.75  
32057 0.25 € 7 1.75  
32460 5.40 € 7 37.80  
32324 4.90 € 7 34.30  
32392 9.20 € 7 64.40 169.75 
2.2 MRT/CT/PET     
34330 1865 1 69.38 69.38 
2.3 Other     
34241 430 1 16.00  
33042 445 1 16.55 32.55 
3. Administration     
01601 210 3 23.44 23.44 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500 FTA 120 St. 534.55 € 9 4810.95 4810.95 
Patient`s co-payment 10.00 € 9 90.00 -90.00 
    4720.95 
4.2 Supportive     
Hexobion, 3x1, 100St 14.21 € 1 14.21 14.21 
Curriculum vitae  217 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
Patient`s co-payment 5.00 € 1 5.00 -5.00 
    9.21 
4.3 Supportive (patient documentation)     
Hexobion, 3x1, 100St 14.21 3 42.63 42.63 
Patient`s co-payment 5.00 € 3 15.00 -15.00 
    27.63 
 
Table D-45: C 8, study period: 03.08.2006-03.02.2007 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 12 22.32  
02101 445 9 148.99  
01311 175 1 6.51  
13220 235 2 17.48 195.30 
2. Diagnostics     
2.1 Laboratory parameter     
32120 0.50 € 13 6.50  
32066 0.25 € 1 0.25  
32070 0.25 € 1 0.25  
32071 0.25 € 1 0.25  
32075 0.25 € 1 0.25  
32324 4.90 € 1 4.90  
32395 19.90 € 1 19.90 32.30 
2.2 MRT/CT/PET     
34330 1865 1 69.38  
34341 2315 2 172.24  
34345 545 1 20.27 261.89 
2.3 Other     
 0 0 0.00 0.00 
3. Administration     
 0 0 0.00 0.00 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500 mg 120 FTA 534.55 € 2 1069.10  
Oxaliplatin 100mg 500ml Glu 5% 700.19 € 4 2800.76  
Campto (Irinotecan) 250mg 500ml NaCl 865.68 € 4 3462.72  
5-FU 5200 mg in 240ml NaCl 91.53 € 4 366.12  
Avastin (Bevacizumab) 450mg 250ml NaCl 2.051.48 € 3 6154.44  
Oncofolic (Folinsäure) 1000mg 500ml NaCl 581.86 € 4 2327.44 16180.58 
Patient`s co-payment 10.00 € 14 140.00 -167.45 
Patient`s co-payment 9.15 € 3 27.45 16013.13 
4.2 Supportive     
Zofran 8 mg 1 Amp. in 250 ml NaCl 71.37 € 4 285.48  
Zofran TAB 8mg, 10St 174.86 € 1 174.86  
Zofran 8mg 5AMP 108.74 € 1 108.74  
Calcium  Braun 10, 20 Amp 10.40 € 1 10.40  
Magnesium Sulfat 10% , 5 Amp 7.08 € 2 14.16  
Imodium, 2mg, 20St 12.91 € 1 12.91  
MCP ratio 100ml 13.48 € 1 13.48  
Vomex A Dragees 6.40 € 1 6.40  
Zantic 5x5ml 15.93 € 1 15.93  
218  Curriculum vitae 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
Tavegil 5AMP 11.50 € 1 11.50  
Buscopan 5x10ml Inj-Lsg 25.78 € 3 77.34  
Heparin 7500 10FS 25.50 € 1 25.50  
Pantozol, 40mg, 100St 128.42 € 2 256.84  
Patient`s co-payment 7.13 € 4 28.52  
Patient`s co-payment 39.15 € 1 39.15 1013.54 
Patient`s co-payment 10.00 € 4 40.00 -167.67 
Patient`s co-payment 5.00 € 12 60.00 845.87 
4.3 Supportive (patient documentation)     
 0.00 € 0 0.00 0.00 
 
Table D-46: C 10, study period: 25.08.-24.10.2006 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
86503 25.56 € 1 25.56  
13500 500 1 18.60  
80112 205 1 7.63 51.79 
2. Diagnostics     
2.1 Laboratory parameter     
32120 0.50 € 1 0.50 0.50 
2.2 MRT/CT/PET     
34440 3430 1 127.60 127.60 
2.3 Other     
01741 4325 1 160.89 160.89 
3. Administration     
01601 210 2 15.62 15.62 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500 mg Tbl. 120 St. 534.55 € 1 534.55 534.55 
Patient`s co-payment 10.00 € 1 10.00 -10.00 
    524.55 
4.2 Supportive     
Movicol Btl. N3 34.86 € 1 34.86  
Adumbran Tbl. N1 (Oxazepam) 10.40 € 1 10.40  
Metamizol, 100ml 16.71 € 1 16.71  
Pantozol, 40mg, 60St 79.55 € 1 79.55  
Iberogast, 50ml 16.70 € 1 16.70 158.22 
Patient`s co-payment 5.00 € 4 20.00 -27.96 
Patient`s co-payment 7.96 € 1 7.96 130.26 
4.3 Supportive (patient documentation)     
 0.00 € 0 0.00 0.00 
 
Table D-47: C 14, study period: 21.11.2006-21.05.2007 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
1. Oncologist fee     
13215 50 6 11.16  
01511 2700 1 100.44  
80112 205 2 15.25  
Curriculum vitae  219 
Digit / Medication Points / € Resource use Costs (€) Sum (€) 
13500 540 2 40.18  
13502 540 2 40.18  
86503 25.56 € 2 51.12  
86505 255.56 € 2 511.12  
01510 1420 7 369.77 1139.21 
2. Diagnostics     
2.1 Laboratory parameter     
32120 0.50 € 9 4.50  
32068 0.25 € 8 2.00  
32058 0.25 € 8 2.00  
32066 0.25 € 8 2.00  
32065 0.25 € 8 2.00  
32069 0.25 € 8 2.00  
32070 0.25 € 8 2.00  
32071 0.25 € 8 2.00  
32075 0.25 € 8 2.00  
32083 0.25 € 8 2.00  
32081 0.25 € 8 2.00  
32057 0.25 € 8 2.00  
32082 0.25 € 8 2.00  
32392 9.20 € 7 64.40  
32324 4.90 € 7 34.30  
32460 5.40 € 8 43.20  
32056 0.25 € 8 2.00  
32072 0.40 € 8 3.20  
32064 0.25 € 8 2.00  
32103 0.60 € 3 1.80  
32104 0.60 € 3 1.80  
32105 0.60 € 3 1.80  
32426 4.60 € 1 4.60 187.60 
2.2 MRT/CT/PET     
 0 0 0.00 0.00 
2.3 Other     
33042 445 1 16.55 16.55 
3. Administration     
01601 210 2 15.62  
40120 0.55 € 2 1.10 16.72 
4. Drugs     
4.1 Antineoplastic     
Xeloda 500 mg 120 FTA N3 534.55 € 6 3207.30  
Avastin 325 mg in 250 ml NaCl 1.631.95 € 3 4895.85 20412.03 
Avastin 490 mg in 250 ml NaCl 2.051.48 € 6 12308.88 -150.00 
Patient`s co-payment 10.00 € 15 150.00 20262.03 
4.2 Supportive     
DexaHexal 8 mg/2 ml 5 Amp. N2 14.21 € 2 28.42 103.39 
MCP AL Tropfen, 30ml, x3 10.78 € 3 32.34 -40.00 
Novalgin Tropfen, 50ml, x3 14.21 € 3 42.63 63.39 
Patient`s co-payment 5.00 € 8 40.00  
4.3 Supportive (patient documentation)     
 0.00 € 0 0.00 0.00 
 
